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Therapeutic decisions are among the most critical tasks made by physicians in every 
day clinical practice. Making such decisions requires an individualized assessment of 
the safety and efficacy profiles of different medications, with either imperfect 
information or uncertainty about the potential outcomes of treatment choices.  
Furthermore, those decisions are influenced by a physician’s education, personality 
traits, and cognitive biases. Previous studies revealed that cognitive biases affect over 
50% of physicians, with overconfidence, risk tolerance, availability bias, and the 
framing effect the most commonly reported. From a decision neuroscience 
perspective, my goal was to better understand how physicians make therapeutic 
decisions. I was specifically interested in the status quo bias (SQ) when applied to 
therapeutic decisions in the medical field. SQ is defined as the preference for “keeping 
things the way they presently are”.  In medicine, SQ occurs when physicians face 
different therapeutic alternatives, but end up keeping the current treatment. 
Therapeutic inertia (TI), a common variant of SQ, is characterized by a physician’s 
decision not to initiate or intensify treatment when treatment goals are unmet. In other 
words, TI occurs when there is evidence of disease progression (e.g.: elevated blood 
pressure despite antihypertensive treatment, elevated glucose despite taking 
medications for diabetes) and physicians do not initiate a new medication or switch to 
a more effective treatment as recommended by best practice guidelines. Such 
suboptimal decisions lead to poorer clinical outcomes and higher health care costs. 
 
In the present work, I outline five key questions which are addressed in sequence by 
my empirical studies. I first begin by introducing the concept of cognitive biases and 
summarizing the results of an exhaustive literature review (Question 1). Then, I 
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elaborate upon the concept of therapeutic inertia and its associated factors (Questions 
2 & 3). Then, I show the results of a newly designed educational intervention to 
ameliorate TI (Question 4), Finally, I present the results of studies evaluating the 
association between arousal response and emotional expressions on therapeutic 
decisions (Question 5).  
 
The focus of my work is on multiple sclerosis (MS), a demyelinating disease that 
represents the paradigm of complex treatment decisions in chronic and progressive 
medical conditions (e.g., hypertension, diabetes, high cholesterol). I first summarize 
the most common factors associated with TI in MS care. Next, I present the rationale 
for the development of an innovative educational intervention applying the traffic light 
system strategy (TLS) to ameliorate the effects of TI. The TLS-based educational 
intervention is designed to help optimize treatment decisions by interrupting the 
automatic status-quo state, and trigger re-evaluation processes elicited by the 
universal warning sign of the color red (Ahmed et al., 2020; Laura Enax, Krajbich, & 
Weber, 2016).  
Thereafter I discuss the results from a feasibility and randomized study testing the 
benefits our successful TLS-educational intervention on reducing TI.  I then explore 
current understanding of the role of autonomic arousal and emotional status in 
decision-making, and more specifically our limited understanding of the arousal 
response in live therapeutic decisions (Saposnik et al, 2020 submitted for publication). 
Finally, I provide an explanation of the possible link between physician’s 
characteristics (e.g. years of experience, expertise in MS care) and the effects and 
mechanism by which the TLS educational intervention may reduce TI with the 
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integration of the arousal state in the modulation of therapeutic choices made by 
expert neurologists (Saposnik et al, 2020 submitted for publication).  
 
The core of this thesis consists of novel work that begins with the development of the 
concept of therapeutic inertia in MS care, and then examines changes in the arousal 
states to test the mechanism by which the TLS educational intervention decreased TI 
among neurologists who are making live treatment decisions.  
 
My discussion is centered on empirical results and theory: I synthetize the 
contributions of my studies within the broader literature and suggest a novel model to 
explain the association between physician’s characteristics and the effects of an 
educational intervention on TI, and the mediating effects of autonomic arousal states 
on the educational intervention-TI link. I conclude with practical implications for 
neuroscience, medical education, and patient care.  
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1.1 A brief description of Medical Decisions 
 
Decision making is defined as the process of examining possibilities, evaluation of 
risks and uncertainties, identifying options, comparing them, and choosing a course of 
action (Elstein & Schwartz, 2002). Medical decision-making is a complex task 
involving a variety of cognitive processes, including the selection and integration of 
best research evidence with clinical expertise and patients’ values.(Elstein & 
Schwartz, 2002; Zikmund-Fisher et al., 2010)  A previous report highlighted the 
importance of teaching about uncertainty to medical students.(Flexner, 2002) 
Decisions based on erroneous assessments may result in incorrect patient and family 
expectations, suboptimal advice, and costly medical errors (Croskerry, 2003). For 
example, medical errors are the third leading cause of death in the United States of 
America (Makary & Daniel, 2016). Medical errors represent 1.7-6.5% of all hospital 
admissions causing up to 100,000 avoidable deaths each year in the USA (Bates et 
al., 1995; Classen, Pestotnik, Evans, & Burke, 1991). Suboptimal medical decisions 
and medical errors cost the USA healthcare system approximately $20 billion annually 
(Andel, Davidow, Hollander, & Moreno, 2012). A recent report from the World Health 
Organization revealed that four out of ten patients in primary and outpatient care are 
harmed (https://www.who.int/features/factfiles/patient_safety/en/ accessed April 17, 
2020).  
The ultimate consequences of suboptimal decisions and medical errors include 
avoidable hospitalizations, medication underuse (i.e.: therapeutic inertia) and overuse, 
and wasted resources that may lead to the progression of medical conditions, poorer 
clinical and cognitive outcomes for patients, and higher healthcare costs (Ioannidis & 




The theoretical framework of medical decision-making  
Medicine is an uncertain science, and physician are not infallible. Most (if not every) 
physician has made or witnessed some form of a mistake (e.g. medical error, near 
miss) in diagnosis and/or treatment in their career.(Graber, 2013; Makary & Daniel, 
2016) But the frequency of those mistakes, and their severity, can be reduced by 
understanding how physicians make decisions. Despite the great technological 
advances in medicine over the last century, uncertainty remains a key challenge in all 
aspects of medical decision-making. The basic structure of decision models used to 
evaluate diagnostic or treatment strategies are binary (Harrison, Milbers, Hudson, & 
Bansback, 2017).  
 
In the last 30 years, several theories have been proposed to define how physicians 
make decisions. Several concepts have emerged to characterize rational decisions, 
medical decisions, diagnostic and therapeutic errors, and the status-quo related to 
lack of treatment initiation or escalation (Ioannidis & Lau, 2001; D. Ontaneda, 
Tallantyre, Kalincik, Planchon, & Evangelou, 2019; Prakash, Sladek, & Schuwirth, 
2019; Redelmeier & Shafir, 1995; Summerfield & Tsetsos, 2015). A recent study 
provides a comprehensive summary of major theories related to models of rationality 
relevant to medical decisions, including: the application of Bayesian probability and 
decision analysis based on expected utility theory (EUT), prospect theory, and dual 
processing theories (DPT) of rational thought, among others (B. Djulbegovic, 
Elqayam, & Dale, 2018). Although the explanation of each theory exceeds the scope 
of this thesis, each of these theories has been assessed regarding information 
components (e.g.: about options, attributes), deliberation components (e.g.: strategies 
that help individuals deliberate about their choices: value, preference), and outcomes 
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measurements. A recent review found that: i) few decision-making interventions are 
explicitly based on a theory or model, and ii) there was no theory that comprehensively 
integrated all components or informed about the design of educational interventions 
aimed at making good decisions.(Bekker et al., 1999; G. Elwyn, Stiel, Durand, & 
Boivin, 2011)  
 
Briefly, Bayesian variants of threshold models use prior information to formalize 
calculations (Vilares & Kording, 2011). For example, these models may capture the 
belief that initiating or intensifying treatment at a certain laboratory threshold provides 
the best outcome (e.g. initiate treatment for the prevention of diabetes with metformin 
when blood hemoglobin A1C test levels are greater than 5.7%) (Hostalek, Gwilt, & 
Hildemann, 2015). 
 
Clinicians commonly face a dilemma when making therapeutic decisions based on the 
probability of a disease, and the harms and benefits associated with a diagnostic test 
(e.g. radiation associated with a computerized tomography scan- [CT]) or treatment 
(e.g. side effects associated with antibiotics, cholesterol lowering therapies). As a 
result, physicians may order a test to decide whether or not initiate treatment, or initiate 
treatment without ordering a test. Most recent advances in medical decision making 
include threshold models (Benjamin Djulbegovic, Hozo, Mayrhofer, van den Ende, & 
Guyatt, 2019), which rely on the expected utility (an economic measure of the 
desirability of an outcome that combines the likelihood of the outcome and the 
satisfaction from it) or variants of these models (Caplin & Glimcher, 2014; Hozo, 
Tsalatsanis, & Djulbegovic, 2018; Tsalatsanis, Hozo, Kumar, & Djulbegovic, 2015). 
EUT suggests that when choosing between different strategies, the decision maker 
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should select the strategy that leads to the outcome with the highest expected utility 
(Note: the expected utility function is represented in the following formula:  
EU(A)=∑o∈OPA(o)U(o); where O is the set of outcomes, PA(o) is the probability of 
outcome o conditional on A, and U(o) is the utility of o. 
 
In medicine, an MRI has a higher expected utility for detecting small stroke or brain 
lesion in MS than computerized tomography, insulin has a higher utility to decrease 
blood sugar for patients with uncontrolled diabetes than other oral medications. 
Medical decisions based on the EUT are therefore based on a “threshold”; the 
probability at which we are indifferent between testing and administering treatment 
without testing. Models based on the EUT do not take into account physician’s intuition 
and experience (e.g. a CT may be a more practical test despite the lower expected 
utility value), or the emotions of the patient (e.g. a patient’s ability to tolerate having 
an MRI due to claustrophobia) or the treating physician when making a decision (B. 
Djulbegovic, Hozo, Beckstead, Tsalatsanis, & Pauker, 2012).   
 
Dual processing theory (DPT) overcomes the limitations and commonly violated 
principles of EUT when decisions are based on physician’s expertise or intuition and 
contradict the highest expected value. DPT is based on the concept that human 
decisions are governed by two distinct processes, commonly referred to as system 1 
(intuitive) and system 2 (analytical). In brief, system 1 refers to an automatic, 
unconscious, fast, and effortless (or routine) mechanism to make most common 
decisions. Conversely, system 2 makes deliberate decisions, which are non-
programmed, conscious, usually slow, and deliberate (Tversky & Kahneman, 1974).  
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Under the DPT framework, it has been suggested that most cognitive biases are 
attributed to intuitive processes (representing the overuse of system 1), or when 
system 1 overrides system 2 (Ely, Graber, & Croskerry, 2011; Mamede, van Gog, van 
den Berge, van Saase, & Schmidt, 2014; van den Berge & Mamede, 2013).  In this 
framework, techniques that enhance system 2 (e.g. my successful educational 
intervention to overcome therapeutic inertia) could counteract these biases, and 
thereby improve diagnostic accuracy and decrease the likelihood of suboptimal 
decisions and medical errors (e.g. therapeutic inertia) (Saposnik, Mamdani, et al., 
2019; Saposnik, Maurino, et al., 2017).   
 
Treatment decisions based on DPT suggest that physicians decide to treat when the 
"threshold probability" at which treatment benefits are greater than treatment harms 
are exceeded. However, they also incorporate other critical components not 
considered under the EUT, such as intuitive cognitive processes, emotional aspects, 
balance between efficacy and side effects of medications, and the experience of 
decision-makers. Physicians also make automatic decisions when specific criteria are 
met (e.g. to initiate antibiotics if fever and signs of an ear infection are present by direct 
visualization in a child with otitis, not requiring a threshold probability).  Decisions 
based on diagnostic tests are better explained using threshold models, because they 
depend on objective evidence and thoughtful consideration of the benefit and harm of 
a test/treatment. Type 1 processes are unique to each decision-maker (e.g. each 
physician has an individual set of skills, knowledge about a condition, and knowledge 
gaps).  Previous studies have shown that when type 1 processes dominate decisions 
exclusively, ordering a diagnostic test does not affect a decision; the decision is based 
on the automatic assessment of knowledge-based benefits and harms of the treatment 
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(e.g. antibiotics for a child with an ear infection) (B. Djulbegovic et al., 2018; B. 
Djulbegovic et al., 2012; Mukherjee, 2010). These findings explain variations in 
physicians’ ordering of diagnostic tests and treatment patterns (due to knowledge-to-
action gaps) as commonly seen in clinical practice. 
 
DPT have been criticized due to the conceptual vagueness, lack of precision (Keren 
& Schul, 2009), lack of consistency between researchers (Gigerenzer, 1996), and 
inferential gaps (Osman, 2004). On the other hand, DPT has been praised for its 
simplicity and embedded heuristics when explaining binary choices and associated 
biases, support from empirical evidence, and its applicability to medical decisions (B. 
Djulbegovic et al., 2012; Mukherjee, 2010; Tsalatsanis et al., 2015).  
 
In summary, the EUT and DPT have different properties, strengths, and limitations. 
Table 1 summarizes the main characteristics and differences between the EUT and 
DPT when applied to medical decisions. I explain below the reasons for choosing the 
DPT as the framework for my studies. Certainly, physicians do not need these theories 
to make diagnostic or therapeutic decisions. However, these theories provide a 
framework to explain medical decisions and ideally overcome suboptimal choices or 
medical errors.  
 
The debate about different theories will continue long after this thesis, as there is no 
single decision model that can fit all medical contexts (B. Djulbegovic & Elqayam, 
2017; B. Djulbegovic et al., 2018). I acknowledge that either EUT, prospect theory or 
DPT could explain therapeutic decisions under uncertainty. Experimental evidence 
supports the highlighted strengths of DPT, a recognized framework to explain medical  
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Table 1. Comparison between EUT and DPT in medical decisions 
Characteristics EUT DPT 
Framework Unimodal (expected utility) 
Dual process  
(system 1 & system 2) 
Decisions based on mathematical 
computations to optimize outcomes   
Normative (decisions should 
be based on computations to 
maximize EU) 
Descriptive (sometimes 
decisions are based on 
computations) 
Mathematical expression  [EU(A)=∑o∈OPA(o)U(o)]*  [ptt ≤ p < prx]† 
 
Accounting for social aspects (e.g. 
accessibility, medical insurance) 
No  
Takes into consideration some 
social aspects of treatment 
decisions 
Accounting for emotional aspects 
Risk preferences  
(e.g. risk aversion) 
Risk preferences, beliefs, 
ambiguity 





















Should always be based on the 
outcome with the highest 
expected utility (EU) 
Also based on social, 
emotional, experience of the 
decision maker 
Strengths 
• - Simple to use 
• - Practical estimations 
• - Considers other relevant  
•    aspects of the decision-   
•    making process (see above) 
Critiques & Limitations 
• - Limited consideration of      
•   emotions 
• - Does not account for  
•   patient’s preferences 
• - Conceptual vagueness 
• - Lack of precision defining     
•   system 1 and 2 
• - Limited neural evidence 
 
Rationale for its application in medicine 
 
Facilitate decisions based on a 
simple clinical parameter 
Overcome the limitations of the 
EUT 
 
* where O is the set of outcomes, PA(o) is the probability of outcome o conditional on A, and 
U(o) is the utility of o.  † where ptt represents testing threshold and prx represents the treatment 
threshold. The probabilities ptt and prx are functions of a decision maker’s attitudes towards 
treatment benefits and harms as well as harms of testing, both derived from type 1 and type 
2 cognitive mechanisms.  
The probability of disease, p can be estimated by statistical evidence, and by the physician’s 
intuition and experience. Further details and examples that exceed this thesis can be found 
elsewhere.(Tsalatsanis et al., 2015)  
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decisions under uncertainty (Davis, McCaffery, Mullan, & Juraskova, 2015; B. 
Djulbegovic et al., 2018; Fargen & Friedman, 2014; Fargen, Leslie-Mazwi, Chen, & 
Hirsch, 2020; Stolper et al., 2011; Tsalatsanis et al., 2015).  More importantly, it 
provides a better framework to explain automatic and deliberate choices under 
uncertainty, also accounting for other relevant components influencing medical 
decisions: social and emotional factors, benefits/harms weight, and physician’s 
experience.  
 
Medical schools and post-graduate training educate physicians to quickly recognize 
patterns or critical aspects of different diseases.(Mamede, van Gog, et al., 2010; 
Prakash et al., 2019; Sibbald, de Bruin, & van Merrienboer, 2013) Physicians apply 
the knowledge they have acquired from previous experience, use information 
available at the time of the assessment, use risk score tools, educational interventions 
or a combination of the above to make automatic or deliberate therapeutic 
decisions.(Gongora-Ortega, Segovia-Bernal, Valdivia-Martinez Jde, Galaviz-DeAnda, 
& Prado-Aguilar, 2012; Meinema, Buwalda, van Etten-Jamaludin, Visser, & van Dijk, 
2019) 
 
What are the brain pathways that facilitate this decision process? 
Studies in decision neuroscience have shown that individuals make goal-directed 
decisions by assigning value to different options, and comparing them to make a 
choice (Hare, Camerer, & Rangel, 2009; Rangel, Camerer, & Montague, 2008). Under 
the DPT, this process occurs under system 2. Participants make goal-directed 
decisions using values computed in the ventromedial prefrontal cortex (vmPFC) (Hare, 
O'Doherty, Camerer, Schultz, & Rangel, 2008; Plassmann, O'Doherty, Shiv, & Rangel, 
2008).  The avoidance of automatic responses (self-control) involves the modulation 
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of value signals encoded in the vmPFC by the dorsolateral prefrontal cortex (DLPFC) 
(Carter & van Veen, 2007; Ochsner & Gross, 2005; Padoa-Schioppa & Assad, 2006).  
The translation of these studies into clinical practice may suggest that physician’s goal-
directed decisions (e.g. ordering a diagnostic, selecting a treatment option) would be 
based on values (e.g. reliability of a test, efficacy of a treatment) computed either in 
the vmPFC or other brain structures. Different brain pathways, involving DLPFC (and 
other brain regions) would modulate automatic medical decisions by either continuing 
with the same treatment (status quo) or making a more valuable treatment choice. To 
the best of my knowledge there are no previous studies assessing value-based 
options among practicing physicians, especially value-based treatment decisions.  
 
In the present work, I elected to use DPT as the theoretical framework to explain 
decisions under uncertainty. As mentioned, DPT helps explain binary choices in the 
medical field (i.e. automatic vs. analytical decisions to treat or not to treat, test or not 
to test), accounts for cognitive biases and personality traits, and includes the 
conceptualization of treatment choices when assessing TI (i.e. treatment escalation 
vs. continuing the same treatment). Furthermore, DPT provides the rationale for 
creation and application of my educational intervention (the “traffic light system”) 
(Saposnik, Mamdani, et al., 2019), the design of our studies, and the background to 
elucidate mechanistic pathways to overcome TI. For example, I show that increased 
arousal is associated with TI.  
 
As our understanding of disease prevention (and progression) continues to be refined 
(particularly in multiple sclerosis), personalized medicine must adapt to account for 
physician’s risk preferences, expertise, and other factors involved in therapeutic 
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decisions (Rotstein & Montalban, 2019; Saposnik, Sempere, et al., 2016a).  The 
present work on therapeutic inertia provides the foundations for future research in this 
area.  
 
1.2 Multiple sclerosis: The paradigm of therapeutic decisions under 
uncertainty 
 
What is Multiple sclerosis and the current treatment?  
Multiple sclerosis (MS) is an autoimmune inflammatory disease of the central nervous 
system (brain, spinal cord) and a leading cause of disability and diminished quality of 
life in young individuals worldwide (Rotstein & Montalban, 2019; Vidal-Jordana & 
Montalban, 2017). MS attacks myelin, the protective covering of the nerves, causing 
inflammation and damage. Myelin is a critical component for the transmission of nerve 
impulses through nerve fibers (Matute-Blanch, Montalban, & Comabella, 2017; 
Rotstein & Montalban, 2019).  
MS can cause symptoms like a lack of coordination, weakness, impaired sensation, 
vision problems, bladder problems, generalized fatigue, cognitive impairment and 
mood changes. Its effects can be physical, emotional, and financial (Burks, Marshall, 
& Ye, 2017; Ernstsson et al., 2016; Giovannoni, 2018; Matute-Blanch et al., 2017). 
The course of MS is typically progressive, characterized by recurrent neurological 
events (e.g. relapses) with complete or partial recovery (Matute-Blanch et al., 2017; 
Rotstein & Montalban, 2019).  
The field of MS research has seen significant changes over the last several years. For 
example, new therapies (i.e. monoclonal antibodies) tested in clinical trials have 
shown to reduce the number of relapses, the number of brain lesions and improving 
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the functional status and quality of life of patients (Feinstein, Freeman, & Lo, 2015; 
Mahad, Trapp, & Lassmann, 2015; Rotstein & Montalban, 2019). Currently, there are 
over 16 approved disease-modifying therapies (DMTs) for MS with varying dosage 
and administration routes (oral, injectable, and infusion), with different safety and 
efficacy profiles. Injectable agents (e.g. interferons, glatiramer) dominated MS care for 
over two decades (Mark S. Freedman, Selchen, Prat, & Giacomini, 2018; Giovannoni, 
2018; Rotstein & Montalban, 2019). Injectable agents for MS promise an 
approximately 30% reduction on the annual relapse rate and have similar risk–benefit 
profiles (e.g. flu-like symptoms being the most common side-effects). The introduction 
of oral agents (e.g. Fingolimod, Dimethyl-fumarate) and new humanised monoclonal 
antibody (e.g. Natalizumab, Alemtuzumab, Ocrelizumab) administered by infusions 
have opened another therapeutic avenue for patients and clinicians. Monoclonal 
antibodies are more effective treatment options (e.g. an ~80% reduction in the annual 
relapse rate) but carry the risks associated with modulation of the immune system 
(e.g. more serious side effects related to infections, risk of a fatal 
leukoencephalopathy, progressive damage or inflammation of the white matter of the 
brain at multiple locations) (D. Ontaneda, Fox, & Chataway, 2015; Sormani & Bruzzi, 
2015). Further details of MS can be found https://mssociety.ca/about-ms/what-is-ms. 
 
The paradigm of therapeutic decisions under uncertainty  
Multiple sclerosis represents an excellent model for the study of treatment decisions 
for chronic and progressive medical conditions under uncertainty (Oh, Vidal-Jordana, 
& Montalban, 2018). The wide availability of treatment options ranging from low 
efficacy/low risk of side effects (e.g. interferons) to high-efficacy/higher risk of serious 
side effects (e.g. monoclonal antibodies), represents a daily challenge that physicians 
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face (Mark S. Freedman et al., 2018; Giovannoni, 2018; Rotstein & Montalban, 2019). 
Given the several ‘unknowns’ (e.g. an individual patient’s response and tolerance of 
side effects under different treatments), each treatment decision bears some degree 
of uncertainty. Physicians’ cognitive biases, beliefs, and risk preferences may also 
influence their therapeutic choices (Blumenthal-Barby & Krieger, 2015; Saposnik, 
Redelmeier, Ruff, & Tobler, 2016).  
 
In this current landscape, physicians strive to balance efficacy and safety with a large 
and diverse therapeutic arsenal. Treatments are tailored based on: i) disease activity 
level (clinical data), ii) individual patient characteristics/preferences, and iii) personal 
expertise/preference (Daniel Ontaneda, Cohn, & Fox).  In this context, it is not 
surprising that the uncertainty related to switching to a new treatment may lead to the 
default choice (e.g. continuing with the ‘known’ treatment profile), or maintaining the 
status quo (e.g. therapeutic inertia) (Fleming, Thomas, & Dolan, 2010; Saposnik & 
Montalban, 2018; Shevchenko, von Helversen, & Scheibehenne, 2014). This scenario 
combining a broad spectrum of treatment options, physician’s cognitive biases, 
management of uncertainty provides a unique opportunity to improve our 
understanding on how physicians make therapeutic decisions. 
 
I have chosen to focus on therapeutic decisions in MS because of well-established 
safety and efficacy profiles amongst first (interferons, glatiramer), second (Fingolimod, 
Cladribine), and third line (monoclonal antibodies) medications in an evolving 




Figure 1. Landscape of MS treatment 
 
 
This figure represents the current landscape of MS treatment. Each box represents first-, 
second- or third-line therapies when consider treatment escalation. Different MS drugs are 
showed represented inside each box. Arrows illustrate the therapeutic range, meaning the 
balance between the efficacy and safety profile. Participants rated the level of agreement with 
this figure using a Likert scale with 0 being the lowest and 10 the highest scores. 
 
Furthermore, I have access to neurologists and MS experts across the world to 
conduct different studies, test my hypothesis, and answer the proposed research 
questions.  However, multiple sclerosis is not the only progressive and chronic medical 
condition, and lessons learned from the study of MS may be extended across medical 
disciplines. Hypertension, diabetes, and high cholesterol represent other highly 
prevalent chronic diseases that lead to the progression of atherosclerosis (buildup of 
fats, cholesterol, and plaque on artery walls). Like MS, there are a broad spectrum of 
treatment options for hypertension, diabetes and high cholesterol (Diaz Rodriguez et 
al., 2014; Lebeau et al., 2014; Lebeau et al., 2016; Manski-Nankervis et al., 2017; 
Mata-Cases et al., 2018; Milman, Joundi, Alotaibi, & Saposnik, 2018). Lessons 




1.3 Therapeutic Inertia in MS care: Conceptualization 
 
Despite recent therapeutic and technologic advances in medicine, we have limited 
information on how physicians make decisions. Medical schools do not properly train 
future doctors in decision making and educate them on risk-management strategies 
(Dijkstra, Pols, Remmelts, Rietzschel, et al., 2015; Mamede et al., 2014). As a result, 
physicians are vulnerable to exhibit cognitive biases that may influence diagnostic and 
therapeutic decisions. One of the most relevant cognitive biases in medicine is the 
status-quo.(Blumenthal-Barby & Krieger, 2015; Fleming et al., 2010; Saposnik, 
Redelmeier, et al., 2016; Thaler & Sunstein, 2008) The most concerning consequence 
of status-quo is therapeutic inertia (TI).(Corathers & DeSalvo, 2020; Redelmeier & 
Shafir, 1995; Ritov & Baron, 1992)  
 
Therapeutic inertia (TI) emerged as a concept to classify suboptimal decisions when 
treatment goals are unmet in three prevalent general medical conditions: 
hypertension, diabetes and chronic obstructive pulmonary disease (Cooke, Sidel, 
Belletti, & Fuhlbrigge, 2012; Khunti et al., 2016; Mata-Cases et al., 2018; Milman et 
al., 2018; Ogura & Harada-Shiba, 2016). The criteria to define ‘unmet therapeutic 
goals or targets’ are based on best practice recommendation guidelines for specific 
medical conditions. TI is being referred as the tendency of physicians to continue the 
same treatment (i.e. status-quo) despite clinical evidence of disease 
progression.(Mohan & Phillips, 2011; Reach, 2014; Saposnik, Sempere, et al., 2016a) 
The invoked explanation for TI, status-quo and other cognitive biases resides in 




TI may be the consequence of physicians’ limited training in risk management and 
formal learning in medical decision-making. TI is a novel concept in MS care. Before 
2016, there were no previous studies evaluating therapeutic inertia and its associated 
factors in MS care (Saposnik, Sempere, et al., 2016a). Given the gaps in the 
conceptualization of therapeutic inertia, I have chosen to focus on TI in MS for this 
work. Previous studies have shown that insufficient knowledge integration and 
knowledge-to-action gaps are among the most common explanations for suboptimal 
therapeutic decisions, medical errors or TI (Fleming et al., 2010; Ioannidis & Lau, 
2001; Maier, Ernst, & Steinhauser, 2019; Makary & Daniel, 2016; O'Connor, Sperl-
Hillen, Johnson, Rush, & Biltz, 2005; Stiegler & Ruskin, 2012).   
 
1.3.1 What are the critical elements to define TI in MS care?  
National and international best practice guidelines have shown that the critical 
elements used to define TI include the clinical course (i.e. the presence of new 
relapses despite being on DMTs), neuroimaging (i.e. presence of new or active lesions 
on a patient’s MRI while being on DMTs) and the functional status of patients (i.e. 
defined by the validated Expanded Disability Status Scale [EDSS]).(Hobart et al., 
2019; Rotstein & Montalban, 2019)  This concept is also known in the MS literature as 
‘no evidence of disease activity’ (NEDA) to illustrate patient’s stability and guide 
treatment (i.e., the combination of lack of a clinical relapse, stable functional status 
and stable MRI suggests an effective treatment response) (Giovannoni, 2018; 
Giovannoni et al., 2015). Conversely, there is consensus that the presence of clinical 
relapse within a time-period and new lesions on MRI warrant treatment escalation. 




Although physicians may also consider other factors when deciding to escalate 
treatment, I lead a recent international study comprising over 300 MS neurologists 
practicing in 25 countries. The study applied a conjoined design and confirmed the 
hierarchy of these three components. Other factors (e.g., age, gender, severity or 
localization of symptoms, pregnancy status) has a much lower (<10%) relative 
importance in therapeutic decisions (Saposnik et al. Manuscript in preparation). As 
shown in Figure 1, the landscape of DMTs for the treatment of MS includes first-line 
therapies (beta interferons, glatiramer acetate, teriflunomide and dimethyl fumarate) 
and second-line therapies (fingolimod) and third-line therapies (monoclonal antibodies 
such as natalizumab, alemtuzumab, ocrelizumab). 
 
The proposed framework of therapeutic decisions in MS care does not consider the 
concept of shared decision-making (SDM), defined as the process by which doctors 
and patients work together to make choices after discussing benefits and risks of 
appropriate treatment options (Glyn Elwyn et al., 2012). Of note, shared decisions 
carry some challenges. For example, a critical aspect of SDM can only take place 
once physicians identify the best course of action before offering and discussing 
treatment options with patients (Hoffmann, Jansen, & Glasziou, 2018; Légaré & 
Witteman, 2013).  The simulated case-scenarios were designed to facilitate binary 
decisions that match clinical practice (therapeutic choices aligned with treatment 
escalation vs. alternatives under the same line of therapy with no treatment 
escalation). As a result, the case-scenarios presented to assess TI should leave 
treatment escalation as the only correct choice for participants.   
 
In summary, the most critical elements that guide physicians towards treatment 
escalation (and thereby towards avoiding TI) include the integration of three 
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components: i) the clinical course, ii) results from neuroimaging, and iii) the functional 
status of patients. The designed simulated-case scenarios to investigate the concept 
of TI were based on internationally accepted and established criteria for treatment 
escalation.  
 
1.3.2 What are the consequences of TI in MS care? 
Previous studies in MS care revealed that a proactive management approach (e.g. 
including earlier use of high-efficacy DMTs and close monitoring of the clinical and 
radiological response to treatment) is associated with slow disease progression, lower 
disability, lesser cognitive impairment, and diminished MRI activity (Duquette, 
Giacomini, Bhan, Hohol, & Schecter, 2016; Noyes & Weinstock-Guttman, 2013; 
Prosperini et al., 2012; Sormani et al., 2013) and lower health care costs (M. S. 
Freedman et al., 2019; Gani et al., 2008). Meta-analysis confirmed that second- and 
third-line DMT are the best available choices for preventing disease progression in 
patients with MS (M. S. Freedman et al., 2019; Tramacere, Del Giovane, Salanti, 
D'Amico, & Filippini, 2015). 
 
In summary, the consequences of TI include increased likelihood of disease 
progression, worsened functional status, loss of independency for activities of daily 
living, higher probability of cognitive impairment with associated increased health care 
costs (M. S. Freedman et al., 2019; Gani et al., 2008; Jongen et al., 2015; McCrone, 
Heslin, Knapp, Bull, & Thompson, 2008; Ness, Haase, et al., 2020; Ness, Schriefer, 





1.3.3 Operational definition of TI in the management of Multiple Sclerosis   
The operational definition of TI in MS includes the combination of evidence of clinical 
relapses and disease activity on the MRI of the brain/spine despite receiving a DMT. 
Scientific organizations and regulatory drug agencies (Federal Drug Agency in the 
United States of America [FDA], European Medicines Agency [MA]) recommend 
treatment escalation from interferons (first-line therapy) to fingolimod or monoclonal 
antibodies in patients who have had at least one clinical relapse in the previous year 
and either 5 or more new lesions or ≥1 gadolinium-enhancing T1 lesion on brain MRI 
(Bermel et al., 2013; Cristiano et al., 2018; Mark S. Freedman et al., 2018; Garcia 
Merino et al., 2017; Prosperini et al., 2014; Rae-Grant et al., 2018; Sormani et al., 
2013). These recommendations are consistent with evidence regarding the risk of 
treatment failure among patients receiving interferon-β (Mark S. Freedman et al., 
2018; Rotstein & Montalban, 2019; Sormani et al., 2016).  
 
1.3.4 Other concepts and operational definitions relevant to my thesis   
Cognitive psychologists suggests that stress, anxiety, and uncertainty trigger the 
expression of biases and personality traits that influence the decision-making process 
(Paulus & Yu, 2012; Platt & Huettel, 2008; L. Zhang, Wang, Zhu, Yu, & Chen, 2015). 
As mentioned, most medical decisions involve uncertainty commonly associated with 
having imperfect information (e.g. diverse clinical presentation for the same condition, 
unknown co-morbid factors, unknown treatment response for an individual, unknown 
medication adherence or tolerance to side effects). In the present work I applied the 
concept of decisions under uncertainty as commonly used by psychologists and 
economists. I assessed several concepts that may influence medical decisions under 
uncertainty, including risk preferences, ambiguity aversion, and physician’s reaction 
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to uncertainty (M. Gerrity, White, DeVellis, & Dittus, 1995; Levy, Snell, Nelson, 
Rustichini, & Glimcher, 2010; Platt & Huettel, 2008).  
Uncertainty comprises two different terms: risk and ambiguity. Ambiguity is a term 
used when the probability of an event or outcome is unknown (Ellsberg, 1961; Platt & 
Huettel, 2008). Aversion to ambiguity is defined as dislike for events with unknown 
probability over events with known probability (Levy et al., 2010). For example, an 
ambiguity-averse individual would rather choose a treatment where the probability of 
benefits or side effects are known (even if these are somewhat unfavourable) over 
one where these probabilities are unknown.  
In contrast, risk involves individual choices when the probability of an outcome is 
known. Risk aversion is defined as the tendency to prefer safe payoffs over 
probabilistic payoffs when the expected value of both options is identical (Camerer & 
Weber, 1992; Levy et al., 2010).  A risk-averse patient would thus prefer a treatment 
that provides a small known improvement with certainty over a treatment that provides 
equal chance of a large improvement or no improvement (50/50). I evaluated risk 
aversion by identifying the safe amount for which a participant was indifferent between 
the safe and the risky option (Christopoulos, Tobler, Bossaerts, Dolan, & Schultz, 
2009). This level is called the certainty equivalent, and reflects the value associated 
with the risky option to facilitate comparison between participants.  
I also used two standardized surveys to assess physicians’ willingness to take risks 
and physician’s tolerance to uncertainty. The German Socio-Economic Panel (SOEP) 
is a comprehensive multi-dimensional survey (and database) that collects information 
to better understand human behavior and decision making in varying social and 
institutional settings and can be compared longitudinally. Although the SOEP survey 
has not been tested as a determinant of medical decisions, previous studies have 
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shown an association between personality traits and social outcomes (Bagnjuk, Konig, 
& Hajek, 2019; Gohlmann, Schmidt, & Tauchmann, 2010; Hajek, Bock, & Konig, 
2017). As a result,  I selected a component from the validated SOEP that specifically 
evaluates participant’s willingness to take risks in different domains (financial matters, 
own health, car driving, own occupation, sports and leisure activities) (Dohmen et al., 
2011).   The second survey measured physicians’ tolerance to  uncertainty in patient 
care, using the physician’s reaction to uncertainty test (M. S. Gerrity, DeVellis, & Earp, 
1990). A shorter version following a factor analysis comprises five questions showing 
reliable psychometric properties (α-Cronbach 0.90). Participants rate the level of 
agreement with the following statements from 0 (strongly disagree) to 5 (strongly 
agree): i) the uncertainty of patient care often troubles me; ii) I find the uncertainty 
involved in patient care disconcerting; iii) I usually feel anxious when I am not sure of 
the diagnosis; iv) uncertainty in patient care makes me uneasy; and v) I am quite 
comfortable with the uncertainty in patient care. Note that the last item is reverse 
coded for consistency. After participants provided a rating for each question, all are 
added to obtain a total score (Cunningham, Bonham, Sellers, Yeh, & Cooper, 2014). 
Previous studies have shown that physician’s low tolerance to uncertainty was 
associated with higher resource utilization and patients being recalled for studies 
(Allison et al., 1998; Carney et al., 2007). Further details of the operational definitions 
for each of these measures are summarized in section 2.2 (Saposnik, Sempere, et al., 
2017). 
 
What is the rationale for using pupil measures in my studies for this thesis?  
Pupil dilation is a marker of autonomic arousal (C.-A. Wang et al., 2018).  Tonic and 
phasic pupil responses are modulated by a constant balance between 
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parasympathetic and sympathetic pathways. From the behavioral perspective, arousal 
states are mediated by the locus coeruleus. fMRI studies showed a correlation 
between pupil size and the activation of the locus coeruleus (Clewett, Huang, Velasco, 
Lee, & Mather, 2018; Peter R Murphy, O'Connell, O'Sullivan, Robertson, & Balsters, 
2014). Importantly, autonomic arousal is an established proxy measure of uncertainty 
(Geng, Blumenfeld, Tyson, & Minzenberg, 2015; Lavin, San Martin, & Rosales Jubal, 
2013; Urai, Braun, & Donner, 2017). Altogether, pupil dilation is a promising indicator 
of how physicians manage uncertainty when making therapeutic decisions. 
Furthermore, pupil dilation could also measure how the TLS educational intervention 
modulates changes in physician’s decisions under uncertainty. 
 
1.4 Five Outstanding questions 
 
I was interested in addressing the following questions:  
 
Question 1: What are the most common cognitive biases and how do they 
affect physicians’ decision-making? More specifically, have there been studies 
on status-quo (also called default bias) in therapeutic decisions?  
The health sector shares commonalities with industrial sectors including vulnerability 
to cognitive biases and human errors.(Stripe, Best, Cole-Harding, Fifield, & 
Talebdoost, 2006; Zeltser & Nash, 2010)  Several cognitive factors and biases affect 
physicians’ thinking process. However, it is not known the prevalence of cognitive 





Question 2: What is the prevalence and what are the most common factors 
associated with TI amongst neurologists with expertise in MS care?  
Therapeutic inertia (TI) is a common phenomenon in the management of chronic 
medical conditions: hypertension, diabetes and chronic obstructive pulmonary disease 
(Cooke et al., 2012; Khunti et al., 2016; Mata-Cases et al., 2018; Milman et al., 2018; 
Ogura & Harada-Shiba, 2016). The most common factors associated with TI were 
related to physician’s training, limited education or expertise in these three medical 
conditions leading to inadequate treatment. I introduced the concept of TI in MS care 
at the beginning of my thesis in 2016.(Saposnik, Sempere, et al., 2016a) The 
consequences of TI include poor patient outcomes, diminished quality of life, and loss 
of productivity.(Gupta, Goren, Phillips, Dangond, & Stewart, 2014; Rotstein & 
Montalban, 2019). My goal was to determine the factors associated with TI in 
neurologists with expertise in MS care.  
 
Question 3: What is the consequence of a physician’s tolerance to uncertainty, 
ambiguity aversion or therapeutic inertia?  
Previous studies have shown that a physician’s low tolerance to uncertainty may lead 
to medical errors (M. S. Gerrity et al., 1990; Yee, Liu, & Grobman, 2014). Status quo 
has also been associated with decisions under uncertainty and medical errors 
(Aberegg, Haponik, & Terry, 2005; Fleming et al., 2010). However, there have been 
no previous studies on the influence of physicians’ tolerance to uncertainty, aversion 





Question 4: What is the efficacy of the traffic light system (TLS) approach to 
ameliorate TI in MS care?  
Educational interventions have been designed to optimize knowledge integration and 
bridge knowledge-to-action gaps for complex medical decisions (e.g. diagnostic 
challenges, varying risk categories, availability of multiple agents with a broad range 
of safety/efficacy ratios) (Dijkstra, Pols, Remmelts, & Brand, 2015). One such 
promising tool was the Traffic Light System (TLS), which links a warning sign (e.g. red 
color) to a prognosis (e.g. risk of disease progression) guiding physicians to make a 
decision (e.g. treatment switch, hospital admission, etc.) (M. S. Murphy & Baker, 2014; 
X. Zhang, Liu, Gu, Wang, & Chen, 2020).   
The TLS relies on a well-established and cross-cultural learned link between a color 
(e.g. red) and an action (e.g. stop, think, make a decision) to modify the natural chain 
of expected events (M. S. Murphy & Baker, 2014; Sonnenberg et al., 2013). It uses 
existing brain pathways such as the inferior frontal gyrus/dorsolateral prefrontal cortex 
(regions implicated in self-control), the posterior cingulate cortex and the ventromedial 
prefrontal cortex implicated in suppressing automatic responses and updating the 
valuation system.(L. Enax, Hu, Trautner, & Weber, 2015; L. Enax, Krapp, Piehl, & 
Weber, 2015).  Using neurocognitive methods, Enax et al. showed that the TLS 
facilitates healthier food choices by interrupting automatic behavior and triggering a 
re-evaluation processes (Laura Enax et al., 2016). An fMRI study showed that TLS 
labels enhance the coupling between brain regions associated with valuation (i.e. 
ventro-medial prefrontal cortex) and self-control (L. Enax, Krapp, et al., 2015).   
Evidence from the literature suggests that medical decisions leading to TI are likely 
related to knowledge-to-action gaps (Gongora-Ortega et al., 2012). The design and 
application of a TLS in MS care would provide a unique opportunity to overcome 
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knowledge-to-action gaps by taking the advantage of existing brain pathways that 
suppress automatic responses and update the valuation system (L. Enax, Hu, et al., 
2015; A. C. Phillips et al., 2016). I therefore designed and tested the feasibility and 
efficacy of a simple educational intervention (supported by a theoretical 
neuroeconomic framework- TLS) in a randomized controlled trial to overcome TI in 
MS care.  
 
Question 5: What is the interaction between an arousal response on the effects 
of an educational intervention (e.g. application of the traffic light system 
approach) to decrease TI in MS?  
My final question aimed to evaluate how the TLS intervention reduce TI and link this 
relationship with the autonomic arousal response via the aforementioned brain 
pathway. Recent studies showed pupil dilation is a marker of central arousal, 
suggesting that individual arousal responsivity may affect decisions under uncertainty 
(Mathot, 2018; Urai et al., 2017). This hypothesis is supported by reports of an 
association between the level of arousal (expressed as phasic pupil response) and 
suboptimal or incorrect decisions in non-therapeutic settings (de Gee, Knapen, & 
Donner, 2014; P. R. Murphy, Vandekerckhove, & Nieuwenhuis, 2014; Urai et al., 
2017). The decision-making process is mediated by the integration of different 
pathways involving the noradrenergic locus coeruleus (a core component of the 
brain’s arousal system), which is directly connected with self-control, automatic 
responses and valuation systems (Cohen, 2005; Ekman & Friesen, 2003; Joshi, Li, 
Kalwani, & Gold, 2016; Mathot, 2018; Phelps, Lempert, & Sokol-Hessner, 2014; C. A. 
Wang & Munoz, 2015). However, it is entirely unclear if and how individual differences 
in arousal responsivity impact treatment decisions in the real world and in real life 
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scenarios. For example, what is the arousal state when expert neurologists are 
exposed to live therapeutic decisions?  I therefore designed an experiment to assess 
differences in arousal responses among expert neurologists while they made 
therapeutic decisions based on auditorily presented simulated case-scenarios. I 
hypothesized that physician’s exposure to uncertainty (elicited by the exposure to 
simulated medical scenarios) would generate an anticipatory arousal response that 
could lead to therapeutic inertia. I hypothesized that the TLS educational intervention 
would ameliorate TI via a reduction in the arousal state of participants.  Participant’s 
expertise, years of practice, and possibly tolerance/aversion to uncertainty and/or 
ambiguity are hypothesized to be cofactors that could contribute to the reduction of TI 
in MS care.  
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2. Summary of the Experimental Approach 
 
To answer these five questions, this thesis draws on four methodological tools: 1) a 
systematic review of the literature regarding the association of physician’s cognitive 
biases and medical decisions; 2) a series of prospective cohort studies to assess most 
common factors associated with TI in expert neurologists; 3) a randomized trial to test 
the efficacy on my behavioral-based educational intervention applying the TLS; and 
4) application of eye-tracking and facial recognition systems to investigate the 
relationship between emotional expressions and TI and arousal state with the TLS and 
TI. I break down these five questions into 6 research studies (Figure 2).  
 
Figure 2.  Integration of research questions, studies, and publications 
 
 
MS: Multiple sclerosis; AA: ambiguity aversion; TI: Therapeutic inertia; TLS: Traffic light system. 
This figure illustrates the integration of the rationale for each study, research questions, 
methodology, and publications related to the present work.  
 
Study 1 focuses on a comprehensive systematic review assessing physician’s 
cognitive biases that may affect medical decisions (Saposnik, Redelmeier, et al., 
2016). Specifically, I have four objectives: 1) identify the most common cognitive 
factors and biases affecting physicians in medical encounters or simulated case-
scenarios, 2) evaluate the influence of cognitive biases on diagnostic accuracy, or 
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therapeutic or management errors, 3) determine their impact on patient outcomes, and 
4) identify literature gaps which could lead to recommendations that advance our 
understanding of therapeutic inertia (see Appendix 1).  
To answer research Questions 2 and 3, I conducted two prospective cohort studies 
(Figure 2). Initially, I assessed factors associated with TI in a cohort of neurologists 
from Spain. I also experimentally assessed the influence of ambiguity aversion and 
physician’s reaction to uncertainty on TI (Saposnik, Sempere, et al., 2017). I then 
tested factors associated with TI in other countries (Argentina, Chile, Canada), 
applying the same study design to verify reproducibility and determine the 
generalizability of my findings (Almusalam et al., 2019). See Appendices 2 and 3.  
 
My fourth research question focused on the development and pilot testing of our TLS- 
based educational intervention (Question # 4, Appendix 4)(Saposnik, Maurino, et al., 
2017). I next assessed the efficacy of the TLS intervention in a larger randomized 
controlled trial (Appendix 5).  
I also tested the acceptance of the TLS intervention by measuring the validated 
usability score (Lewis & Sauro, 2009; Saposnik, Tobler, et al., 2018).  
  
My fifth study focused on evaluating the relationship between arousal states 
(measured by pupil dilation), application of the TLS, and therapeutic decisions. 
Specifically, I was interested in evaluating how the TLS educational intervention 
modified the way physicians manage decisions under uncertainty. As mentioned, 
autonomic arousal (measured by pupil dilation from baseline) is an established proxy 
measure of uncertainty.(Geng et al., 2015; Lavin et al., 2013; Urai et al., 2017) To test 
this relationship, neurologists with expertise in multiple sclerosis used the educational 
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intervention during their evaluation of simulated case-scenarios. I aimed to: i) evaluate 
the relationship between arousal responses and TI, ii) investigate how the validated 
TLS educational intervention (Saposnik, Mamdani, et al., 2019) affected arousal 
responses and TI, and iii) assess whether arousal responses modulated the 
association between the educational intervention and TI (i.e. mediation analysis) (see 
Appendix 6). 
Given that emotions influence decision-making, I also tested the relationship between 
emotions and affective states (as captured by muscle facial activity and emotional 
expressions) and TI amongst neurologists caring for MS patients when making 
therapeutic decisions. I used a validated machine learning algorithm from AFFDEX 
software to code for facial muscle activations, and predefined mapping to emotional 
expressions (disgust, fear, surprise) (Saposnik, Oh, et al., 2019) (see appendix 7).  
Owing to this combination of methods and the sequential design of my studies, I was 
able to investigate these five questions systematically, beginning with the assessment 
of literature gaps followed by the creation and evaluation of the TLS-based educational 
intervention, and concluding by evaluating how physicians handle uncertainty and how 
the TLS intervention change physician’s decisions by measuring arousal responses. 
 
To bring this PhD to completion has required significant persistence through 
adversity. This program was costly, due to the significant number of expert participants 
(e.g. neurologists with expertise in the management of MS) required to test the 
consistency of our results. The total operating funding obtained for completing these 
studies was CHF 232,000 (USD 242,000), which is beyond the equipment and funding 
available at many institutes in the world. As a practicing staff neurologist at St. 
Michael’s Hospital, affiliated to the University of Toronto in Canada, I took a sabbatical 
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year to complete all required credits at UZH. Then, I returned to Canada to complete 
the studies related to my PhD while provide clinical service with educational, clinical 
and research commitments. I had multiple financial and time constraints because as 
a self-funded international PhD student I had to obtained financial support for each of 
the described studies. Furthermore, I carried out the last study (see Appendix 6) by 
myself, including setting-up a mobile eye-tracking lab to assess arousal states and TI.  
Given the limited availability of colleague neurologists to participate on my research 
projects, I recruited expert neurologists from across Canada, which required 
substantial organization and travelling. Finally, there was a single (and costly) software 
provider (iMotions.com) that integrates data on arousal and emotional states with 
simulated case-scenarios and the designed experiments (e.g.: ambiguity aversion, 
risk preferences of participants), as the timing and precision of synchronized time 
points is critical for the interpretation of results. Despite these challenges and 
constraints, the combination of methods and strategic design of the studies have 
provided us a unique insight with practical implications for neuroscientists, clinicians, 
policymakers, and patients with MS. By identifying the determinants of TI, testing the 
efficacy of the TLS- educational intervention to ameliorate the effects of TI, and 
describing the underlying arousal and emotional states associated with TI, I hope to 
improve our current understanding of medical decision-making, and offer practical 
solutions to a common problem that physicians face when making treatment decisions 






2.1 Study 1:  Cognitive Biases associated with Medical Decisions: 
A Systematic Review  
 
Methods: In this primarily narrative systematic review (Saposnik, Redelmeier, et al., 
2016) [Appendix 1], I evaluated existing evidence on the relation between cognitive 
biases affecting physicians and medical decisions. Under the concept of cognitive 
biases (e.g. framing effect, status-quo), I also included personality traits (e.g. aversion 
to risk or ambiguity) that may systematically affect physicians’ judgments or decisions, 
independent of whether or not they result in immediate medical errors. We searched 
MEDLINE and the Cochrane Library databases for relevant articles on cognitive 
biases from 1980 to May 2015. I included studies conducted on physicians that 
evaluated at least one cognitive factor using simulated case scenarios and reported 
an associated outcome written in English. Data quality was assessed by the 
Newcastle-Ottawa scale.  
Over 32 types of cognitive biases have been described (Croskerry, 2003). Importantly, 
some of these may reflect personality traits that could result in choice tendencies that 
are factually wrong, whereas others reflect decisions that are potentially suboptimal, 
although there is no objectively “correct” decision (e.g. risk aversion, tolerance to 
ambiguity). Both factors were included here. This review had four objectives: 1) to 
identify the most common cognitive biases by subjecting physicians to real world 
situations or case-vignettes, 2) to evaluate the influence of cognitive biases on 
diagnostic accuracy and medical errors in management or treatment, 3) to determine 
which cognitive biases have the greatest impact on patient outcomes, and 4) to identify 
literature gaps in this specific area to guide future research. After addressing these 
objectives, I conclude by highlighting the practical implications of our findings and by 
outlining an action plan to advance the field. 
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Results and discussion: Among 114 publications, 20 studies comprising 6810 
physicians met the inclusion criteria. Nineteen cognitive biases were identified.  
All studies found at least one cognitive bias or personality trait to affect physicians. 
Overconfidence, lower tolerance to risk, the anchoring effect, and information and 
availability biases were associated with diagnostic inaccuracies in 36.5% to 77% of 
case-scenarios. Five out of seven (71.4%) studies showed an association between 
cognitive biases and therapeutic or management errors. Of 2 (10%) studies evaluating 
the impact of cognitive biases or personality traits on patient outcomes, only one 
showed that higher tolerance to ambiguity was associated with increased medical 
complications (9.7% vs 6.5%; p =.004). Most studies (60%) targeted cognitive biases 
in diagnostic tasks, fewer focused on treatment or management (35%) and on 
prognosis (10%). Literature gaps include potentially relevant biases (e.g. status-quo, 
aggregate bias, feedback sanction, hindsight bias) not investigated in the included 
studies. Moreover, only 5 (25%) studies used clinical guidelines as the framework to 
determine diagnostic or treatment errors. Most studies (n=12, 60%) were classified as 
low quality.  
More importantly, only 35% of studies provided information on the association 
between cognitive biases or personality traits and medical errors (Baldwin et al., 2005; 
Perneger & Agoritsas, 2011; Redelmeier & Shafir, 1995; Reyna & Lloyd, 2006; Sorum 
et al., 2003; Stiegler & Ruskin, 2012; Yee et al., 2014), with scarce information on their 
impact on patient outcomes, preventing us from making definite conclusions.(Baldwin 
et al., 2005; Yee et al., 2014)  
Our study (Saposnik, Redelmeier, et al., 2016) added relevant information regarding 
the influence of cognitive biases particularly in physicians on diagnostic inaccuracies, 
suboptimal management and therapeutic errors, and patient outcomes. Our first 
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objective allowed the identification of additional biases (e.g. framing effect, decoy 
effect, default bias) and physician’s personality traits (e.g. low tolerance to uncertainty, 
aversion to ambiguity), by including fourteen further studies not previously included in 
a previous systematic review on the same topic (Blumenthal-Barby & Krieger, 2015). 
I also completed a systematic quality assessment of each study using a standardized 
tool and identified gaps related to the influence of cognitive biases on medical errors 
(Wells G et al., 2013).   
 
In summary, I highlighted the importance of recognizing physicians’ personality traits 
and cognitive biases. I acknowledged the substantial literature gaps, limiting our 
understanding of the impact of cognitive biases (especially on the status-quo) and 
physician’s personality traits on medical decisions. Although cognitive biases may 
affect a wide range of physicians (and influence diagnostic accuracy, management, 
and therapeutic decisions), their true prevalence remains unknown. I proposed the 
inclusion of more comprehensive study designs and the specific assessment of status-
quo, ambiguity aversion, and physician’s tolerance to uncertainty to evaluate their 
effects on medical decisions (e.g.: suboptimal decisions, therapeutic inertia) and 
patient outcomes in live simulated case-scenarios. I anticipate that this information 
would provide new insights that may affect patient outcomes (e.g. avoidable 
hospitalizations, complications related to a procedure or medication, request of 
unnecessary tests) by helping practicing physicians attenuate the prevalence of 
suboptimal decisions and medical errors (Andel et al., 2012; Graber, 2013; Stangierski 





2.2 Study 2: Factors associated with Therapeutic Inertia 
 
Methods:  
I first conducted a study among practicing neurologists actively involved in the care of 
patients with MS from across Spain (Saposnik, Sempere, et al., 2017) [Appendix 2]. I 
then replicated this study in Argentina, Chile, Canada and also included a smaller 
sample from Spain (Almusalam et al., 2019) [Appendix 3]. Overall, the studies 
comprised simulated case-scenarios, 3 standardized surveys, and 4 behavioral 
experiments that were designed during my PhD. The simulated MS case-scenarios 
were derived from the most common clinical encounters as identified by experts in the 
field. Behavioral experiments were designed to assess risk and ambiguity aversion in 
the health and financial domains (Anderson & Mellor, 2008; Levy et al., 2010; 
Saposnik, Sempere, et al., 2017). As described, ambiguity aversion is defined as 
dislike for events with unknown probability over events with known probability (Levy et 
al., 2010). Specifically, participants were asked to choose between a visual option with 
known 50/50 probability of winning 400 or 0 Euros versus an option with unknown 
probability of the same outcomes. Grey bars represented the degree to which the 
winning probability was unknown (see Figure 3 below). The degree of ambiguity 
aversion was defined as the proportion of times participants chose the 50/50 option 
over the ambiguous option involving the same outcomes. As the overall level of 
ambiguity aversion was pronounced in this sample (mean 61.7% preference for 50/50 
option, i.e. the option with known probabilities) and to avoid using an arbitrary criterion, 
I classified participants as highly ambiguity averse if they chose the 50/50 (known 
probability) option in each of the nine scenarios (Binmore, Stewart, & Voorhoeve, 
2012). In order to evaluate the consistency of the relationship with the primary 
outcome, I also analyzed another definition of ambiguity aversion (choice of the known 
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probability when facing option 5, instead of the option with 50% unknown probability) 
(Figure 3).  
 
Figure 3. Design of experiments to assess ambiguity aversion  
 
Participants were told to imagine two different types of urns. For urn type A, they knew that 
50% of the balls were red and the other 50% were blue. For urn type B, they did not know the 
exact proportion of blue to red balls, with the grey bar representing the unknown proportion of 
balls ranging from 10 to 90% to represent different degrees of uncertainty across scenarios. 
  
I also assessed risk aversion as another factor that may influence clinical decisions 
(Gross et al., 2003).  Risk aversion is defined as the tendency to prefer safe payoffs 
over probabilistic payoffs when the expected value of both options is identical 
(Camerer & Weber, 1992; Levy et al., 2010).  A risk-averse patient would thus prefer 
a treatment that provides a small improvement with certainty over a treatment that 
provides a larger or no improvement with equal chance (50/50). I evaluated risk 
aversion by identifying the safe amount for which a participant was indifferent between 
the safe and the risky option (Christopoulos et al., 2009). This indifference amount, 
called certainty equivalent, reflects the value associated with the risky option and 
facilitates comparison between participants. For example, participants were asked 
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what would be the minimal certain payoff that they would prefer over the equiprobable 
gamble of winning 400 or 0 Euros (expected value of 200 euros). The degree of risk 
aversion of each individual corresponded to the difference of the expected value of 
the risky option (200 euros) minus the participant’s response (proxy of certainty 
equivalent). A similar visual design and methodology was used to elicit aversion to risk 
and ambiguity in the health domains (Saposnik, Sempere, et al., 2016b). Participants 
were asked to choose between Treatment A (50% probability of survival) or 
“Treatment B” (the probability of survival is unknown) with the grey bars quantifying 
how much is unknown about the probability of survival.  
I also used two standardized surveys to assess physicians’ willingness to take risks 
and tolerance to uncertainty. The German Socio-Economic Panel (SOEP) is a 
validated survey that evaluates willingness to take risks in different domains (financial 
matters, own health, driving, own occupation, etc.) (Dohmen et al., 2011).   I used 
questions of the form: “How would you rate your willingness to take risks in the 
following areas….”? Areas included financial matters, driving, occupation, etc. and 
responses could range from 0 (not at all) to 10 (very much). 
The second survey measured physicians’ tolerance to  uncertainty in patient care, 
using the reaction to uncertainty test (M. S. Gerrity et al., 1990). The short version 
comprises five questions to be rated from 0 to 5 that when added gives a total score 
(Cunningham et al., 2014; M. Gerrity et al., 1995).  Tolerance to uncertainty was 
analyzed as a continuous variable and categorical by the median split of the total 
score.  
The primary outcome of the studies was prevalence of therapeutic inertia represented 
as the proportion of participants with TI in at least one simulated case-scenario.  I also 
created the TI score, which was calculated by dividing the number of case scenarios 
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where participants showed TI over the number of case scenarios that were designed 
to measure TI (n=8). The higher the score the higher the degree of TI (Saposnik, 
Montalban, et al., 2018; Saposnik, Sempere, et al., 2017). Secondary outcome 
measures included the association between tolerance to uncertainty, risk aversion, 
and the SOEP surveys on the one hand with TI and therapeutic decisions on the other 
hand. 
 
Results and discussion:  
In the initial study from across Spain (Saposnik, Sempere, et al., 2017), TI was present 
in 68.8% (66/96) of participants. MS expertise and a higher number of MS patients 
seen per week were associated with a significantly lower risk of TI (p<0.01). Linear 
regression analysis suggests that the assessment of 10 more MS patients per week 
(from a baseline of 16) was associated with lower risk of TI (adjusted coefficient -10.2; 
95%CI -18.4 to -2.0). Ambiguity aversion in the financial domain was associated with 
TI (86.4% vs 63.5%; p=0.042). Given the high correlation between specialty status 
with the number of MS patients seen per week (spearman 0.52; p<0.0001), we kept 
the former in the multivariable models.  
Multivariable logistic regression analysis showed that high aversion to ambiguity in the 
financial domain was the strongest predictor of TI (adjusted OR 7.39; 1.40-38.9). 
Ambiguity aversion in the health domain was not associated with TI (76.9% vs. 65.7%; 
adjusted OR 1.79, 95%CI 0.61-5.25).  
Low tolerance to uncertainty (based on the validated physician’s reaction to 
uncertainty survey) was associated with higher prevalence of TI (85.4% vs. 56.4%; 
adjusted OR 4.73, 1.63-13.7). The association between TI and low tolerance to 
uncertainty was independent of the association between TI and high ambiguity 
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aversion.  Conversely, willingness to take risk in multiple domains (as measured by 
the SOEP survey) were not associated with TI.  
In the comparative study across four countries (Almusalam et al., 2019), 226 
neurologists with expertise in MS care agreed to participate. The completion rate was 
86.3% (195/226). The prevalence of TI was 72.8% (142/195); similar to the previous 
study in Spain (Saposnik, Sempere, et al., 2017). The mean TI score for the 
accountable 8 case-scenarios was 1.68 (±1.5), suggesting that for every 10 case-
scenarios with moderate to high risk of disease progression, there would be two 
suboptimal decisions (e.g. lack of treatment intensification for a more effective drug) 
when warranted by best practice guidelines. The TI score (SD) in the Canadian group 
was significantly lower compared to groups from other countries (0.98 ± 1.15 vs. 1.95 
± 1.52; p<0.001).  
Other than participants’ country of origin, the multivariable analysis revealed that 
higher number of MS patients per week (OR 0.44; 95%CI 0.22-0.88) and years of 
practice (OR 0.93, 95%CI 0.86-0.99) were associated with lower likelihood of TI, 
whereas aversion to ambiguity was associated with two-fold higher likelihood of TI 
(OR 2.25; 95%CI 1.02-5.0) (Almusalam et al., 2019). 
 
In conclusion, these international studies showed that 7 out of 10 neurologists with 
expertise in MS care make suboptimal decisions in at least one out of five simulated 
encounters. The most common factors associated with higher risk of TI included: lower 
expertise in MS care (e.g. lower years of experience and lower number of MS patients 




2.3 Study 3: Overcoming therapeutic inertia 
 
This third group of studies assessed the feasibility and efficacy of my educational 
intervention applying the TLS. I proposed a specific strategy to facilitate physician’s 
identification of patients with disease progression; those who require treatment 
intensification. In the first pilot study, I evaluated the feasibility of the TLS educational 
intervention (Saposnik, Maurino, et al., 2017) [Appendix 4]. In the second, larger study 
I evaluated the efficacy of our educational intervention in reducing TI (Saposnik, 
Mamdani, et al., 2019) [Appendix 5]. 
 
Methods:  
My pilot study (Saposnik, Maurino, et al., 2017) was a double-blind, parallel group, 
randomised clinical trial. Inclusion criteria included neurologists who are actively 
involved in managing MS patients. Participants were exposed to 20 simulated case-
scenarios (10 cases at baseline, and 10 cases post-randomization to usual care vs. 
the TLS educational intervention) with and without evidence of MS progression 
(valence 80%). The educational intervention employed the TLS (See Figure 4 below) 
to facilitate decisions, allowing participants to easily recognize high-risk scenarios 
requiring treatment escalation. The TLS consisted of a short, structured, single 
session intervention of 5 min duration.  
 
The rationale for the design of the TLS was based on the DPT for binary choices in 
therapeutic decisions. The TLS educational intervention would facilitate optimal 
therapeutic responses by decreasing automatic responses attributed to system 1 of 
the DPT and increasing system 2 pathways. For example, simulated case-scenarios 
showing evidence of disease progression would be associated with the red color of 
42 
 
the TLS, which would trigger a warning sign (meaning “a change is needed“), so 
participants would retrieve the value of alternative therapeutic options and escalate 
treatment (See Figure 4 below). In other words, this process would facilitate optimal 
decisions by requiring participants to make a deliberate choice by retrieving the stored 
value of different medications for MS and therefore decreasing TI. 
 
Figure 4: The traffic light system (TLS) educational intervention 
Panel A. TLS based algorithm to guide physician’s treatment decisions in MS care   
 
 
This figure illustrates how the TLS educational intervention facilitates the decision-making 
process using traffic light terminology. Participants were exposed to Panel A with a brief 
introduction of the TLS and then to practice a case-scenario (see Panel B below) to see how 
this educational intervention would work before starting the simulated-case scenarios. The 
TLS system creates a link between a color, a risk level, and an action: red light (“high risk”/ 
“stop and think”), yellow light (“intermediate risk” / “reassess soon”) and green light (“low 
risk”/”continue the same strategy”). The simulated case-scenario provided updated 
information about a patient’s current clinical status and evidence of disease progression. This 
information was coupled with the association of the color “red” and a warning sign (“a change 
is needed”), thereby facilitating treatment escalation and avoiding the status-quo. As a result, 
the TLS educational intervention facilitates optimal therapeutic decisions by decreasing 
automatic responses attributed to system 1 of the DPT and increasing system 2 pathways.  
43 
 
Panel B. Example of simulated case-scenario for the application of the TLS 
 
 
I also measured differences between blocks to invoke decision fatigue. The control 
group responded as they would do in their usual clinical practice not exposed to the 
educational intervention. The primary feasibility outcome was the proportion of 
participants who completed the study and the proportion of participants who correctly 
identified a high-risk case-scenario with the ‘red traffic light’. My target was a 70% 
accuracy rate in the recognition of the ‘red-traffic light’. Secondary outcomes included 
decision fatigue (defined as an increment of TI in the second block of case-scenarios 
compared to the first block) and the efficacy of the educational intervention measured 
as a reduction in TI for MS treatment.  
 
In the larger randomised, controlled trial, 90 participants (neurologists who provide 
care to MS patients) were randomly assigned to the TLS intervention (n=45) or to the 
control group (n=45) (Saposnik, Mamdani, et al., 2019).  I used the same educational 
intervention employing the TLS.  
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The primary outcome was the efficacy of the TLS intervention measured as a reduction 
in TI. I used the TI score as defined in my pilot study: the number of case scenarios in 
which a participant showed TI divided by the total number of case scenarios where TI 
was possible (score ranging from 0 to 1, with higher values representing higher degree 
of TI). Differences greater than or equal to 0.5 in the TI score were deemed as clinically 
meaningful (Saposnik, Mamdani, et al., 2019).  
Furthermore, participants also had to rate each available medication based on the 
efficacy and safety profile using a visual analog scale (0 being the lowest and 10 the 
highest clinical value) representing the contemporary landscape of MS treatment. I 
created a global score representing the sum of 11 available medications (range: 0-
110; with the highest score indicating the highest clinical value). I was interested in 
assessing the association between the global rating of MS treatments and TI. An 
overall high score would reflect physicians’ favorable perception of the differential 
benefits of second- and third-line therapies commonly used for treatment escalation. 
In addition, participants rated a figure representing the current paradigm of treatment 
escalation (i.e. first, second, and third line therapies) (Figure 1). My goal was to 
evaluate the association between physician’s level of agreement with the current 
paradigm of treatment escalation (0 being the lowest and 10 the highest agreement 
with treatment escalation) and the TI score. The proportion of participants showing TI, 
the associations between the global medication score and figure agreement rate with 




Results and discussion:  
In my pilot study, of the 25 participants, 14 were randomly assigned to the control 
group and 11 to the TLS intervention group. TI was present in 72.0% of participants in 
at least one case scenario. For the primary feasibility outcome, the completion rate of 
the study was 100% (25/25 participants). Overall, 77.4% of participants correctly 
identified the ‘red traffic light’ for clinical scenarios with high-risk of disease 
progression. Similarly, 86.4% of participants correctly identified the ‘yellow traffic light’ 
for cases that would require a reassessment within 6 to 12 months.  
For the secondary fatigue outcome, within-group analysis showed a significant 
increased prevalence of TI in the second block of case-scenarios (decision fatigue) 
among participants randomized to the control group (TI pre-intervention 57.1% vs. TI 
post-intervention 71.4%; p=0.015), but not in the active group (TI pre-intervention 
54.6% vs. TI post-intervention 63.6%; p=0.14). For the efficacy outcome, I found a 
non-significant reduction in TI for the targeted intervention compared to controls 
(22.6% vs. 33.9% post-intervention; OR 0.57; 95%CI 0.26-1.22). This non-significant 
difference was expected as this pilot study was underpowered for the efficacy 
outcome. 
I concluded that the TLS educational intervention was feasible and shows some 
promising results in the identification of high-risk scenarios to reduce decision fatigue 
and TI. This pilot study provided the basis for the next step to evaluate the efficacy of 
the TLS in reducing TI. 
The larger randomized trial assessing the efficacy of the TLS showed a significant 
reduction in TI scores in the intervention group (1.47, 95%CI 1.32-1.61) compared to 
controls (1.93; 95%CI 1.79-2.08); p=0.001. Similarly, the TLS group had a lower 
prevalence of TI compared to controls (0.67, 95%CI 0.62-0.71 vs. 0.82, 95%CI 0.78-
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0.86; p=0.001). The mean global medication score was 68.1 (± 11.0), whereas the 
mean agreement rate with figure 1 representing the MS landscape was 8.1 (±1.9).   
The multivariate analysis, adjusted for age, MS expertise, years of practice, and risk 
preference showed a significant reduction in TI for participants randomized to the TLS 
vs control group (β - 0.68, 95%CI: -1.24; -0.11). Specialist status (p=0.002), higher 
years of experience (p=0.007), and ambiguity aversion (p=0.043) were also 
associated with lower TI score. 
Similarly, the multivariable analysis revealed a 70% reduction in TI after the TLS 
intervention compared to controls (OR 0.30; 95%CI 0.10-0.89). The adjusted models 
showed good discrimination (c-statistic=0.74) and calibration (goodness-of-fit test p= 
0.52). The TLS educational intervention consistently lowered TI in the intervention 
group across all TI categories (from participants with low to high TI scores, see Figure 
5B of Appendix 5) (Saposnik, Mamdani, et al., 2019).  
The analysis of individual responses revealed that for every 100 MS patients 
with expected disease progression (e.g. both clinical and radiological evidence of 
disease activity), there will be over 24 patients who will remain with the same treatment 
if managed by neurologists not exposed to the TLS educational intervention (control 
group). That number would be decreased to 10 patients if treated by neurologists who 
received the TLS educational intervention.  
The multivariable analysis adjusted for the pre-specified covariates revealed that a 
higher global medication score was associated with lower TI score (p<0.0001). 
Similarly, a higher level of agreement with figure 1 representing the landscape of MS 
for treatment escalation was also associated with lower TI score (p-value<0.0001). 
These findings suggest that neurologists with a low global score for the MS treatments 
or those who disagree with the current MS treatment landscape had a significant 
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higher likelihood of TI.  For every 10-point increase in the global medication score, 
there was a 2.0% reduction in the TI score.  For every one-point increase in rating the 
MS landscape figure, there was a 11.2% reduction in the TI score.   
The TLS educational intervention was effective among participants with high and low 
global medication scores (p<0.0001). There was a 70.9% (95%CI 43.7%-98.1%) 
reduction in the TI score for participants in the high global medication score group and 
a 41.9% (95%CI 17.2%-66.6%) reduction in the TI score for participants in the low 
global medication score group. Similarly, my educational intervention was effective in 
reducing TI (p<0.0001) among participants who rated figure 1 representing the 
landscape above and below the median score. There was a 65.9% (95%CI 44.5%-
87.2%) reduction in the TI score for participants who highly rated figure 1 and an 
87.8% (95%CI 49.0%-100%) reduction in the TI score for those participants who rated 
the figure 1 below the median score. 
 
There are few proven effective educational interventions to optimize medical decisions 
in the literature. A metanalysis of 44 studies comprising 4380 medical professionals 
showed that cognitive reflection improved diagnostic performance (Prakash et al., 
2019). However, most of these studies were not based on a theoretical neuroeconomic 
framework (G. Elwyn et al., 2011). A Cochrane review showed that decision-aids were 
among the most effective strategies to bring about more informed, value-based 
choices, and improved patient-practitioner communication (Stacey et al., 2017). 
However, there were limited decision-aid tools to assist neurologists in the treatment 
management of patients with MS. 
The TLS offered a unique opportunity to facilitate therapeutic decisions in the medical 
field, in particular in areas with lacking decision-aid tools such as MS care. For 
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example, a TLS-based intervention showed the benefits of triaging children with fever 
by simplifying the decision of hospital admissions based on color-coded risk 
categories.(M. S. Murphy & Baker, 2014) A similar strategy was used in community 
mental health by facilitating early assessment of patients with psychosis.(Ashir & 
Marlowe, 2009)  
I concluded that the TLS educational intervention lowered the incidence of TI in MS 
care irrespective of age, expertise, years for training, and risk preference of 
participants, which would lead to better patients’ outcomes. Participants with low 
perceptions of benefits of the current MS therapies and those with a lower level of 
agreement with the contemporary paradigm of treatment escalation had higher TI. The 
TLS educational intervention was associated with a 68% reduction in the TI score or 
70% reduction in the odds of TI, irrespective of participant’s specialty, years of 
practice, beliefs of the benefits of the current MS therapies and the agreement with 
the paradigm of treatment escalation. In other words, participants exposed to the TLS 
educational intervention appropriately choose a higher efficacy treatment (e.g. 
Monoclonal antibodies) instead of the status-quo related to continuing with the same 
agents (e.g. Glatiramer, Interferon) when evidence of disease progression. The effect 
of my educational intervention was similar for all categories of TI scores.  
 
Usability of the TLS: I also tested the usability of the TLS educational intervention. I 
surveyed 50 neurologists from Chile, Argentina, and Canada to assess the usability of 
our TLS educational intervention using the System Usability Score (SUS) (Lewis & 
Sauro, 2009; Saposnik, Tobler, et al., 2018). The SUS is a validated 10-item 
questionnaire with five response options. The primary outcome was the average and 
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95% confidence interval (CI) of the SUS score. Values above 68 are considered highly 
usable (Bangor, Kortum, & Miller, 2009; Lewis & Sauro, 2009).  
Results and discussion: the average usability score was 74.7 (95%CI 70.1–79.2). 
There was one outlier with a score of 35. The usability score excluding the outlier was 
76.8 (95%CI 72.7–80.8). The multivariate analysis revealed no association between 
participants' characteristics and the SUS score. I concluded that my proven effective 
educational intervention had high usability among neurologists (Saposnik, Tobler, et 
al., 2018).  
 
2.4 Study 4: Autonomic Arousal and Emotional Expressions 
Mediates Treatment Decisions among Physicians 
 
As mentioned, pupil dilation is a marker of autonomic arousal, which is a reliable proxy 
for uncertainty (Geng et al., 2015; Lavin et al., 2013; Urai et al., 2017). Thus, pupil 
dilation might be used as an indicator of how physicians handle uncertainty when 
making therapeutic decisions. In addition, pupil dilation would also indicate how the 
TLS educational intervention induces changes in physician’s decisions under 
uncertainty. 
In the fourth group of studies, I evaluated the relationship between arousal (measured 
by pupil dilation), a proven effective educational intervention, and therapeutic 
decisions amongst neurologists with expertise in multiple sclerosis (MS). Then, I 
explored the relationship between emotions and affective states (as captured by 
muscle facial activity and emotional expressions) and TI in this group of neurologists 





2.4.1 Study on arousal state and TI [Appendix 6] 
The main objectives of this study were: i) to evaluate the relation between arousal 
responses and TI, ii) to investigate how my previously tested and effective educational 
intervention (Saposnik, Mamdani, et al., 2019) affects arousal responses and TI, and 
iii) to assess whether arousal responses mediated the association between the 
educational intervention and TI (i.e. mediation analysis). 
 
Methods: In this randomised controlled trial I enrolled 34 neurologists who cared for 
patients with MS. Participants were randomly assigned to the TLS educational 
intervention (intervention group, see Figure 4) or usual care (control group). 
Participants listened to 20 audio-recorded simulated case-scenarios; 16 simulated 
case-scenarios required treatment escalation and therefore assessed TI, whereas for 
the remaining four cases, treatment escalation was not recommended. All participants 
were exposed to the same case-scenarios presented in random order. All simulated 
case-scenarios were presented auditorily (via headphones connected to the 
computer) to avoid interference of visual stimulation and automatic eye movements 
with pupil responses. Participants sat in a room with standardized illumination (see 
below) with their head fixated by a chin rest and looked at screen while listening to the 
case-scenarios.  Pupil dilation was assessed in time-periods (T) where critical medical 
information was provided (T1: clinical data, T2: neurological status, T3: MRI data).  
The selection of the specific information delivered during those specific time periods 
was based on the current available evidence from the literature (Rotstein & Montalban, 
2019), also supported by our recent worldwide results from a conjoint analysis 
(manuscript in preparation, data available upon request). 
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Arousal was measured as the degree of pupil dilation from baseline. Pupil time-series 
were z-scored to allow comparison of pupil dilation between and within simulated 
case-scenarios, critical time-periods, and participants. The average pupil size 
(measured at T0, i.e., 1500ms - 500ms before scenario onset) was taken as pupil 
baseline (P. R. Murphy et al., 2014). For each simulated case-scenario, I determined 
arousal responses as the time period-specific maximal z-scored pupil dilation minus 
the mean baseline z-scored pupil size during T0 (Mathot, 2018; Privitera, Renninger, 
Carney, Klein, & Aguilar, 2010).  Values greater than 0.1 z-scored difference were 
classified as high arousal periods, following previous research (P. R. Murphy et al., 
2014).   
The primary outcome was therapeutic inertia (TI), defined as lack of treatment 
escalation when warranted based on evidence of disease progression.  
 
Statistical considerations: I applied three analytical approaches: i) comparison of 
arousal responses across critical time-periods, ii) treatment-effect analysis evaluating 
the association between arousal responses and TI, and iii) a mediation analysis to 
assess how the association between individual participant characteristics (e.g.: age, 
expertise in MS, years of practice, risk preferences) and TI may be mediated by 
arousal responses. For (i) I used non-parametric tests (Wilcoxon and Mann-Whitney 
tests for continuous and categorical variables, respectively).  For (ii) I compared high 
vs. low arousal between groups stratified by intervention period (pre- vs. post-
intervention). I used generalized estimating equations (GEE) to assess relationships 
between the variables of interest with TI accounting for clustering (repeated 
observations on participants). I used the following matrix structure: family (binomial), 
link (logit), correlation (exchangeable). This analysis was controlled for the pre-defined 
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explanatory variables, including participant’s age, specialist status (MS expert vs. 
general neurologists), and years of practice, risk preferences, and ambiguity aversion 
as identified in my previous research (Saposnik, Sempere, et al., 2017).  To test the 
treatment effect of the educational intervention (TLS), I used difference-in-differences 
models (also called untreated control group design with pre- and post-test) (Antonakis, 
Bendahan, Jacquart, & Lalive, 2010).  This allowed us to measure the treatment effect 
of the TLS intervention by comparing the change over time (post-test minus pre-test 
performance) between the intervention and control group. Pupil dilation for each 
participants and case-scenario was tested as a mediator (see below). As a result, I 
was able to evaluate whether the benefits of the educational intervention on TI were 
mediated by individual arousal responsivity.  
 
Mediation analysis (iii) is a technique commonly used in the social sciences and 
consumer research to explain a relation between an independent variable (e.g. 
demographic variables) and an outcome via a third variable (called ‘mediator’) (see 
below Figure 5) (MacKinnon, Fairchild, & Fritz, 2007; VanderWeele, 2016).  The 
greatest value of mediation analysis in RCT data is that it can establish whether the 
effects of the intervention (or any independent variable preceding the outcome of 
interest) on the outcome are mediated by another standardized measured covariate. 
Here we measured whether the effect of the TLS intervention on TI is mediated by 
pupil-indexed arousal. The Sobel test determined the significance of the mediation 
effect, where p-values <0.05 indicate a significant mediator (Antonakis et al., 2010).  
I used the two-stage least squares (2SLS) regression approach to test for endogeneity 




Figure 5: Schematic representation of the relationship between autonomic 
arousal the TLS educational intervention and therapeutic inertia in MS care 
 
Schematic representation of generic mediation analysis. The structural equation model 
used for the mediation analysis characterizes the relationship between the independent 
variable X (i.e.: TLS educational intervention) and dependent variables (e.g. age, years of 
practice, MS expert, risk preference) that are related with an outcome of interest Y (TI). The 
mediating variable M (pupil enlargement from baseline) is hypothesized to be intermediate in 
the relation between the educational intervention and TI. This figure illustrates the direct, 
indirect, and total effect of the educational intervention on TI with pupil dilation as the mediator. 
Pupil responses mediated the effect of the intervention on TI. The Sobel test confirmed that 
the mediation effect was significant (p=0.029). The effect of covariates on pupil dilation are 
omitted in the graph for simplicity.  
 
 
Results and discussion: Of 38 potentially eligible participants, 34 (89.4%) 
neurologists completed the study. Before the intervention, there were no differences 
between groups. TI was present in 50.0% (17/34) of all participants. Pupil dilation was 




i) Arousal responses predict therapeutic inertia: I first analyzed differences of pupil 
dilation by time periods. Overall, pupil size increased for each time period relative to 
baseline (F-test for linear regression analysis, all p<0.0001). The results remained 
robust after adjustment for the pre-specified covariates (p<0.0001).  Pupil size 
increased significantly (p<0.0001 adjusted for multiple comparisons, Tukey method) 
across all ten paired combinations of time-period comparisons (e.g. T1 vs. T0, T1 vs. 
T2, T1 vs. T3,….T4 vs. T3), except for the comparison between T1 vs T3 (p=0.96). 
For every additional standard deviation of pupil dilation, the odds of TI increased by 
51% for T1 (95%CI 1.12-2.03), by 31% for T2 (95%CI 1.08-1.59) and by 49% for T3 
(95%CI 1.13-1.97). The intervention significantly reduced TI (RR 31.5%; 95%CI 16.1-
47.0).  
 
ii) Time relative to intervention (pre vs. post) and group allocation (intervention 
vs. control) affect arousal responses:  
Pupil size did not differ significantly between intervention and control groups before 
the intervention but did so after the intervention for T2, T3, and T4 (See appendix 6) 
Overall, the multivariable analysis showed that in the post-intervention period, 
participants in the control group had significantly enlarged pupils compared to the 
intervention group for T2 (p=0.049), T3 (p=0.004), and T4 (p<0.0001). No difference 
was observed for T1 (p=0.47) (see Figure 6 below).  
The analysis of dichotomized pupil response (maximum peak minus mean baseline 
greater than or equal to 0.1 z-scored difference as a high arousal vs. below 0.1 z-
scored difference -low arousal response) showed similar results (see Appendix 6). 
Effect of the educational intervention on TI: I found that participants in the educational 
intervention group had a significant 31.5% (95%CI 16.1-47.0) reduction in TI 
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compared to the control group (See Figure 4 in Appendix 7). Linear regression 
analysis adjusted for participant age, gender, expertise, risk preference and pupil 
dilation showed that for every therapeutic decision, there was a significant TI decrease 
of 5.0% (-5.0%, 95%CI -0.8%, -9.3%) in the intervention group. The difference-in-
difference analysis revealed no evidence for confounding endogenous effects. 
 
Figure 6. Effects of intervention and group allocation on pupil responses  
 
This figure shows pupil-linked 
arousal responses (peak minus 
mean baseline) separately for 
TLS intervention and control 
groups, stratified by the 
intervention period.  
 
* p<0.01 for the comparison of 
pupil responses between control 
and intervention groups.  
 
Note that lower responses in the 
intervention group extend to T4, 
where no critical information was 
provided, which may suggest that 
the protective effect of the 
intervention extends into the 
period when participants made 






iii) Mediation analysis: Arousal responses explained 29.0% of the mediated effect of 
the educational intervention on TI. Other factors (e.g. age, sex, risk preference), had 
a non-significant or a negligible effect. The sensitivity analyses of adding or removing 
covariates (i.e., risk preference, age, sex, academic practice) revealed no significant 
changes in the β coefficients (<10%) of the direct or indirect effects.  
The role of autonomic arousal for therapeutic decision making has so far been entirely 
unexplored. In the present study, I addressed this gap in the framework of therapeutic 
decisions in MS care, with a focus on decisions not to escalate treatment when 
recommended by best practice guidelines. I analyzed pupil dilation as an established 
marker of autonomic arousal (Mathot, 2018; Urai et al., 2017) and found that both 
continuously measured pupil dilation and dichotomized high vs. low phasic pupil 
responses were associated with TI.  Our data suggest that the intervention may 
ameliorate TI by reducing arousal responses to critical information. Indeed, pupil 
dilation mediated the effects of the educational intervention on TI (explaining 29% of 
the total mediated effect).   
Previous studies have shown that uncertainty drives rapid pupil-linked arousal 
responses, affecting behavioral choices (Urai et al., 2017) and updating the valuation 
system based on the presented evidence (de Gee et al., 2014).  Phasic pupil size 
increases are associated with suboptimal or erroneous decisions involving high level 
of uncertainty (Maier et al., 2019; Wessel, Dolan, & Hollingworth, 2018). Similarly, I 
presented critical clinical information delivered during the specific time-periods (T1, 
T2, and T3) simulated MS scenarios to allow participants to update the valuation of 
each treatment option. My results are consistent with this notion. The TLS educational 
intervention may reduce arousal by reducing uncertainty and thereby facilitating 
alternative behavioral strategies. Specifically, the warning function of a red traffic light 
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highlights the need for switching to a more effective treatment (Saposnik, Mamdani, 
et al., 2019) and may concurrently boost confidence in the therapeutic decision. 
These findings improve our current understanding of the link between pupil dilation as 
a marker of an autonomic arousal response and physician’s decisions. Critical 
information (i.e., clinical course, functional status and results of recent brain imaging) 
increases physician’s arousal and stronger arousal responses are associated with 
suboptimal therapeutic decisions (i.e., therapeutic inertia).  
Individual arousal responses mediated the treatment effect of an educational 
intervention and therapeutic decisions in MS care [see Figure 7 below].   
 
Figure 7. Proposed pathways to explain the relationship between my successful 
TLS educational intervention and TI  
 
 
This figure illustrates the proposed integration of autonomic, behavioral (decision-making), 
and participant characteristics associated with TI. The reduction in TI (therapeutic decision) 
by the educational intervention is mediated by lowering the arousal response. Other covariates 
may also directly or indirectly influence TI, but in the present study had negligible or non-
existent effects (mediation effect <3%). 
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Given that I used MS care as a model of complex therapeutic decisions arising in the 
management of chronic diseases, these findings may also apply to other medical 
conditions (e.g. hypertension, diabetes, high cholesterol). 
 
2.4.2 Study on emotional expressions and TI [Appendix 7] 
Emotions play a critical role in our daily decisions (Ekman & Friesen, 2003; Phelps et 
al., 2014). However, it remains unclear how and what sort of emotional expressions 
are associated with therapeutic decisions in multiple sclerosis (MS) care.  
In this study, I evaluated facial muscle activation (and emotional expression) 
associated with therapeutic choices, particularly TI. I also sought to evaluate the 
mediation effect between a physical (e.g. facial muscle activity) or emotional (fear, 
disgust, surprise) response with a therapeutic decision. Given the known associations 
between specific facial muscle activation and emotional expression (anger, fear, 
disgust, surprise, etc.) with an increased attention response that precedes 
participants’ choices (FeldmanHall, Glimcher, Baker, & Phelps, 2016; McDuff, Kodra, 
Kaliouby, & LaFrance, 2017; Stöckli, Schulte-Mecklenbeck, Borer, & Samson, 2018), 
I hypothesized that facial muscle activity (e.g. upper lip raise) and emotional 
expression (disgust, surprise) would increase participants’ awareness and therefore 
mediate the relationship between aversion to ambiguity and TI.  I assessed emotional 
expressions amongst physicians who care for people living with multiple sclerosis 
(MS) as this care model is representative of the paradigm of complex therapeutic 
decisions (e.g. multiple therapeutic options with a broad therapeutic range- e.g. 





Methods: I invited neurologists with expertise in MS to participate in a face-to-face 
study across Canada. Participants answered questions regarding their clinical 
practice, aversion to ambiguity, and the management of 10 simulated case-scenarios. 
I recorded facial muscle activations and their associated emotional expressions during 
the study, while participants made therapeutic choices.  
I used AFFDEX, a machine learning algorithm software that detects emotional 
expressions based on facial muscle activity (iMotions, 2016; Stöckli et al., 2018).  
AFFDEX has been validated in more than 7.5 million faces from over 87 countries 
showing an excellent accuracy (area under the curve greater than 0.9) 
(https://www.affectiva.com/how/how-it-works/, accessed May 6, 2020). This algorithm 
uses different features to identify 34 facial landmarks (e.g. eye corners, eye centers, 
nose tip, mouth corner) with a threshold area, discarding background regions (See 
Appendix 7).  
The region of interest (ROI) contains the whole face including eyes, mouth and nose. 
AFFDEX applies distinct analytical procedures to identify emotional expressions 
(https://developer.affectiva.com/mapping-expressions-to-emotions/) (See figure 8 
below). During this study, facial detection was recorded to analyze each video frame. 
Eye blinking and closure were filtered-out.  Facial muscle activity is the main unit of 
study in emotional expressions. Facial movements are detected and mapped on 
probability values of emotional states (e.g. sadness, joy, disgust, anger, surprise, fear, 
contempt). The probabilities returned by the AFFDEX module range between zero and 
one. A value of zero indicates no evidence and a value of one the highest evidence 
that a certain emotion is fully expressed.(iMotions, 2016)  I used raw values of each 
individual’s facial expression to directly compare amongst participants. This approach 
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mitigates potential errors in the algorithms created to represent emotional expressions 
due to lack of matching with pre-defined facial muscle activity. 
 




This figure illustrates the facial landmarks and regions of interest in AFFDEX software. This 
information is integrated by the iMotions computational software with specific time-points when 
presented the simulated case-scenarios.  
 
I used a proxy measure of participants’ arousal by combining the level of attention (a 
summary measure of the timeframe each participant was looking at the screen) and 
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engagement (a weighted sum of facial expressions). I compared facial muscle activity 
and emotional expressions between participants with and without TI.  
Mixed effects models and mediation analyses were used to evaluate the relationship 
between ambiguity aversion, facial muscle activity/emotional expressions and TI 
measured as a binary variable and a continuous score (Saposnik, Oh, et al., 2019).    
 
Results and discussion: Of 38 invited participants, 34 (89.4%) neurologists 
completed the study. The mean age [standard deviation (SD)] was 44.6 (11.5) years; 
38.3% were female and 58.8% self-identified as MS specialists. Overall, 17 (50%) 
participants showed TI in at least one case-scenario and the mean (SD) TI score was 
0.74 (0.90). Nineteen (55.9%) participants had aversion to ambiguity in the financial 
domain. The multivariate analysis adjusted for age, sex and MS expertise showed that 
aversion to ambiguity in the financial domain (OR 1.56, 95%CI 1.32-1.86) was 
associated with TI.  Most common muscle activations included mouth open (23.4%), 
brow furrow (20.9%), brow raise (17.6%), and eye widening (13.1%). Most common 
emotional expressions included fear (5.1%), disgust (3.2%), sadness (2.9%), and 
surprise (2.8%).  After adjustment for age, sex, and physicians’ expertise, the 
multivariate analysis revealed that brow furrow (OR 1.04; 95%CI 1.003-1.09) and lip 
suck (OR 1.06; 95%CI 1.01-1.11) were associated with an increase in TI prevalence, 
whereas upper lip raise (OR 0.30; 95%CI 0.15-0.59), and chin raise (OR 0.90; 95%CI 
0.83-0.98) were associated with lower likelihood of TI. Disgust and surprise were the 
emotional expressions associated with a lower TI score (disgust: p<0.001; surprise: 
p=0.008) and lower prevalence of TI (ORdisgust: 0.14, 95%CI 0.03-0.65; ORsurprise: 0.66, 
94%CI 0.47-0.92) after adjusting for covariates. The mediation analysis showed that 
brow furrow was a partial mediator explaining 21.2% (95%CI 14.9%-38.9%) of the 
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association between aversion to ambiguity and TI score, followed by nose wrinkle 
12.8% (95%CI 8.9%-23.4%).  Similarly, disgust was the single emotional expression 
(partial mediator) that attenuated (-13.2%, 95%CI -9.2% to -24.3%) the effect of 
aversion to ambiguity on TI.  
 
Previous studies suggest that the neural mechanisms mediating the relation between 
affect and decisions depend on a participant’s emotional arousal and engagement with 
the specific choice to be made. (Phelps et al., 2014) For example, disgust has been 
associated with the activation of the insular cortex which may lead to increased arousal 
modulating the neural responses to aversion to ambiguity, which results in influencing 
subsequent decision-making (Klucken et al., 2012; Mataix-Cols et al., 2008).  Disgust 
was also shown to increase arousal by modulating emotion-specific attention (van 
Hooff, van Buuringen, El M'rabet, de Gier, & van Zalingen, 2014).  This finding is also 
consistent with an increased arousal score associated with disgust (and its muscle 
components) in my study.    
These findings are in keeping with this proposed framework as they support an 
association between facial metrics and emotional expressions (disgust) which may 
increase participant’s awareness/arousal (reflected by increased arousal scores) 
regarding a compelling decision, thereby showing a reduction in ambiguity aversion 
and lowering the likelihood of TI. I concluded that facial metrics (e.g. brow furrow, nose 
wrinkle) and emotional expressions (e.g. disgust) are associated with physicians’ 
choices and partially mediate the effect of aversion to ambiguity on TI (Saposnik, Oh, 
et al., 2019). 
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3. General Discussion 
 
I focused on five key questions: i) the understanding of most common biases (i.e. 
status-quo) and personality traits associated with physicians’ decisions, ii) factors 
associated with TI, iii) the role of ambiguity aversion on TI, iv) the development and 
testing the feasibility and efficacy of my educational intervention using the TLS, and v) 
the arousal state and emotional expressions associated with therapeutic inertia (TI).  
In other words, this work comprises a sequence of studies that started with the 
development of the concept of TI, an outstanding paradigm in daily physicians’ 
decisions. I sought to elucidate factors associated with TI, the roles of arousal 
responses and emotional states on live treatment decisions in MS care. I started with 
the conceptualization of TI and ended by identifying determinants and potential 
mechanisms associated with the likelihood of TI.  
 
3.1 Cognitive biases and physician’s decisions 
 
The recognition of physicians’ cognitive biases are critical to optimize medical 
decisions, prevent medical errors, provide more realistic patient expectations, and 
contribute to decreasing the rising health care costs altogether (Andel et al., 2012; van 
den Berge & Mamede, 2013; Zwaan, Thijs, Wagner, van der Wal, & Timmermans, 
2012).  I addressed my objectives comprising different medical specialties 
(anesthesiology, pathology, obstetrics, pediatrics, occupational health, among others) 
(Baldwin et al., 2005; Crowley et al., 2013; Meyer, Payne, Meeks, Rao, & Singh, 2013; 
Redelmeier & Shafir, 1995; Saposnik et al., 2013; Stiegler & Ruskin, 2012; Yee et al., 
2014). The most critical findings include the high prevalence of cognitive factors and 
biases (i.e., anchoring and framing effects, information biases) and personality traits 
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(e.g. tolerance to uncertainty) among physicians, although a precise magnitude is 
unknown. I was particularly interested in the potential effects of status-quo bias and 
ambiguity aversion on physician’s treatment decisions. There were no studies 
addressing this question. Studies evaluating physicians’ overconfidence, the 
anchoring effect, and information or availability bias suggest an association with 
diagnostic inaccuracies (Bytzer, 2007; Crowley et al., 2013; Friedman et al., 2001; 
Mamede, Schmidt, et al., 2010; Mamede, van Gog, et al., 2010; Meyer et al., 2013; 
Reyna & Lloyd, 2006).  Moreover, anchoring, information bias, overconfidence, 
premature closure, representativeness and confirmation bias may be associated with 
therapeutic or management errors (Perneger & Agoritsas, 2011; Redelmeier & Shafir, 
1995; Sorum et al., 2003; Stiegler & Ruskin, 2012; Yee et al., 2014).  My results were 
in agreement with a previous systematic review (Blumenthal-Barby & Krieger, 2015).  
Misinterpretation of recommendations and lower comfort with uncertainty were 
associated with overutilization of diagnostic tests (e.g. prostate-specific antigen blood 
test for the diagnosis of prostate cancer in men)(Sorum et al., 2003).  Physicians with 
better coping strategies and tolerance to ambiguity could be related to optimal 
management (e.g. lower instrumental vaginal deliveries and lower obstetrical 
errors)(Yee et al., 2014).   
I also found sparse data for addressing the relation between physicians’ cognitive 
factors/biases and patient’s outcomes. Only one study showed higher complications 
(OR 1.51, 95%CI 1.10-2.20) among patients cared for by physicians with higher 
tolerance to ambiguity (Yee et al., 2014).  Finally, I identified gaps in the literature as 
only few (<50%) of an established set of cognitive biases (Croskerry, 2003) were 
assessed. Other listed and relevant biases were not studied (e.g. status-quo bias, 
aggregation bias, feedback sanction, hindsight bias). The quality assessment for the 
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included studies was low to moderate (Saposnik, Redelmeier, et al., 2016). More 
importantly, only 35% of studies provided information on the association between 
cognitive biases or personality traits and medical errors (Baldwin et al., 2005; Perneger 
& Agoritsas, 2011; Redelmeier & Shafir, 1995; Reyna & Lloyd, 2006; Sorum et al., 
2003; Stiegler & Ruskin, 2012; Yee et al., 2014). 
 
In conclusion, although cognitive factors/biases may affect a wide range of physicians 
(and influence diagnostic accuracy, management, and therapeutic decisions), their 
true prevalence remains unknown. Thus, substantial gaps limit our understanding of 
the impact of cognitive factors/biases on medical decisions. I proposed the design of 
more comprehensive studies to evaluate the effect of physicians’ personality traits and 
biases on treatment decisions in live simulated medical encounters. This can be 
accomplished by identifying physician characteristics, combining validated surveys 
and experiments commonly used in behavioral economics to elicit several critical 
personality traits (e.g. tolerance to uncertainty, aversion to risk and ambiguity), and 
cognitive biases (e.g. status-quo, illusion of control). I believe that this information 
would provide new insights that may translate into better outcomes (e.g. avoidable 
hospitalizations, optimized treatment decisions, lower complications related to a 
procedure or medication, request of unnecessary tests) (Andel et al., 2012; Graber, 





3.2 Factors associated with Therapeutic Inertia 
 
Therapeutic decisions are among the most critical tasks made by physicians every 
day (Gurmankin, Baron, Hershey, & Ubel, 2002). Physicians face the challenge to 
tailor treatment based on: i) disease activity level, ii) risk of progression, iii) individual 
patient preferences and characteristics, and iv) personal expertise, in order to identify 
the optimal balance between safety and efficacy profiles of different medications or 
interventions with either imperfect or uncertain information (Blumenthal-Barby & 
Krieger, 2015; Bruck et al., 2013).  
My work focused on physicians-level factors associated with TI. Previous studies 
evaluating the management of different medical conditions (e.g. hypertension, 
diabetes, chronic pulmonary obstructive disease) suggest that 50 to 70% of clinicians 
do not intensify therapy when indicated by best practice guidelines (Mohan & Phillips, 
2011; O'Connor et al., 2005; Okonofua et al., 2006; L. S. Phillips et al., 2001).   
I developed the concept of TI in MS care and conducted a series of studies in different 
countries (e.g. Spain, Argentina, Chile, Canada) to identify the most common 
physician-level factors associated with inertia. 
Total aversion to ambiguity was observed in one out of four participants in my study 
(Saposnik, Mamdani, et al., 2019; Saposnik, Sempere, et al., 2017). I showed that 
ambiguity-averse behavior increased with increasing probability for gains (See 
Appendix 2, Results study, supplemental file).  The most striking finding was that 
aversion to ambiguity in the financial domain was an independent determinant, 
increasing the likelihood of TI by at least two-fold. Neurologists with expertise in the 
care of patients with MS who showed aversion to ambiguity were two- to seven-fold 
more likely to develop TI after accounting for potential confounders (e.g. age, years of 
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practice, expertise, number of patients seen per week, practice setting). This is a new 
contribution to the medical literature.  
Although most of my studies showed that ambiguity aversion in the financial domain 
was associated with an increased likelihood of TI, risk-prone behavior outweighed 
ambiguity aversion in the Canadian cohort. This finding may be due to the smaller 
sample size of studies conducted in Canada (Saposnik, Montalban, et al., 2018). 
Other factors associated with higher TI included less expertise in MS care, as reflected 
by either the low number of MS patients seen per week, or by the specialty status (e.g. 
general neurologists who see patients with MS but are not specialists in this field) 
(Saposnik, Sempere, et al., 2017). Other studies showed better therapeutic decisions 
among neurologists with expertise in MS care (Galea et al., 2013; Hobart et al., 2019).  
Other factors associated with TI included a physician’s low tolerance to uncertainty 
and the country of practice, with Canada having the lowest TI scores in our research 
samples (Almusalam et al., 2019; Saposnik, Sempere, et al., 2017). Neurologists with 
low tolerance to uncertainty had a four-fold higher prevalence of TI (Saposnik, 
Sempere, et al., 2017). Similar results were found in our larger study cohort (p=0.045) 
(Almusalam et al., 2019). These findings are also supported by the association 
between low tolerance to uncertainty and a physician’s lower performance in medical 
residency and among obstetricians (Iannello, Mottini, Tirelli, Riva, & Antonietti, 2017; 
Yee et al., 2014).  
 
My results have practical implications. I showed that either a simple ambiguity aversion 
experiment or a tolerance-to-uncertainty survey (without a medical focus) can help to 
identify TI among neurologists and MS experts with different cultural background, 
education, practice setting and clinical training (Almusalam et al., 2019). This is 
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another contribution to the literature.  Physician’s status quo reflected by the lack of 
treatment escalation may lead to greater disability of MS patients, increasing the 
health care costs, and production losses due to incapacity to work. In Europe, the 
mean annual cost per person with MS has been estimated at €23 000 for EDSS score 
0.0–3.5, rising as disability increases to €46 000 for EDSS score 4.0–6.5 and €77 000 
for EDSS score 7.0–9.5.(Kobelt, Berg, Lindgren, Fredrikson, & Jonsson, 2006) 
Taken together, TI may be explained, at least in part, by: i) the aversion of neurologists 
to escalate treatment when the available options can have more serious side effects; 
ii) neurologist’s knowledge gaps regarding risk profile of new treatments, and iii) status 
quo tendency reflected by participants’ preference to continue with a known 
medication profile vs. the unknown risks of a new agent. Other studies have found that 
TI was associated with lack of training and clinical uncertainty (Kerr et al., 2008). 
Physicians with better coping strategies and more tolerance to ambiguity may be more 
likely to choose optimal treatments leading to better patients’ outcomes (Yee et al., 
2014). 
These results lead to my next question: given the magnitude of clinical inertia, can I 
design an effective educational intervention to overcome the effects of TI?  
 
3.3 The Traffic Light System educational intervention ameliorates TI 
 
I started by designing a behavioral-based educational intervention applying the traffic 
light system (TLS). Each color of the TLS provides a heuristic cue by facilitating the 
recognition of a difficult situation that prompts a decision (Figure 4). TLS systems 
couple the color red with a risky situation (e.g. disease progression if treatment is not 
intensified) that should prompt a behavioral change: the selection of a new medication 
to intensify treatment. Previous studies using fMRI revealed the existing brain regions  
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associated with valuation (i.e. ventro-medial prefrontal cortex) and self-control (L. 
Enax, Krapp, et al., 2015). As such, the TLS would help optimize treatment decisions 
by interrupting the automatic status-quo state by triggering a re-evaluation processes 
elicited by the universal warning sign of the color red (Laura Enax et al., 2016). 
Research studies show optimal food selection when adding color-labels to products 
with unhealthy components (e.g. high glucose, high sodium, high cholesterol) (Laura 
Enax et al., 2016; L. Enax, Krapp, et al., 2015; Orriols et al., 2010; X. Zhang et al., 
2020). Similar findings were observed in the decision to admit children with fever by 
guiding pediatricians regarding the course of action (M. S. Murphy & Baker, 2014).  
In the pilot study conducted among neurologists from Spain to assess the feasibility of 
the TLS-based educational intervention, I showed feasibility with a 100% completion 
rate and promising results with a non-significant 43% reduction in TI post-intervention. 
These results lead to my larger randomized controlled trial, which assessed the 
efficacy of the TLS educational intervention in reducing TI among 90 neurologists from 
Argentina. Although similar (and more complex) strategies to facilitate treatment 
decisions in MS care exist, our intervention is the only one that has been empirically 
tested (M. S. Freedman et al., 2013; Stangel et al., 2014).   
The TLS educational intervention was associated with 70% reduction in the odds of 
TI. In other words, participants identified the red traffic light as a risky clinical situation 
for disease progression and chose a higher efficacy treatment (e.g. Monoclonal 
antibodies) instead of continuing with the same non-effective medications (e.g. 
Glatiramer, Interferon). The effect of the TLS educational intervention was similar for 
all categories of TI scores. My results were robust at the participant level and when 
analyzing individual responses for both outcome definitions of TI (categories of TI and 
TI score)(Saposnik, Mamdani, et al., 2019).  
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There are few effective interventions in medical education that are associated with 
improvements in clinically meaningful outcomes (Albarqouni, Hoffmann, & Glasziou, 
2018). A recent systematic review evaluated 302 controlled studies that investigated 
the effect of evidence-based educational interventions. Of 85 articles that met the 
inclusion criteria, 46 (54%) studies were randomised trials, and 51 (60%) included 
postgraduate level participants. Although the authors evaluated outcomes in multiple 
domains (e.g. self-efficacy, knowledge, behavior change), none of the studies 
assessed the benefit to patients (Albarqouni et al., 2018). To the best of my 
knowledge, the TLS constitutes the first effective educational intervention based on 
existing brain pathways that is supported by a theoretical framework (e.g.: dual 
process theory) (Evans, 2003; Tversky & Kahneman, 1974, 1981).  
 
In the evolving landscape of MS treatment, new and more effective agents with 
improvements in safety profiles are becoming available (Saposnik & Montalban, 
2018). Despite such advances, many MS patients remain undertreated (Montalban et 
al., 2018; Rae-Grant et al., 2018). Our results suggest that the TLS is a useful medical 
educational intervention, in-keeping with previous research showing better outcomes 
in the management of obesity, children with fever presenting to emergency rooms, 
and the selection of healthy food choices (M. S. Murphy & Baker, 2014; Sonnenberg 
et al., 2013). 
 
In conclusion, I pilot-tested the feasibility and then assessed the efficacy of the TLS 
educational intervention. I found a significant 70% reduction of TI with our TLS 
intervention, irrespective of participants medical education, practice settings and 
perception of the current treatment landscape in MS care. The TLS educational 
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intervention facilitates optimal therapeutic decisions by decreasing automatic 
responses (attributed to system 1 of the DPT), and increasing system 2 pathways 
through detection of the color red (“a change is needed“), facilitating the retrieval and 
evaluation of alternative therapeutic options, culminating in treatment escalation 
(moving away from the automatic responses associated with TI). 
 
These findings have practical clinical and health policy implications, which may not 
only lead to improved patient outcomes, but also lead to the implementation of 
educational interventions in physicians managing high-risk and complex patients. The 
TLS intervention has the potential to be translated to other highly prevalent medical 
conditions, including the management of hypertension, diabetes, and dyslipidemia 
commonly affecting individuals at high-risk of cardio- and cerebrovascular diseases.   
 
3.4 Autonomic Arousal Mediates Biased Treatment Decisions  
 
Upon demonstrating feasibility, usability, and efficacy of the educational intervention, 
I was interested in understanding how the TLS would reduce TI, including an 
evaluation of the role of emotional expressions on TI.  Several research groups have 
shown that task-evoked changes in pupil size correlate with different cognitive 
processes, including conflict processing, surprise, target detection, working memory, 
attention, and awareness (Geng et al., 2015; Lavin et al., 2013; Preuschoff, t Hart, & 
Einhauser, 2011; Privitera et al., 2010).  Geng et al. showed that evoked-pupil 
diameter reflects uncertainty during attentional selection, and that uncertainty initiates 
the involvement of prefrontal cognitive control mechanisms to help disambiguate 
sensory information and determine the correct response (Geng et al., 2015). Others 
have shown that uncertainty may trigger rapid pupil-linked arousal responses, 
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affecting behavioral choices (Urai et al., 2017) and  evaluation of newly presented 
evidence (de Gee et al., 2014).  My educational intervention may reduce arousal by 
decreasing uncertainty about the best course of action, and thereby facilitate 
alternative decision strategies instead of the status-quo.  
 
I was also cognisant of the influence of emotions on therapeutic decisions, which is 
largely an unexplored field. To the best of my knowledge (based on a literature review 
conducted on May 15, 2020), no studies have evaluated facial muscle activation and 
emotional expression among physicians making decisions. By using a machine 
learning algorithm software (AFFDEX) that detects emotional expressions based on 
facial muscle activity, I analyzed facial muscle activation and the emotional 
expressions of neurologists while they were making therapeutic decisions. I found that 
emotional expressions (e.g. disgust and surprise) were associated with lower TI. I also 
recorded which facial manifestations of emotional expressions were associated with 
TI. Disgust was the single emotion that attenuated the effect of aversion to ambiguity 
in the financial domain on TI. Disgust has been associated with the activation of the 
insular cortex, which may lead to increased arousal and modulate the neural response 
to aversion to ambiguity (influencing subsequent decision-making) (Klucken et al., 
2012; Mataix-Cols et al., 2008).  Disgust was also shown to increase arousal by 
modulating emotion-specific attention (van Hooff et al., 2014).  These findings were 
also consistent with an increased arousal score associated with disgust (and its 
muscle components) in my study.    
Traditionally, the striatum, the amygdala, the medial prefrontal, orbitofrontal and 
insular cortices are thought to process emotional aspects of the decision-making 
process (Lerner, Li, Valdesolo, & Kassam, 2015; Phelps et al., 2014). Moreover, the 
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dorsolateral and anterior prefrontal cortices and the posterior parietal cortex may 
modulate cognitive aspects of decisions (Cohen, 2005). Previous studies have shown 
that stress reduces activity in the dorsolateral and orbital parts of the prefrontal cortex 
while enhancing amygdala activity, leading to decreased goal-directed behavior and 
increased emotional responses (e.g. fear, disgust, contempt) (Otto, Misra, Prasad, & 
McRae, 2014; Sokol-Hessner, Camerer, & Phelps, 2013).  My findings are in keeping 
with this proposed framework, as they support an association between facial metrics 
and emotional expressions (disgust), increasing a participant’s awareness/arousal, 
and reducing ambiguity aversion/lowering the likelihood of TI. I hypothesize that the 
TLS educational intervention decreases the stress associated uncertainty related to 
treatment options, thus increasing goal-directed behavior (i.e. treatment escalation) 
and decreasing emotional responses (e.g. fear, disgust, contempt) associated with TI.  
Taken together, these findings suggest that interventions reducing TI may partly rely 
on emotional factors (Saposnik, Maurino, et al., 2017) and arousal responses, which 
both play a more important role in medical decision-making than hitherto assumed. 
Given the limited training most physicians undergo in risk management and medical 
decision-making, my results support the notion that physicians are vulnerable when 
handling decisions under uncertainty, especially if they have an aversion to ambiguity 
(Dijkstra, Pols, Remmelts, & Brand, 2015; Kostopoulou, Russo, Keenan, Delaney, & 
Douiri, 2012; Monrouxe et al., 2017).  
These findings also have practical clinical implications. Using the autonomic arousal 
response as a marker of effectiveness, I was able to identify 25% of physicians making 
suboptimal decisions and estimate the inertia-reducing benefits of novel educational 
interventions. Consequently, these results open avenues to tailor educational 
interventions and formal risk-assessment training to decision makers (medical 
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students, family doctors, and specialists) and conditions. In the future, this approach 
may help optimize therapeutic decisions for other more prevalent chronic diseases 
(e.g. hypertension, diabetes) leading to better clinical outcomes and improved medical 
education.    
In summary, the critical medical information commonly used by physicians to make 
complex treatment decisions (i.e., clinical course, functional status of the patient and 
results of recent brain imaging), triggers an increased arousal response, which are 
associated with suboptimal therapeutic decisions (i.e., therapeutic inertia). Moreover, 
the inertia-reducing effects of an educational intervention appear to be mediated by a 
reduction in the arousal state. The second study confirms our findings from two 
observational studies (Saposnik, Mamdani, et al., 2019; Saposnik, Sempere, et al., 
2017) that ambiguity aversion is associated with an increased TI (Saposnik, Oh, et al., 
2019). I showed an association between emotional expressions (i.e. disgust), 
ambiguity aversion, and TI. For example, disgust may reduce the effects of ambiguity 




The described studies have several limitations that deserve comment. First, although 
my aimed was to be as systematic as possible in reviewing the literature, I cannot rule 
out involuntary omissions (Saposnik, Redelmeier, et al., 2016). I was not able to 
conduct a meta-analysis due to significant differences in study design, diversity of 
definitions and data reported, outcome measures, and the overall small number of 
studies evaluating specific cognitive factors or biases. Second, as described in the 
literature most of the studies were based on simulated case-scenarios, which may not 
truly reflect therapeutic decisions in clinical practice. Third, some of my studies 
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(Saposnik, Maurino, et al., 2017; Saposnik, Oh, et al., 2019) had a small sample size, 
which may affect the precision of estimated coefficients and the generalizability of the 
results. Fourth, the variability of participant’s characteristics, practice settings, and 
level of education may explain some disparities when cross-comparing studies 
conducted in different countries (Almusalam et al., 2019; Saposnik, Sempere, et al., 
2017).  Fifth, I have no information regarding the long-term benefits of the TLS 
education intervention on TI given the study design.  Future research will be needed 
to investigate this question. Sixth, as mentioned, most of studies included in this thesis 
do not consider the concept of shared decision-making. However, shared decisions 
can only take place once physicians identify the best course of action before 
discussing appropriate treatment options with patients.   Seventh, pupil size is not a 
standard measure in clinical practice. As a result, my study should be interpreted as a 
proof-of-concept, suggesting that there is value in testing this metric in future studies. 
Eighth, arousal responses may have different triggers and effects than the ones I 
tested and be dependent on sensory modality (e.g. auditory vs. visual presentation of 
case-scenarios) and educational strategy. Furthermore, I tested arousal responses 
related to our designed TLS intervention, which may differ from autonomic responses 
associated with other educational interventions or tested by other methods (i.e.; 
galvanic skin responses, heart rate variability). Ninth, despite the extensive validation 
of the AFFDEX software, the association between emotional states and TI may require 
further assessment given the high variability of muscle group activations that are 
mapped to emotional expressions. It is possible that other emotions may influence TI 
but were not detected in our study due to lack of power.  As such, my results should 
be interpreted with caution considering there are no other similar studies available for 
comparison. Despite these limitations, my studies provide critical information on the 
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foundations of therapeutic decisions among practicing physicians, how they handle 
uncertainty and a proven strategy to overcome TI.  
 
3.6 Future Directions 
 
My work provides critical information on the foundations of therapeutic inertia. By 
elucidating cognitive biases and factors associated with TI (and developing an 
effective educational intervention), my studies open opportunities for investigation in 
behavioral sciences, clinical research, guideline-based decisions, and medical 
education.(Schwartz, 2011, 2013) For example, further studies may facilitate the 
identification of physicians at high risk of having TI by evaluating physical, emotional, 
and behavioral responses, such that educational interventions can be tailored to these 
individuals. These results also raise further questions in translational research. For 
example, future studies using fMRI and computational modelling would provide 
information regarding the location of encoded values for therapeutic decisions and the 
underlying brain pathways (e.g. involvement of the DLPFC, vmPFC, locus coeruleus 
and amygdala) associated with TI. For example, I would evaluate the specific brain 
pathways associated with the implementation of the TLS system using fMRI.  My work 
on therapeutic inertia provides the foundations for future research in this area.  
Another crucial next step would be to translate this knowledge into the development 
of programs in medical education. For example, the addition of new courses that 
integrate risk management strategies with the learned foundations on therapeutic 
decisions in graduate and postgraduate medical education could foster more optimal 
decision-making and overcome current clinical gaps.  
Another consideration is the application of biosensors and wearable devices already 
implemented in patient care for diagnostic and therapeutic decisions (Carroll, 
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Kobylecki, Silverdale, Thomas, & group, 2019; Lambert, Bumgarner, & Tarakji, 2019; 
Lown et al., 2020; Semaan et al., 2020). Advances in eye-tracking and biosensor 
technologies, machine learning, and artificial intelligence may lead to the creation of 
hardware and software to warn of suboptimal decisions by relying on live autonomic 
arousal responses in routine clinical practice.  Although this idea may not be feasible 
at the present time, developing technology that incorporates augmented reality using 
smart glasses or wearable biosensors (tested in consumer research; (Muhammad 
Sayem, Hon Teay, Shahariar, Fink, & Albarbar, 2020; Peake, Kerr, & Sullivan, 2018))  
could facilitate the application of color-coded warning signs (either based on pupil or 
heart rate variability as markers of central arousal) to assist physicians with diagnostic 
and therapeutic decisions (Shi, Zhao, Liu, Gao, & Dou, 2019). Given the unconscious 
process of autonomic responses (triggered by new information presented in medical 
encounters), which usually precedes clinical decisions, this approach would bring 
another layer of safety to prevent medical errors.    
I expect that the implementation of these strategies could result in better medical 
decisions and result in improved patient outcomes (e.g. lower disability, better quality 
of life), more effective and patient-oriented clinical encounters, and lower health care 




4. General Conclusion 
 
• Making decisions in medical care is a difficult task involving a variety of cognitive 
processes (Glimcher & Fehr, 2014). Decisions based on erroneous assessments 
may result in unrealistic patient and family expectations, suboptimal advice, and 
incorrect treatment. Suboptimal decision making and medical errors are exemplified 
by the concept of therapeutic inertia (TI). 
• How doctors handle uncertainty (e.g. having imperfect information, an unknown 
treatment response for a particular patient, personal cognitive biases or personality 
traits) is highly relevant to therapeutic decision-making (Kerr et al., 2008; Levy et 
al., 2010; Mohan & Phillips, 2011; Reach, 2014; Saposnik, Mamdani, et al., 2019; 
Saposnik, Sempere, et al., 2017; Saposnik, Sempere, et al., 2016a). 
• Given that most therapeutic choices are binary, I used the framework provided by 
the DPT to explain medical decisions under uncertainty, incorporating physician’s 
cognitive biases, risk preferences, and ambiguity aversion.    
• Multiple sclerosis is a paradigm of complex treatment decisions due to the 
increasingly broad landscape of medications with different efficacy and safety 
profiles, which makes it an ideal condition in which to evaluate TI.  
• The central question of this thesis revolves around how physicians handle 
uncertainty and how they can avoid making suboptimal decisions. I broke down this 
problem into five specific inquiries with the following conclusions:   
o Are cognitive biases common? Our systematic review found that cognitive 
biases and personality traits affect over 50% of practicing physicians across 
different specialties and highlighted literature gaps related to the impact of 
status-quo and aversion to ambiguity on treatment decisions. 
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o What is the prevalence and what are the most common factors associated with 
TI? How does physician’s aversion to ambiguity and low tolerance to uncertainty 
influence their treatment choices? I found that TI is a common phenomenon 
affecting over 60% of physicians who care for patients with different chronic 
medical conditions, and 60-90% of MS neurologists. TI is evident in nearly one 
out of four treatment decisions with correspondingly negative consequences for 
patients and the health care system (Almusalam et al., 2019; Saposnik, 
Mamdani, et al., 2019; Saposnik, Sempere, et al., 2017).  Neurologists’ aversion 
to ambiguity, low tolerance to uncertainty, and expertise are the most common 
physician-level determinants of TI.  
o What can be done to ameliorate the effects of TI? Our innovative TLS 
educational intervention was designed to take advantage of an existing learned 
pathway that couples the color red with a learned warning sign, and prevents 
automatic responses related to the status-quo (no treatment change when 
warranted by best practice recommendations) (L. Enax, Krapp, et al., 2015; 
Saposnik, Mamdani, et al., 2019; X. Zhang et al., 2020). In a randomized 
controlled trial, our TLS educational intervention decreased the likelihood of TI 
by 70% (Saposnik, Mamdani, et al., 2019). The effects of the TLS were 
independent of demographic factors, physician’s expertise, practice setting, and 
different perceptions about the current available treatment.  
o Physician’s favorable ratings of the benefits of MS medications (measured by 
the global medication score) and level of agreement with the paradigm with 
treatment escalation were associated with lower TI.  
o The TLS educational intervention would facilitate optimal therapeutic responses 
by decreasing automatic responses attributed to system 1 of the DPT, and 
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increasing the following system 2 pathways: a simulated case-scenario showing 
evidence of disease progression → identification of red color of the TLS → 
triggers a warning sign (“a change is needed“) → retrieval of the value 
associated with alternative therapeutic options → treatment escalation (moving 
away from continuation with the same treatment as represented by TI).    
o What is the relationship between our successful TLS educational intervention, 
arousal responses, emotional expressions, and TI?  I observed that i) critical 
medical information provided in specific time-periods during the presentation of 
simulated case-scenarios elicited a phasic arousal response across all 
participants in the pre-intervention period, ii) the control group had a significant 
pupil enlargement in the post-intervention period when comparing TLS 
intervention groups for most critical time periods, iii) despite the limited power of 
this study, the difference-in-differences analysis revealed a significant 31.5% 
(95%CI 16.1-47.0) reduction in TI if neurologists were exposed to the 
educational intervention, and iv) arousal responses regulate the treatment effect 
of our TLS educational intervention and therapeutic decisions in MS care.  
o The role of emotions in decision-making cannot be ignored. When applying a 
validated machine learning algorithm, disgust and surprise were associated with 
a lower TI. It is possible that other emotions that were less frequently expressed 
in our study also play a role in decreasing TI.   
 
• The results of my studies suggest that pupil dilation, a marker of central arousal, is 
an indicator of how physicians handle uncertainty when making therapeutic 
decisions. The arousal response also mediates how the TLS-based educational 




• In other words, the TLS educational intervention decreases the stress associated 
with uncertainty related to treatment options, thus increasing goal-directed behavior 
(i.e. treatment escalation) and decreasing emotional responses (e.g. fear, disgust, 
contempt) associated with TI. 
• An optimal treatment choice is based on the assessment of the benefits and side 
effects (risks) of a specific medication, with the overarching goal of patients 
achieving the best possible outcome for patients. The decision to continue with the 
same medication (i.e. TI) or escalate to a more efficacious treatment is based on 
computations of medications value commonly influence by ambiguity aversion, 
physician’s expertise, and regulatory aspects of the country of practice.  
• The findings of my studies have practical clinical implications in patient care, post-
graduate medical education, and health policy.  We are now able to identify how 
physicians manage uncertainty when making treatment decisions.  We can estimate 
the inertia-reducing benefits of our novel TLS educational intervention and use the 
autonomic arousal response as a marker of their effectiveness that is unaffected by 
demand effects or cognitive biases. Consequently, these findings open avenues to 
tailor educational interventions and formal risk-assessment training to decision 
makers (medical students, family doctors, and specialists) and conditions. 
Furthermore, the public, patients and their families may demand a formal training in 
medical decision-making (e.g. increased awareness of biases, foundations of TI, 
decision-theory) of future doctors enrolled at medical schools. In the future, this 
approach may help optimize long-term therapeutic decisions for other and more 
prevalent chronic diseases (e.g. hypertension, diabetes, high cholesterol) leading 




• As a corollary of my studies, physicians should update their evaluation of treatment 
options based on new clinical information provided by simulated MS scenarios.  
• I hope that these results increase awareness among health care providers, patients 
and their families, and policymakers to recognize the importance of identifying 
factors influencing physician’s decisions, understanding how they handle 
uncertainty and implementing strategies to ameliorate TI and avoid medical errors.  
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Abstract
Background: Cognitive biases and personality traits (aversion to risk or ambiguity) may lead to diagnostic
inaccuracies and medical errors resulting in mismanagement or inadequate utilization of resources. We conducted a
systematic review with four objectives: 1) to identify the most common cognitive biases, 2) to evaluate the
influence of cognitive biases on diagnostic accuracy or management errors, 3) to determine their impact on patient
outcomes, and 4) to identify literature gaps.
Methods: We searched MEDLINE and the Cochrane Library databases for relevant articles on cognitive biases from
1980 to May 2015. We included studies conducted in physicians that evaluated at least one cognitive factor using
case-vignettes or real scenarios and reported an associated outcome written in English. Data quality was assessed
by the Newcastle-Ottawa scale. Among 114 publications, 20 studies comprising 6810 physicians met the inclusion
criteria. Nineteen cognitive biases were identified.
Results: All studies found at least one cognitive bias or personality trait to affect physicians. Overconfidence, lower
tolerance to risk, the anchoring effect, and information and availability biases were associated with diagnostic
inaccuracies in 36.5 to 77 % of case-scenarios. Five out of seven (71.4 %) studies showed an association between
cognitive biases and therapeutic or management errors. Of two (10 %) studies evaluating the impact of cognitive
biases or personality traits on patient outcomes, only one showed that higher tolerance to ambiguity was
associated with increased medical complications (9.7 % vs 6.5 %; p = .004). Most studies (60 %) targeted cognitive
biases in diagnostic tasks, fewer focused on treatment or management (35 %) and on prognosis (10 %). Literature
gaps include potentially relevant biases (e.g. aggregate bias, feedback sanction, hindsight bias) not investigated in
the included studies. Moreover, only five (25 %) studies used clinical guidelines as the framework to determine
diagnostic or treatment errors. Most studies (n = 12, 60 %) were classified as low quality.
Conclusions: Overconfidence, the anchoring effect, information and availability bias, and tolerance to risk may be
associated with diagnostic inaccuracies or suboptimal management. More comprehensive studies are needed to
determine the prevalence of cognitive biases and personality traits and their potential impact on physicians’
decisions, medical errors, and patient outcomes.
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Background
Medical errors occur in 1.7-6.5 % of all hospital
admissions causing up to 100,000 unnecessary deaths
each year, and perhaps one million in excess injuries in
the USA [1, 2]. In 2008, medical errors cost the USA
$19.5 billion [3]. The incremental cost associated with
the average event was about US$ 4685 and an increased
length of stay of about 4.6 days. The ultimate conse-
quences of medical errors include avoidable hospitaliza-
tions, medication underuse and overuse, and wasted
resources that may lead to patients’ harm [4, 5].
Kahneman and Tversky introduced a dual-system
theoretical framework to explain judgments, decisions
under uncertainty, and cognitive biases. System 1 refers
to an automatic, intuitive, unconscious, fast, and
effortless or routine mechanism to make most common
decisions (Fig. 1). Conversely, system 2 makes deliberate
decisions, which are non-programmed, conscious,
usually slow and effortful [6]. It has been suggested that
most cognitive biases are likely due to the overuse of
system 1 or when system 1 overrides system 2 [7–9]. In
this framework, techniques that enhance system 2 could
counteract these biases and thereby improve diagnostic
accuracy and decrease management errors.
Concerns about cognitive biases are not unique to
medicine. Previous studies showed the influence of cog-
nitive biases on decisions inducing errors in other fields
(e.g., aeronautic industry, factory production) [10, 11].
For example, a study investigating failures and accidents
identified that over 90 % of air traffic control system er-
rors, 82 % of production errors in an unnamed company,
and 50–70 % of all electronic equipment failures were
partly or wholly due to human cognitive factors [10].
Psychological assessments and quality assessment tools
(e.g. Six Sigma) have been applied in many sectors to
reduce errors and improve quality [12–15].
The health sector shares commonalities with indus-
trial sectors including vulnerability to human errors
[11, 14]. Therefore, a better understanding of the
available evidence on cognitive biases influencing
Fig. 1 A model for diagnostic reasoning based on dual-process theory (from Ely et al. with permission).[9] System 1 thinking can be influenced by multiple
factors, many of them subconscious (emotional polarization toward the patient, recent experience with the diagnosis being considered, specific cognitive
or affective biases), and is therefore represented with multiple channels, whereas system 2 processes are, in a given instance, single-channeled and linear.
System 2 overrides system 1 (executive override) when physicians take a time-out to reflect on their thinking, possibly with the help of checklists. In
contrast, system 1 may irrationally override system 2 when physicians insist on going their own way (e.g., ignoring evidence-based clinical decision rules
that can usually outperform them). Notes: Dysrationalia denotes the inability to think rationally despite adequate intelligence. “Calibration” denotes the
degree to which the perceived and actual diagnostic accuracy correspond
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medical decisions is crucial. Such an understanding is
particularly needed for physicians, as their errors can
be fatal and very costly. Moreover, such an understand-
ing could also be useful to inform learning strategies to
improve clinical performance and patient outcomes,
whereas literature gaps could be useful to inform future
research.
In the last three decades, we learned about the import-
ance of patient- and hospital-level factors associated
with medical errors. For example, standardized ap-
proaches (e.g. Advanced Trauma Life Support, ABCs for
cardiopulmonary resuscitation) at the health system level
lead to better outcomes by decreasing medical errors
[16, 17]. However, physician-level factors were largely ig-
nored as reflected by reports from scientific organiza-
tions [18–20]. It was not until the 1970s that cognitive
biases were initially recognized to affect individual physi-
cians’ performance in daily medical decisions [6, 21–24].
Despite these efforts, little is known about the influence
of cognitive biases and personality traits on physicians’
decisions that lead to diagnostic inaccuracies, medical
errors or impact on patient outcomes. While a recent
review on cognitive biases and heuristics suggested that
general medical personnel is prone to show cognitive
biases, it did not answer the question whether these
biases actually relate to the number of medical errors in
physicians [25].
In the present (primarily narrative) systematic review,
we therefore reviewed the literature reporting the
existing evidence on the relation between cognitive
biases affecting physicians and medical decisions. Under
the concept of cognitive biases, we also included person-
ality traits (e.g. aversion to risk or ambiguity) that may
systematically affect physicians’ judgments or decisions,
independent of whether or not they result in immediate
medical errors. Over 32 types of cognitive biases have
been described [26]. Importantly, some of these may
reflect personality traits that could result in choice ten-
dencies that are factually wrong, whereas others reflect
decisions that are potentially suboptimal, although there
is no objectively “correct” decision (e.g. risk aversion,
tolerance to ambiguity). Both of these factors were
included here.
Our review has four objectives: 1) to identify the most
common cognitive biases by subjecting physicians to real
world situations or case-vignettes, 2) to evaluate the
influence of cognitive biases on diagnostic accuracy and
medical errors in management or treatment, 3) to
determine which cognitive biases have the greatest
impact on patient outcomes, and 4) to identify literature
gaps in this specific area to guide future research. After
addressing these objectives, we conclude by highlighting
the practical implications of our findings and by
outlining an action plan to advance the field.
Methods
Data sources
We conducted a literature search of MEDLINE and the
Cochrane Library databases from 1980 to May 2015 by
using a pre-specified search protocol (Additional file 1). We
used a permuted combination of MeSH terms as major
subjects, including: “medical errors”, “bias”, “cognition”,
“decision making”, “physicians”, and “case-vignettes” or
“case-scenarios”. In-line with the learning and education
literature, case-vignettes, clinical scenarios or ‘real world’
encounters are regarded as the best simple strategy to
evaluate cognitive biases among physicians [27]. In
addition, this approach has also the advantage of facilitating
the assessment of training strategies to ameliorate the
influence of cognitive biases on medical errors. We there-
fore restricted our sample to studies that used case-
vignettes or real-world encounters.
Results of the combination of search terms are listed
in the Additional file 1. We also completed further
searches based on key words, and reviewed references
from previously retrieved articles. All articles were then
combined into a single list, and duplicates (n = 106) were
excluded (Fig. 2).
Study selection
Candidate articles examining cognitive biases influencing
medical decisions were included for review if they met
the following five inclusion criteria: First, the study was
conducted on physicians. Second, at least one outcome
measure was reported. Third, at least one cognitive
factor or bias was investigated and defined a priori.
Fourth, case-vignettes or real clinical encounters were
used [28]. Fifth, the study was written in English. We
analyzed the number of articles that fulfilled our
inclusion criteria on each cognitive factor or bias,
methodological aspects, and the magnitude of effect (as
prevalence or odds ratios) on diagnostic or therapeutic
decisions. We excluded studies that were not the pri-
mary source. We analyzed the original data as reported
by the authors. Studies not providing raw data were also
excluded (e.g. review articles, letters to Editors).
A recent systematic review was focused on medical
personnel in general rather than physicians, and
therefore included a different set of studies in their
analysis than those that are of interest when considering
the impact of cognitive biases on physicians’ medical
decision-making and medical errors (the focus of the
current study) [25].
Data extraction
We extracted data according to the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement (Fig. 2) [29]. Two reviewers (GS,
librarian) assessed titles and abstracts to determine
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eligibility. Data were extracted using standardized collec-
tion forms. Information was collected on country of ori-
gin, study design, year of publication, number of studied
cognitive biases, population target (general practitioners,
specialists, residents), decision type (e.g. diagnosis, treat-
ment, management), unadjusted vs. adjusted analysis
(for measured confounders, such as age, years of train-
ing, expertise), type of outcome (see below), data quality,
and summary main findings. We also included descrip-
tive elements (attributes) of the medical information
provided for each case-scenario. The main outcomes
were any form of medical error [26, 30], including:
underuse or overuse of medical tests, diagnostic accur-
acy, lack of prescription or prescription of unnecessary
medications, outcomes of surgical procedures, and
avoidable hospitalizations.
Data quality
We used the Newcastle-Ottawa Scale (NOS) to assess
the quality of studies (see Additional file 2) [31]. The
NOS is a quality assessment tool for observational
studies recommended by the Cochrane Collaboration
[32]. It assigns one or two points for each of eight items,
categorized into three groups: the selection of the study
groups; the comparability of the groups; and the
ascertainment of the outcome of interest. Previous
studies defined NOS scores as: 7–9 points considered as
high quality, 5–6 as moderate quality, and 0–4 as low
quality [33]. For example, studies that do not provide a
description of the cohort, ascertainment of the exposure,
adjustment for major confounders, or demonstration
that the outcome of interest was not present at the
beginning of the study were ranked as low quality [31].
Results
We identified 5963 studies for the combination of
MESH terms “decision making” and “physicians”. Of
these, 114 fulfilled the selection criteria and were re-
trieved for detailed assessment. Among them, 38 articles
used case-vignettes or real case scenarios in physicians
(Fig. 2). Combinations of other search terms are shown
in the Additional file 1: Table S1. Twenty studies com-
prising 6810 physicians (median 180 per study; range:
36–2206) met the inclusion criteria (Fig. 2) [30, 34–52].
Fig. 2 PRISMA flow diagram
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In 55 % (n = 11) of the retained studies, results were ad-
justed for confounders, such as age, gender, level of training
(see Additional file 1 for further details). Importantly, only
five (25 %) studies used clinical guidelines as the framework
to determine diagnostic or treatment errors, illustrating the
scarcity of research on evidence-based decision making
(e.g. GRADE: decisions based on levels of evidence
provided by randomized trials, meta-analysis, etc).
Population target
Eight (40 %) studies included residents, six (30 %)
studies included general practitioners, six (30 %) studies
included internists, three (15 %) studies included emer-
gency physicians and seven (35 %) studies included other
specialists (Table 2). Ten (50 %) studies were conducted
in the USA. Only six (30 %) studies classified errors
based on real life measures, such as patient encounters,
pathological images or endoscopic procedures, whereas
the remaining 14 used narrative case-vignettes. Studies
included a wide variety of medical situations, most
commonly infections (upper respiratory tract, urinary
tract) and cardiovascular disease (coronary disease, cere-
brovascular disease) (Table 1). In summary, the included
studies covered a wide range of medical conditions and
participants.
Data quality
All studies were designed as cohort studies evaluating
cognitive biases. According to the NOS, the majority of
studies (n = 12, 60 %) were low quality, seven (35 %)
studies ranked moderate and only one ranked as high
quality [43] (see Additional file 2: Table S2 for details).
All studies were classified as representative of the entire
population (defined as how likely the exposed cohort
was included in the population of physicians).
Presence of most common cognitive biases (Objective 1)
Our first objective was to evaluate the most common
cognitive biases affecting physicians’ decisions. Altogether,
studies evaluated 19 different cognitive biases (Table 1
and Additional file 1).
It is important to bear in mind that these studies do not
systematically assess each cognitive bias or personality
traits. As a result, it is not possible to provide a true
estimate of the prevalence of all cognitive biases among
physicians. Overall, at least one cognitive factor or bias
was present in all studies. Studies evaluating more than
two cognitive biases, found that 50 to 100 % of physicians
were affected by at least one [39, 50, 52]. Only three
manuscripts evaluated more than 5 cognitive biases in the
same study, in-line with the narrow scope of most studies
[39, 50, 52]. One third of studies (n = 6) were descriptive,
i.e., they provided the frequency of the cognitive bias
without outcome data [36, 37, 39, 44, 48, 51].
The most commonly studied personality trait was
tolerance to risk or ambiguity (n = 5), whereas the
framing effects (n = 5) and overconfidence (n = 5) were
the most common cognitive biases. There was a wide
variability in the reported prevalence of cognitive biases
(Fig. 3). For example, when analyzing the three most
comprehensive studies that accounted for several cogni-
tive biases (Fig. 4), the availability bias ranged from 7.8
to 75.6 % and anchoring from 5.9 to 87.8 %, suggestive
of substantial heterogeneity among studies. In summary,
cognitive biases may be common and present in all in-
cluded studies. The framing effect, overconfidence, and
tolerance to risk/ambiguity were the most commonly
studied cognitive biases. However, methodological limi-
tations make it difficult to provide an accurate estima-
tion of the true prevalence.
Effect of cognitive biases on medical tasks (Objective 2)
Our second objective concerned the assessment of the in-
fluence of cognitive biases on diagnostic, medical manage-
ment or therapeutic tasks. Most studies (12/20; 60 %)
targeted cognitive biases in diagnostic tasks, 7 (35 %) stud-
ies targeted treatment or management tasks, and 2 studies
(10 %) focused on errors in prognosis. The main measure
was diagnostic accuracy in 35 % (7/20) of studies (Fig. 5).
Overall, the presence of cognitive biases was associated
with diagnostic inaccuracies in 36.5 to 77 % of case-
scenarios [30, 35, 40, 42, 45, 52, 53]. A study including 71
residents, fellows, and attending pathologists evaluated
2230 skin biopsies with a diagnosis confirmed by a panel
of expert pathologists. Information biases, anchoring
effects, and the representativeness bias were associated
with diagnostic errors in 51 % of 40 case-scenarios
(compared to 16.4 % case-scenarios leading to incorrect
diagnoses not related to cognitive biases; p = 0.029) [52].
Only seven (35 %) studies provided information to evalu-
ate the association between physicians’ cognitive biases and
therapeutic or management errors [38, 41–43, 46, 47, 50].
Five out of the seven (71.4 %) studies showed an as-
sociation between cognitive biases and these errors
[38, 43, 46, 47, 50]. One study showed that overutili-
zation of screening for prostate cancer among healthy
individuals was associated with lower aversion to
uncertainty (p < 0.01) [46]. In another study including 94
obstetricians who cared for 3488 deliveries, better coping
strategies (p < .015) and tolerance to ambiguity (p < .006)
were associated with optimal management (reflected by
lower instrumental vaginal deliveries) and lower errors
[43]. In a study including 32 anesthesiology residents,
several cognitive biases (anchoring, overconfidence, pre-
mature closure, confirmation bias, etc.) were associated to
errors in half of the 38 simulated encounters [50]. Two
studies evaluating triage strategies for patients with
bronchiolitis and coronary artery disease showed no
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Methods Clinical problem Type of decision Cognitive
bias (n)
Type of cognitive bias Data
quality*





Ross 1999 UK 407 Survey Depression Treatment and
management
1 Outcome bias 6
Graber 2000 USA 232 Survey Headache, abdominal pain,
depression
Diagnosis 1 Information bias 4
Sorum 2003 USA, France 65 Survey Prostate cancer Diagnosis 1 risk aversion 4
Baldwin 2005 USA 46 Experimental Brochiolitis Management 2 risk aversion, Ambiguity tolerance 5
Friedman 2005 USA 216 Survey NR Diagnosis 1 Overconfidence 4
Reyna 2006 USA 74 Survey Unstable angina Diagnosis and
management
1 risk aversion 5
Bytzer 2007 Denmark 127 Video-cases Reflux, epigastric pain Diagnosis 1 Infromation bias 4
Dibonaventura 2008 USA 2206 Survey Immunization Treatment 2 omissions and naturalness bias 4
Mamede 2010 Netherlands 36 Experiment Hepatitis, IBD, MI, Wernicke,
Pneumonia, UTI, Meningitis
Diagnosis 1 Availability, Reflective
reasoning
5






Diagnosis 1 Deliveration without
attention
3
Gupta 2011 USA 587 Survey Abdominal pain, headache,
trauma, asthma, chest pain
Diagnosis 1 Outcome bias 6
Perneger 2011 Switzerland 1439 Survey HIV infection Treatment-Prognosis 1 Framing effect 4







10 anchoring, availability bias,
premature closure, feedback bias,
framing effect, confirmation bias,
omission
4
Ogdie 2012 USA 41 Narratives NR Diagnosis 9 Anchoring, availability, framing effect,
blind obedience, confirmation
3
Meyer 2013 USA 118 Survey Abdominal pain, headache
and rash, fever and arthralgias
Diagnosis 1 Overconfidence 4
Crowley 2013 International 71 Pathology cases Vesicular and diffuse dermatitides Diagnosis 8 anchoring, availability bias,
confirmation bias, overconfidence
4
Saposnik 2013 Canada 111 Case-scenarios from real
practice
Stroke Prognosis 2 Overconfidence, anchoring 5
Msaouel 2014 Greece 153 Survey Tuberculosis, CAD Diagnosis 2 Gambler’s and Conjunction fallacy 5
Yee 2014 USA 94 Experimental Deliveries Management and
Treatment
1 Ambiguity tolerance/aversion 7



















































association between personality traits (e.g. risk aversion or
tolerance to uncertainty) and hospital admissions [41, 42].
In summary, our findings suggest that cognitive biases
(from one to two thirds of case-scenarios) may be associated
with diagnostic inaccuracies. Evidence from five out of seven
studies suggests a potential influence of cognitive biases on
management or therapeutic errors [38, 43, 46, 47, 50].
Physicians who exhibited information bias, anchoring effects
and representativeness bias, were more likely to make
diagnostic errors [38, 43, 46, 50].
Further studies are needed to identify what the most
common cognitive biases and the most effective strat-
egies to overcome their potential influence of medical
tasks and errors.
Effect of physician’s cognitive biases on patient outcomes
(Objective 3)
The third objective of the present study was to determine
the impact of cognitive biases on patient outcomes (e.g.
avoidable hospitalizations, complications related to a pro-
cedure or medication, exposure to unnecessary invasive
tests, etc). Only two (10 %) studies provided information
to answer this question, both evaluating physicians’
tolerance to uncertainty [41, 43]. In a study evaluating
obstetrical practices, higher tolerance to ambiguity was as-
sociated with an increased risk of postpartum hemorrhage
(9.7 % vs 6.5 %; p = .004). The negative effects persisted in
the multivariable analysis (for postpartum hemorrhage:
OR 1.51, 95 % CI 1.10–2.20 and for chorioamninitis: OR
1.37, 95 % CI 1.10–1.70) [43]. This phenomenon could be
explained by overconfidence and underestimation of risk
factors associated with maternal infections or puerperal
bleeding. On the other hand, a study including 560 infants
with bronchiolitis presented to the emergency department
cared for by 46 pediatricians showed similar admission
rates among physicians with low and high risk aversion or
discomfort with diagnostic uncertainty (measured using a
standardized tool) [41].
In summary, there too little evidence to make definitive
conclusions on the influence of physicians’ personality
traits or cognitive biases on patient outcomes.
Literature gaps and recommendations (Objective 4)
We systematically reviewed gaps in the literature. First,
most of the studies (60 %) provided a qualitative defin-
ition of cognitive biases based on the interpretation of
comments made by participants (e.g. illustrative quotes),
lacking a unified and objective assessment tool [39, 50].
Second, the unit of study varies from study to study. For
example, some authors report results based on the
number of physicians involved in the study, whereas
others report the results based on the number of case-
scenarios. Third, limited information is currently avail-
able on the impact of cognitive biases on evidence-based
care, as only 15 % of the studies were based on or
supported by clinical guidelines (Table 2). Fourth, only
one study evaluated the effect of an intervention (e.g.
reflective reasoning) to ameliorate cognitive biases in
physicians [35]. Fifth, most studies were classified as low
quality according to NOS criteria. However, this scale is
regarded as having a modest inter-rater reliability. We
need consensus among researchers on the best tools to
Fig. 3 Prevalence of most common cognitive biases as reported by
different studies. Numbers represent percentages reflecting the
frequency of the cognitive factor/bias. Panel a represent the
prevalence of the framing effect. Panel b represent the prevalence
of prevalence of tolerance to risk and ambiguity. Panel c represents
the prevalence of overconfidence. Overall, overconfidence and low
tolerance to risk or ambiguity were found in 50-70 % of participants,
whereas a wide variation was found for the framing effect
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assess the quality of manuscripts. Sixth, only two studies
evaluated the influence of physicians’ biases on patient
outcomes. Finally, considering the great majority of
studies (85 %) targeted only one or two biases (Table 1),
the true prevalence of cognitive biases influencing
medical decisions remains unknown.
As mentioned, medical errors are common in medical
practice [5]. Physicians’ biases and personality traits may
explain, at least in part, some medical errors. Given the
wide practice variability across medical disciplines,
decisions on screening tests, surgical procedures,
preventative medications, or other interventions (e.g.
thrombolysis for acute stroke, antibiotics for an under-
lying infection, etc.) may not require the same cognitive
abilities it is therefore likely that studies from one
discipline cannot be transferred automatically to a differ-
ent discipline. By extension, physicians’ personality traits
(e.g. aversion to ambiguity, tolerance to uncertainty) or
cognitive biases (e.g. overconfidence) may not equally in-
fluence patient outcomes or medical errors in all
disciplines. Time-urgency of the medical decision may be a
relevant characteristic. Thus, a discipline-based research ap-
proach may be needed. There is scarce information in some
disciplines and areas, including anesthesiology (decisions
on procedures and anesthetic agents), emergency care,
obstetrics and gynecology (e.g. decisions on procedures and
primary care on women’s health), endoscopic procedures
(e.g. gastrointestinal, uropelvic), neurology (e.g. decision in
multiple sclerosis and stroke care).
Discussion
Early recognition of physicians’ cognitive and biases are
crucial to optimize medical decisions, prevent medical
errors, provide more realistic patient expectations, and
Fig. 4 Prevalence of cognitive biases in the top three most comprehensive studies [39, 50, 52] Numbers represent percentages reflecting the
frequency of the cognitive bias. Note the wide variation in the prevalence of cognitive biases across studies
Fig. 5 Outcome measures of studies evaluating cognitive biases. Numbers represent percentages. Total number of studies = 20. Note that 30 % of
studies are descriptive and 35 % target diagnostic accuracy. Only few studies evaluated medical management, treatment, hospitalization or prognosis
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Table 2 Participants, attributes and outcomes of included studies
















Redelmeier GPs and Neurologist 4 10-11 yes Treatment
recommendations
4 unadjusted 5 Multiple options decreased the likelihood of
medication prescription for pain and carotid
endarterectomy by 26 % and 35 %, respectively
Ross GPs 3 NA No Descriptive 5 adjusted 6 GPs were less likely to arrange a further consultation
for female patients than for male patients (OR = 0.55).
GPs with a pessimistic belief about depression were
less likely to discuss non-physical symptoms or social
factors; More experienced GPs were less likely to
conduct a physical examination (OR = 0.60).
Graber GPs 2 8-9 No Descriptive 1 adjusted 4 GPs were less likely to believe a serious medical
condition among patients with history of depression
or somatic symptoms
Sorum GPs 32 5 yes Probability of
ordering a test
4 adjusted 4 PSA were more likely ordered among GPs with
discomfort for uncertainty and those who
expressed regret.
Baldwin Pediatric ED physicians 397 NA No Admission rates 4 adjusted 5 Risk aversion scores higher for physicians with
>15 years of experience. Admissions rates did not
differ between high and low risk adverse physicians
(31.1 vs 30.1; p = 0.91). Adjusted admission rates did
not different between high and low discomfort with




36 (9) >20 No Diagnostic
accuracy
5 adjusted 4 Overconfident found in 41 % of residents and in
36 % faculty.
Reyna GPs and specialists 9 NA Yes Diagnostic
accuracy and
management
6 adjusted 5 Physicians deviated from Guidelines in terms of
discharge. GP were more risk averse and less likely to
discharge patients. Experts achieved better case-risk
discrimination by processing less information
Bytzer Specialists 5 NA No Diagnostic
accuracy
6 unadjusted 4 Only 23 % endoscopists gave the same diagnosis for
the two identical video-cases. The great majority were
affected by prior information bias.
Dibonaventura Physicians 2 11–12 No Descriptive 4 unadjusted 4 Naturalness bias present in 40 %, omission bias in
60 % of participants




5 unadjusted 5 Availability bias increased with years of training.




12 >20 No Diagnostic
accuracy
6 unadjusted 3 Conscious deliberation improved the likelihood of
correct diagnosis in physicians, but not in medical
students problems were complex, whereas reasoning
mode did not matter in simple problems. In contrast,




















































Table 2 Participants, attributes and outcomes of included studies (Continued)
Gupta ED Physicians 6 >20 No Descriptive 1 adjusted 6 Outcome bias tends to inflate ratings in the presence of
a positive outcome more than it penalizes scenarios with
negative ones.
Perneger GPs and specialists,
and patients (1121)
1 5 No Rating of new
drug
6 adjusted 4 Physicians and patients provided higher value to the
hypothetical new medication when presented in relative
terms. Compared to descriptive information, relative
mortality reduction (OR 4.40; 3.05 – 6.34), Number needed
to treat (OR 1.79; 1.21 – 2.66), and relative survival extension






Management 1 unadjusted 4 1. Developed a cognitive factor/bias catalogue, 2. Top 10
cognitive biases and personality traits: anchoring, availability
bias, omission bias, commission bias, premature closure,
confirmation bias, framing effect, overconfidence, feedback
bias, and sunk cost.
3. Errors perceived by faculty to be important to
anesthesiology were indeed observed frequently among
trainees in a simulated environment.
Ogdie Residents 41 NA No Descriptive 6 unadjusted 3 Most common biases: anchoring (88 %), availability (76 %),
framing effect (56 %), overconfidence (46 %)
Meyer Physicians 4 6-11 No Diagnostic
accuracy
2 unadjusted 4 Higher confidence was related to decreased requests for
additional diagnostic tests (P = .01); higher case difficulty was





40 NA No Diagnostic
accuracy
6 unadjusted 4 Overall, biases occurred in 52 % of incorrect cases compared
to 21 % correct. Most common biases-Availability (20 %) and
satisfying biases (22.5 %) the two most common. All the rest,





10 5-7 No Probability
of death or
disability
6 adjusted 5 Higher confidence was not associated with better outcome
predictions. 70 % of underestimated the risk of the death or
disability, 38 % overestimated death at 30 days.
Msaouel Residents 2 4, 5 No Descriptive 1 adjusted 5 Gambler’s fallacy in 46 %, conjunction bias 69 %
Yee Specialists
(Obstetricians)
3488 NA No Management 6 adjusted 7 Physicians with a higher tolerance of ambiguity were less
likely to deliver patients by operative vaginal delivery
(11.8 % vs 16.4 %; p = 0.006). The effect disappeared in the
adjusted analysis (OR 0.77, 95 % CI 0.53-1.1)
NA not available, GP general practitioners
aType of outcome measured: 1 = probability, 2 = rating, 3 = ranking, 4 = yes/no choice, 5 = discrete choice, 6 = more than 2 alternatives




















































contribute to decreasing the rising health care costs
altogether [3, 8, 54]. In the present systematic review, we
had four objectives. First, we identified the most commonly
reported cognitive biases (i.e., anchoring and framing
effects, information biases) and personality traits (e.g. toler-
ance to uncertainty, aversion to ambiguity) that may poten-
tially affect physicians’ decisions. All included studies found
at least one cognitive factor/bias, indicating that a large
number of physicians may be possibly affected [39, 50, 52].
Second, we identified the effect of physician’s cognitive
biases or personality traits on medical tasks and on med-
ical errors. Studies evaluating physicians’ overconfidence,
the anchoring effect, and information or availability bias
may suggest an association with diagnostic inaccuracies
[30, 35, 40, 42, 45, 52, 53]. Moreover, anchoring, informa-
tion bias, overconfidence, premature closure, representa-
tiveness and confirmation bias may be associated with
therapeutic or management errors [38, 43, 46, 47, 50].
Misinterpretation of recommendations and lower comfort
with uncertainty were associated with overutilization of
diagnostic tests [46]. Physicians with better coping
strategies and tolerance to ambiguity could be related to
optimal management [43].
For our third objective – identifying the relation between
physicians’ cognitive biases and patient’s outcomes- we
only had very sparse data: Only 10 % of studies provided
data on this area [41, 43]. Only one study showed higher
complications (OR 1.51, 95 % CI 1.10–2.20) among pa-
tients cared for by physicians with higher tolerance to am-
biguity [43]. The fourth and final objective was to identify
gaps in the literature. We found that only few (<50 %) of
an established set of cognitive biases [26] were assessed, in-
cluding: overconfidence, and framing effects. Other listed
and relevant biases were not studied (e.g. aggregation bias,
feedback sanction, hindsight bias). For example, aggrega-
tion bias (the assumption that aggregated data from clin-
ical guidelines do not apply to their patients) or hindsight
bias (the tendency to view events as more predictable than
they really are) both compromise a realistic clinical
appraisal, which may also lead to medical errors [18, 26].
More importantly, only 35 % of studies provided informa-
tion on the association between cognitive biases or person-
ality traits and medical errors [38, 41–43, 46, 47, 50], with
scarce information on their impact on patient outcomes,
preventing us from making definite conclusions [41, 43].
Furthermore, the quality of the included studies was classi-
fied as low to modest according to NOS criteria, as most
studies provided limited descriptions of the exposure and
research cohort, and none contributed with follow-up data
(e.g. sustainability and reliability of the effects or long-term
outcomes) (Additional file 2).
When comparing the previous systematic review on
patients and medical personnel [25] with ours, some
commonalities are apparent. Both reviews agree on the
relevance of the topic, identify that a systematic analysis
of the impact of cognitive biases on medical decisions is
lacking despite substantial work completed in the last
two decades [25]. Having a different objective, the
authors nicely summarized the number of studies that
investigated each cognitive bias either in patients or
medical personnel [25]. Similarly, cognitive biases seem
to be common among physicians as identified in 80 %
(n = 51) of studies included in Blumenthal-Barby and
Krieger’s review and all selected studies (n = 20) evaluat-
ing at least one outcome in the present review [25].
However, both studies were not able to provide an accur-
ate estimate of the true prevalence of cognitive biases or
personality traits affecting medical decisions in physicians.
On the other hand, our study adds relevant information
regarding the influence of cognitive biases particularly in
physicians on diagnostic inaccuracies, suboptimal manage-
ment and therapeutic errors, and patient outcomes. Our
first objective allowed the identification of additional biases
(e.g. framing effect, decoy effect, default bias) or physician’s
personality traits (e.g. low tolerance to uncertainty, aversion
to ambiguity), by including 14 further studies. We also
completed a systematic quality assessment of each study
using a standardized tool and identified gaps related to the
influence of cognitive biases on medical errors [31].
What can be done?
The identification and recognition of literature gaps consti-
tute the first step to finding potential solutions. Increasing
awareness among physicians and medical students is an
important milestone. A comprehensive narrative review
comprising 41 studies on cognitive interventions to reduce
misdiagnosis found three main effective strategies: increas-
ing knowledge and expertise, improving clinical reasoning,
and getting help from colleagues, experts and tools [55].
First, reflective reasoning counteracts the impact of
cognitive biases by improving diagnostic accuracy in sec-
ond- (OR 2.03; 95 % CI, 1.49–2.57) and first-year residents
[OR (odds ratio) 2.31; 95 % CI, 1.89–2.73] [35]. Second, the
implementation of tools (e.g. cognitive checklist, calibra-
tion) may overcome overconfidence, the anchoring and
framing effects (Fig. 5) [8, 9, 56]. Third, heuristics
approaches (shortcuts to ignore less relevant information
to overcome the complexity of some clinical situations)
can improve decision making. As shown by Marewski and
Gigerenzer, the identification of three rules (search for
predictors to determine their individual importance, stop
searching when relevant information was already obtained,
and a criteria that specifies how a decision is made) may
facilitate prompt decisions and may help physicians to
avoid errors in some clinical situations [21, 57, 58].
The inclusion of training in cognitive biases in gradu-
ate and postgraduate programs might foster medical
education and thereby improve health care delivery [59].
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A commitment from academic institutions, scientific
organizations, universities, the public, and policy-makers
would be needed to reduce a defensive medical practice
[60, 61]. An initial step towards this goal may be the
‘Choosing wisely’ strategy [62, 63].
What are the practical implications of our findings?
As shown, cognitive biases and personality traits may
affect our clinical reasoning processes which may lead to
errors in the diagnosis, management, or treatment of
medical conditions [6, 26]. Errors perceived by faculty to
be relevant were indeed observed in 50–80 % of trainees
in real practice [50]. Misdiagnosis, mismanagement, and
mistreatment are frequently associated with poorer
outcomes, which are the most common reasons for
patients’ dissatisfaction and medical complaints [54, 64, 65].
Our study has several limitations that deserve
comment. First, although we aimed to be as systematic
as possible in reviewing the literature, we cannot rule
out involuntary omissions. It is also possible that our re-
sults may be somewhat limited by the strictness of our
inclusion criteria. Second, we were not able to complete
a formal meta-analysis due to the diversity of definitions
and data reported, and small number of studies evaluat-
ing specific cognitive biases. In particular, a limited num-
ber of studies evaluated the same constructs. Moreover,
across studies we often found a lack (in 30 % of studies)
or heterogeneity in the outcome measures, mixed
denominators (some studies report their findings based
on the number of participants, while others based on
case-scenarios) [41, 43, 52], and different scope (e.g.
some studies are descriptive, [36, 37, 39, 44, 48, 51]
whereas others [7, 30, 35, 42, 43, 47, 50, 52] target
diagnostic or therapeutic errors). Third, most studies use
hypothetical case-vignettes which may not truly reflect
medical decisions in real life. Fourth, the assessment of
the number of medical elements included in each case
scenario may not be consistent (some were reported by
authors and others estimated based on the description
of case-scenarios) [35, 40, 51]. Fifth, the use of the NOS
to assess the quality of studies has been criticized for
having modest inter-rater reliability [66, 67].
Despite the aforementioned limitations, our study re-
flects the relevance and potential burden of the problem,
how little we know about the implications of cognitive
biases and personality traits on physicians’ decisions,
and their impact on patients-oriented outcomes. Our
findings may also increase physicians’ awareness of own
personality traits or cognitive biases when counseling or
advising patients and their family members that may
lead to medical errors. From a health policy perspective,
this information would provide additional insights on
medically relevant cognitive biases and personality traits
that contribute the rising health care costs [3, 68].
Conclusions
In the present systematic review, we highlighted the
relevance of recognizing physicians’ personality traits and
cognitive biases. Although cognitive biases may affect a
wide range of physicians (and influence diagnostic
accuracy, management, and therapeutic decisions), their
true prevalence remains unknown.
Thus, substantial gaps limit our understanding of the im-
pact of cognitive biases on medical decisions. As a result,
new research approaches are needed. We propose the
design of more comprehensive studies to evaluate the effect
of physicians’ personality traits and biases on medical errors
and patient outcomes in real medical encounters and inter-
ventions or using guideline-based case-vignettes. This can
be accomplished by identifying physician characteristics,
combining validated surveys and experiments commonly
used in behavioral economics to elicit several critical per-
sonality traits (e.g. tolerance to uncertainty, aversion to risk
and ambiguity), and cognitive biases (e.g. overconfidence,
illusion of control). Prospective studies evaluating and com-
paring different training strategies for physicians are needed
to better understand and ameliorate the potential impact of
cognitive biases on medical decisions or errors. In addition,
effective educational strategies are also needed to overcome
the effect of cognitive biases on medical decisions and in-
terventions. Together, this information would provide new
insights that may affect patient outcomes (e.g. avoidable
hospitalizations, complications related to a procedure or
medication, request of unnecessary tests, etc) and help
attenuate medical errors [3, 68, 69].
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Abstract
Background: The management of multiple sclerosis (MS) is rapidly changing by the introduction of new and more
effective disease-modifying agents. The importance of risk stratification was confirmed by results on disease
progression predicted by different risk score systems. Despite these advances, we know very little about medical
decisions under uncertainty in the management of MS. The goal of this study is to i) identify whether
overconfidence, tolerance to risk/uncertainty, herding influence medical decisions, and ii) to evaluate the frequency
of therapeutic inertia (defined as lack of treatment initiation or intensification in patients not at goals of care) and
its predisposing factors in the management of MS.
Methods/Design: This is a prospective study comprising a combination of case-vignettes and surveys and
experiments from Neuroeconomics/behavioral economics to identify cognitive distortions associated with medical
decisions and therapeutic inertia. Participants include MS fellows and MS experts from across Spain. Each participant
will receive an individual link using Qualtrics platform© that includes 20 case-vignettes, 3 surveys, and 4 behavioral
experiments. The total time for completing the study is approximately 30–35 min. Case vignettes were selected to
be representative of common clinical encounters in MS practice. Surveys and experiments include standardized test
to measure overconfidence, aversion to risk and ambiguity, herding (following colleague’s suggestions even when
not supported by the evidence), physicians’ reactions to uncertainty, and questions from the Socio-Economic Panel
Study (SOEP) related to risk preferences in different domains. By applying three different MS score criteria (modified
Rio, EMA, Prosperini’s scheme) we take into account physicians’ differences in escalating therapy when evaluating
medical decisions across case-vignettes.
Conclusions: The present study applies an innovative approach by combining tools to assess medical decisions
with experiments from Neuroeconomics that applies to common scenarios in MS care. Our results will help
advance the field by providing a better understanding on the influence of cognitive factors (e.g., overconfidence,
aversion to risk and uncertainty, herding) on medical decisions and therapeutic inertia in the management of MS
which could lead to better outcomes.
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Background
The field of multiple sclerosis (MS) has seen significant
changes over the last several years [1, 2]. Clinicians and pa-
tients welcomed the introduction of disease-modifying
therapy (DMT) for MS in the mid-1990s. Injectable agents,
all with rather similar risk–benefit profiles, dominated MS
care for over a decade. The approval of Natalizumab
marked a change with the introduction of a more effective
treatment option, but also entailed new risks associated
with modulation of the immune system (e.g., risk of pro-
gressive multifocal leukoencephalopathy - PML) [2, 3].
More recently, the introduction of oral agents and new
humanised monoclonal antibodies administered by infu-
sion have opened yet another avenue for patients and clini-
cians [4]. Currently, there are over a dozen of DMTs
available to treat MS, with varying availability around the
world. Significant heterogeneity exists in the efficacy and
risks associated with these therapies [5–7]. Therefore, clini-
cians have the challenge of tailoring treatment based on i)
disease activity level (clinical and radiological data), ii) indi-
vidual patient characteristics/preferences, iii) personal ex-
pertise/preference, in order to identify the optimal balance
between efficacy and safety Table 1 (See Additional file 1
for data on some currently available agents) [8].
Risk stratification in MS
An understanding of the risk of untreated multiple scler-
osis is crucial to make therapeutic decisions Table 2 [8]. In
addition, physicians’ preferences and beliefs in effective-
ness of treatment and drug safety profiles may influence
their decisions. Disease activity/progression can be di-
vided into physical, cognitive and radiological markers.
Examples include number of attacks per year, number of
disabling attacks, disability scales (clinical), lesion vol-
ume, GAD enhancing lesions, brain atrophy (MRI), and
cognitive decline (e.g., using SDMT, PASAT, OR MoCA
scales) [9]. Two scoring systems (Rio score and Modified
Rio score) demonstrate good predictive value for MS
progression. The Rio score includes MRI, clinical relapse
and EDSS criteria, whereas the modified Rio score in-
cludes MRI and clinical relapse criteria (Fig. 1) [10]. A
high risk profile using the modified Rio (score ≥2) in-
cludes either an MRI with more than 5 new T2 lesions
(1 point) or 1 relapse in the first year (1 point) or two
relapses within the first year of treatment (2 points) or
the combination of these criterions [11]. These scores
have been used to identify and predict response to Inter-
feron β. For example, the modified Rio score in the
PRISM trial revealed that participants who did not
responded to Interferon β had a similar probability of
disability progression as those assigned to the placebo
group. Conversely, responders to Interferon β had a
52 % reduction in disability progression compared to
placebo and non-responders (p < 0.0001). MS patients
with a modified Rio score greater than or equal to 2 had
a 65 % increased risk of disability progression (HR =
4.60; p < 0.001) [12]. A Canadian group concluded that a
change in treatment may be considered in patients with
relapsing remitting MS if there is a high level of concern
in any one domain (relapses, progression or MRI), a
medium level of concern in any two domains, or a low
level of concern in all three domains [13]. The European
Table 1 Comparative adverse events of different DMTs [7, 8]
Disease modifying agent Adverse events







Glatiramer acetate • ISRs
• Benign systemic reaction
Mitoxantrone • Cardiac toxicity
• Leukemia















Dimethyl fumarate • Flushing
• Gastrointestinal
• PML





• Autoimmune thyroid disease
ISRs injection-site reactions, LFT liver function test, PML progressive multifocal
leukoencephalopathy, ITP idiopathic thrombocytopenic purpura, BCC basal
cell carcinoma
Saposnik et al. BMC Neurology  (2016) 16:58 Page 2 of 9
Medicines Agency approves escalating therapy with
Natalizumab or Fingolimod in patients who had at least
one relapse in the previous year while on Interferon β
and either ≥9 T2-hyperintense lesions on brain MRI or
≥1 contrast-enhancing lesion MRI activity alone after
the first year of treatment was associated with three- to
fivefold increased risk of relapses or disability compared
with stable patients. These recommendations have been
supported by several prospective studies [14, 15].
Selection of a first line therapy will likely depend on sev-
eral factors. Traditionally, and due to the availability of ex-
tended safety data, injectable agents may be the first
choices. Given the comparable efficacy data between the
injectable agents the selection of a therapy will be deter-
mined mostly by side effect profiles. Subjects with head-
aches, depression, and a history of liver dysfunction may
experience worsening of these comorbidities when ex-
posed to interferons. Monitoring for interferons includes
following liver function tests, complete blood counts, and
monitoring depression [8]. Given the availability of more
effective drugs, the treatment paradigm is likely to change.
However, it is expected there will be wide variability on
the timing of this paradigm shift (e.g., starting more effect-
ive therapies as first line treatment) based on patients’ and
physicians’ tolerance to risk, estimation of the clinical
course, regional funding programs, among other factors.
As a result, it is vital to identify situations for which physi-
cians take the opportunity of escalating treatment when
indicated (e.g., progression of disease determined by clin-
ical relapses, EDSS disability score and imaging data).
Therapeutic inertia: a new paradigm in MS
Therapeutic inertia is a term introduced in 2006 to de-
fine the lack of treatment initiation or intensification in
patients not at goals of care [16–19]. Some examples in-
clude failure to intensify treatment in patients with per-
sistent elevated blood pressure or blood glucose [16, 20,
21]. Reasons to explain therapeutic inertia include the
lack of training and cultural organization in the practice
at “treating to target”, competing demands and clinical
uncertainty [22, 23]. In the context of MS, therapeutic
inertia is defined lack of treatment initiation or intensifi-
cation when there is evidence of disease progression (based
on clinical and radiological data). In the present study,
Table 2 Risks of untreated relapsing MS
Treatment targets Evidence of association Long-term outcome
T2 lesion volume Increase of 0.8–l ml/year Correlates with increased relapse frequency and long term
disability outcomes.
T1 black hole conversion 40–50 % of lesions go on to form black holes Correlation with clinical measures and disability progression.
Brain atrophy 0.5–1 %/year in MS vs. <0.1 % in healthy controls Correlation with cognitive outcomes and EDSS in the long term.
Clinical relapses Annualized relapse rate in placebo arms: 0.5–1.38 Relapses associated with decreased quality of life.
Relapses associated with accrual of disability.
Earlier onset of SPMS.
Disability accrual Average change of 0.27 EDSS points/per relapse Increased likelihood of long term disability.
MRI and lesional activity associated with disability progression
Reproduced with permission from Ontaneda et al. [8]
Fig. 1 Modified with permission from Sormani et al. defining and scoring response to IFN‑β in multiple sclerosis. Nat. Rev.
Neurol. doi:10.1038/nrneurol.2013.146
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disease progression was defined according to the modified
Rio score, where patients had one or more recurrent at-
tacks and/or an MRI with 5 or more new T2 lesions while
receiving treatment with a disease- modifying agent [11].
Another more recent criterion strongly associated with risk
of relapse or disability progression was the presence of iso-
lated gadolinium-enhancing lesions [14, 15].
Medical decision making
Making decisions in medical care is a complex task involv-
ing a variety of cognitive processes [24]. Decision making is
defined as the process of examining possibilities, risks, un-
certainties, and options, comparing them, and choosing a
course of action [25, 26]. Decisions based on erroneous as-
sessments may result in incorrect patient and family expec-
tations, and potentially suboptimal advice, treatment, and
prognosis. Moreover, many decisions are made with limited
information from observational studies or clinical trials that
may not apply to particular patients. Uncertainty is one of
the most important reasons contributing to the status quo
and making proactive therapeutic decisions [17, 23, 27].
We need a better understanding on how physicians decide
about different therapeutic options under uncertainty for
patients with MS.
The problem
Despite the availability of different markers for risk
stratification in patients with MS, it is difficult for expert
clinicians to select the best strategy when the progres-
sion pattern of the disease is uncertain. MS experts and
clinicians are trained to quickly recognize patterns or
critical aspects of particular situations [28]. Some clini-
cians apply the knowledge they have acquired from pre-
vious experience, others use information available at the
time of the assessment, others use risk score tools or a
combination of the above. However, it is not known how
MS experts behave in clinical scenarios with ambiguous
outcomes (unknown probability or uncertain risk of an
outcome) or when more therapeutic options become avail-
able. In addition, we have a limited understanding about
physicians’ beliefs and preferences on the widely available
therapeutic options for the optimal management of MS.
Moreover, there is still lack of evidence-based ap-
proaches to incorporate patients’ preferences such as
medication disutility into the shared decision making
process [29]. As our understanding of MS risk continues
to be refined, how to account for the uncertain risks, ben-
efits, and preferences at the individual level is a current
challenge for the practice of personalized medicine.
The proposed solution: bringing together
advances in MS treatment and Neuroeconomics
The expected utility theory states that decision makers
choose between risky or uncertain options by comparing
their expected utility values (i.e.,: the weighted sums ob-
tained by adding the utility values of outcomes multiplied
by their respective probabilities) [30]. More importantly,
patients’ preferences and physicians’ recommendations
will change depending on the utility function of their
current health status. For example, patients at low risk of
developing MS progression may prefer to avoid ‘risky’
treatments (as they have low gains while having a risk of
developing side effects), whereas high-risk patients would
prefer the most effective treatment even if need to take
higher risks (as they have a higher chance of having a pro-
gression leading to more disability) (Fig. 2) [24, 31].
Rationale
Neuroeconomics is the science that studies the principles
of how we make decisions [30, 32]. The neuroscience of
decision making is based on behavioral economic concepts
and mathematical approaches, such as game theory, to pre-
dict and model how people make their own choices [33].
The application of principles from Neuroeconomics
(decision neuroscience) will facilitate the recognition of
physicians’ therapeutic preferences and beliefs about
DMT for MS in the real world [34] (Fig. 3). Given the
greater availability of treatment options, MS treatment
will likely become more challenging. It requires a fine
balance between the modest benefits of the less expen-
sive, safer, and traditional DMTs versus new agents, usu-
ally more costly with potential harmful side effects. The
so called ‘intermediate agents’ (e.g., Fingolimod) may
have a ‘decoy effect’ (Phenomenon whereby consumers
tend to have a specific change in preference between
two options when also presented with a third -less pref-
erable- option becomes available) [35, 36].
There is limited evidence of the application of the ex-
pected utility theory to clinical scenarios from the physi-
cians’ perspective. A better understanding of physicians’
beliefs and preferences under uncertainty would likely
improve the quality of care, patients’ satisfaction, and
likely improve clinical outcomes by increasing awareness
on the therapeutic inertia in MS.
Objectives
1) To evaluate tolerance to risk and ambiguity among
MS experts under situations of uncertainty.
2) To assess the prevalence of ‘therapeutic inertia’.
3) To determine the influence of tolerance to risk/
ambiguity, overconfidence and herding on medical
decisions.
Research questions
1) How MS experts’ perceptions of risk and tolerance
to ambiguity influence their recommendations?
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2) What is the prevalence of therapeutic inertia among
physicians with expertise in MS?
3) What is the impact of tolerance to risk and
ambiguity, overconfidence and herding on
therapeutic decisions?
Methods
We are proposing a prospective web-based study com-
prising 20 MS case-vignettes, 3 standardized surveys,
and 4 behavioral experiments (see Additional file 1).
MS case-scenarios were derived from the most
common situations in clinical practice as identified by
experts in the field. Surveys include three standard-
ized questions related to aversion to risk from The
German Socio-Economic Panel (SOEP) study. The
SOEP is a longitudinal study of private households
that include household composition, occupational
biographies, employment, earnings, health and satis-
faction indicators [37, 38]. The English version is
available online [39].
Fig. 3 Framework
Fig. 2 Illustrative comparison of risk aversion changes as a function of wealth and health
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Based on our previous work including a systematic litera-
ture review of studies evaluating cognitive biases or distor-
tions in the medical field, we selected tolerance to risk and
ambiguity, overconfidence, herding, and decisions about
someone else [40]. We used the physician’s reaction to un-
certainty test to assess tolerance to risk or ambiguity in pa-
tient care [41]. This questionnaire comprised an initial pool
of 61 items [41]. Factor analysis of the 428 respondents re-
vealed a high accuracy (Cronbach's alpha = 0.90). The short
version of this questionnaire includes five questions [42].
Behavioral experiments were designed to elicit risk and
ambiguity aversion in the health and financial domains
[43, 44], herding (decisions influenced by other colleagues)
[45], decisions about someone else vs. own, and overconfi-
dence (perception that own judgments are more accurate
or in the top 50 % of the studied population) [46].
Participants
Neurologists actively involved in the care of patients
with MS from across Spain will be invited to participate
in our study. Invitations are facilitated by the Spanish
Society of Neurology (Sociedad Española de Neurologia).
We use Qualtrics platform for the design and implemen-
tation of our study. It is expected physicians will be able
to complete the study within 30 min.
Participating physicians will receive fair market compen-
sation for the time involved in completing the survey.
Outcome measures
The primary outcome of the study is the proportion of
participants who exhibit aversion to ambiguity and thera-
peutic inertia [19, 43]. Ambiguity aversion is defined as is
a preference for known risks over unknown risks [43].
This can be elicited through the experiments #16 and #17
in the health and financial domains (Additional file 1).
Therapeutic inertia will be assessed based on the se-
lected treatment options in case-scenarios with recur-
rent relapses, appearance of new brain lesions in follow
up MRI’s while taking a disease modifying agent over a
specified period. Secondary outcome measures include
the association between risk aversion, overconfidence,
and herding with therapeutic decisions and the assess-
ment of therapeutic inertia using different criteria.
Sample size calculation
Based on the results of pilot studies evaluating other
medical conditions (e.g., atrial fibrillation) and our sys-
tematic review on the frequency of cognitive distortions
affecting physicians [40], we require a sample size of 120
physicians (60 per group) (Table 3) to reach 90 % power
to detect a conservative 20 % absolute difference in
therapeutic inertia between participants exposed and not
exposed to cognitive distortions.
Feasibility
the study interventions are simple and doable. The protocol
includes clinical scenarios commonly observed in clinical
practice. According to the Spanish Neurological Society
(Sociedad Española de Neurología-SEN), there are over
1600 neurologists, 13 specialized MS centers comprising
approximately 200 specialists in the field in Spain. Assum-
ing a low response rate of 50 %, the completion of our study
is feasible considering the required sample size to reach a
power of 90 % with an alpha of 5 %.
Analytical plan
To address objective 1, we will characterize participants’
risk and ambiguity aversion as identified by the corre-
sponding experiments (Additional file 1, behavioral bat-
tery questions (Q) #1 to 4.
To address objective 2, we evaluate therapeutic inertia
(TI) as elicited by 10 case-vignettes. We will created a TI
score representing the number of cases that participants
did not escalate treatment (numerator) over 10 (denom-
inator) multiplied by 100. The diversity of case-scenarios
will also allow the analysis of therapeutic inertia using
different criteria (e.g., modified Rio score, European
Medicines Agency, isolated GAD-enhanced lesions).
To address objective 3, we will complete a univariate
and multivariable analysis to determine the influence of
risk aversion, tolerance to ambiguity, overconfidence and
herding on therapeutic decisions and TI score.
Chi squared tests will be used to compare categorical
variables; t-test or Kruskal-Wallis tests will be used to
compare mean and median differences for continuous
variables. The primary analysis will evaluate the associ-
ation between physicians’ responses in the behavioral
component of the survey with responses in the case-
scenarios. A multivariable analysis will be completed to
determine the association between physicians’ character-
istics with the primary outcome of interest. Adjustment
includes the following variables: age, sex, years of experi-
ence, expertise, volume of MS patients seen per week,
and practice setting (academic vs. community). All tests
were 2-tailed, and p-values <0.05 will be considered
significant.
Knowledge translation strategies
We plan to take a multifaceted approach to knowledge
translation, targeting the following audiences for com-
munication: 1) Neurologist, 2) the clinical academic
Table 3 Sample size calculation
Powera 90 % 85 % 80 %
N (per group) 60 53 46
aThe power was calculated to detect a 20 % absolute difference between
groups (40 % vs 20 %) with an alpha of 5 % (two-sided) for all of the
calculations in the table
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community, 3) the media, 4) policy-makers, and 5) MS
patients and their families. We expect to generate high
impact publications and media interest to inform the
public and influence MS care programs. This work is
also expected to increase awareness about therapeutic
inertia among MS experts and to contribute toward new
guidelines for the management of MS. We are working
with key stakeholders to discuss the most effective dis-
semination strategy and target the key messages for all
audiences.
Discussion
Patients and physicians caring for patients with MS are
confronted with important uncertainties concerning the
diagnosis, prognosis, disease course, and disease-
modifying therapies. In the recent years, new therapeutic
alternatives became available for management of MS [5,
47]. These advances were achieved by targeting different
pathophysiological mechanisms, producing more effect-
ive DMTs, but accompanied by either higher risk of in-
fections, or more serious side effects [48]. As a result,
MS experts have an expanded therapeutic arsenal com-
pared to a decade ago. Decisions are not merely about
the selection of an injectable interferon or Glatiramer
(given daily or every other day) usually accompanied by
skin reactions or flu-like symptoms, but rather the indi-
vidual selection of the most appropriate DMT (e.g., dose,
administration type, efficacy and safety profile) according
to disease severity, patient’s clinical status and prefer-
ence. Consequently, more effective agents are now more
accessible for MS patients who failed traditional DMT
[5, 49].
Interestingly, physicians have limited education in both
risk management and in formal training in decision
making [50, 51].
We are proposing a novel approach in expanding re-
search of MS care by combining case-vignettes with the
assessment of cognitive distortions through experiments
in Neuroeconomics (Decision Neuroscience). The appli-
cation of Neuroeconomics’ principles may help over-
come those barriers by identifying and increasing
awareness about cognitive distortions (e.g., overconfi-
dence, tolerance to risk and ambiguity, etc.) that may
lead to suboptimal decisions (e.g., therapeutic inertia)
[18, 25, 52].
This study will provide evidence about: i) how MS ex-
perts make decisions under uncertainty, ii) how MS ex-
perts would change their preferences based on their
tolerance to risk and ambiguity, iii) the prevalence of
therapeutic inertia based on different criteria for escalat-
ing therapy (modified Rio, European Medicines Agency),
and iv) the influence of cognitive distortions on thera-
peutic inertia.
DIScUTIR MS is designed as a pilot study to deter-
mine the feasibility of assessing tolerance to risk and
ambiguity, therapeutic inertia, and associated factors
among practicing physicians with expertise in MS.
The results of our study will also facilitate crucial in-
formation to understand current MS care practices and
how physicians’ preferences (e.g., risk aversion) have a
global impact on medical and daily life decisions.
Some limitations need to be acknowledged. First,
the small sample size of MS experts from a single
country (Spain) would limit the generalizability of the
results. However, DIScUTIR MS is designed as a pilot
study to determine the feasibility of a larger world-
wide study. Second, the concept and definition of
therapeutic inertia applied to MS care is not widely
disseminated. Some colleagues may also argue about
the absence of an accepted definition of therapeutic
inertia in MS care. However, we used a widely accept-
able definition of TI supported by studies showing
health care improvements in the management of key
and widely prevalent conditions (i.e.,: blood pressure
and diabetes).
Despite the aforementioned limitations, our study
will increase physicians’ awareness of crucial situa-
tions under uncertainty in the management of MS.
The results of DIScUTIR MS will provide a starting
point to ignite discussions about a widely accepted
definition of therapeutic inertia in MS care. This is
relevant considering the lack of MS guidelines con-
cerning clinical scenarios under uncertainty or pro-
gression of disease [53, 54].
The identification of clinical or radiological progres-
sion in MS should at least set the time of ‘thera-
peutic momentum’ to consider escalating treatment,
especially when cost-effective options are available. In
this setting, physicians may want to take that oppor-
tunity to discuss risk-benefit scenarios in a way simi-
lar to how financial advisors assess their clients’
preferences and risk tolerance when advising about a
variety of investment portfolios. An open discussion
in risky situations following the appropriate documen-
tation of disease progression would ameliorate the
therapeutic inertia and may lead to more optimal de-
cisions in the care of patients with MS.
Ethics approval
The protocol was approved by the Research Ethics Board
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Availability of data and materials
The appendix contains all details of the protocol.
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Objectives: Limited information is available on physician-related factors influencing 
therapeutic inertia (TI) in multiple sclerosis (MS). Our aim was to evaluate whether phy-
sicians’ risk preferences are associated with TI in MS care, by applying concepts from 
behavioral economics.
Design: In this cross-sectional study, participants answered questions regarding the 
management of 20 MS case scenarios, completed 3 surveys, and 4 experimental para-
digms based on behavioral economics. Surveys and experiments included standardized 
measures of aversion ambiguity in financial and health domains, physicians’ reactions to 
uncertainty in patient care, and questions related to risk preferences in different domains. 
The primary outcome was TI when physicians faced a need for escalating therapy based 
on clinical (new relapse) and magnetic resonance imaging activity while patients were on 
a disease-modifying agent.
results: Of 161 neurologists who were invited to participate in the project, 136 coop-
erated with the study (cooperation rate 84.5%) and 96 completed the survey (response 
rate: 60%). TI was present in 68.8% of participants. Similar results were observed for 
definitions of TI based on modified Rio or clinical progression. Aversion to ambiguity 
was associated with higher prevalence of TI (86.4% with high aversion to ambiguity vs. 
63.5% with lower or no aversion to ambiguity; p = 0.042). In multivariate analyses, high 
aversion to ambiguity was the strongest predictor of TI (OR 7.39; 95%CI 1.40–38.9), 
followed by low tolerance to uncertainty (OR 3.47; 95%CI 1.18–10.2).
conclusion: TI is a common phenomenon affecting nearly 7 out of 10 physicians caring 
for MS patients. Higher prevalence of TI was associated with physician’s strong aversion 
to ambiguity and low tolerance of uncertainty.
Keywords: multiple sclerosis, disease-modifying therapy, neuroeconomics, decision-making, risk aversion
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inTrODUcTiOn
Making decisions in medical care is a complex task (1). Physicians 
have limited education in both risk management and decision-
making at medical schools (2). Decisions based on erroneous 
assessments may result in incorrect patient and family expecta-
tions, and potentially suboptimal advice, treatment, and outcome.
In behavioral economics, uncertainty is a generic term that 
comprises risk and ambiguity. Risk applies to events with known 
probability (3). In contrast, ambiguity is a term reserved for 
events for which probabilities are unknown (3). Typically, people 
are averse to both ambiguity and risk, and the two aversions are 
independent of each other (4). Uncertainty is one of the most 
important contributing factors affecting decisions in medical 
care (5, 6). However, limited information is available regarding 
the role of aversion to ambiguity in medical decisions.
Appropriate multiple sclerosis (MS) care involves complex 
medical decisions as it requires consideration of multiple short- 
and long-term factors (e.g., imaging results, disease progression, 
patient’s characteristics, and their preferences, etc.). No evidence 
of disease activity is emerging as a new standard for treatment 
response and may be associated with improved long-term disabil-
ity outcomes. A more proactive management strategy, including 
earlier use of high-efficacy DMTs and close monitoring of the 
clinical and radiological response to treatment, is recommended 
to slow the progression of physical and cognitive impairments 
in patients with relapsing-remitting multiple sclerosis (RRMS) 
(7–9). Treatment escalation has been shown to reduce relapse 
rates, disability progression, and magnetic resonance imaging 
(MRI) activity (10).
Therapeutic inertia (TI) is a term introduced in 2006 to define 
the absence of treatment initiation or intensification in patients 
when treatment goals are unmet (11–14). In the context of MS, 
TI is defined as the lack of treatment initiation or escalation when 
there is evidence of disease activity (based on the clinical course 
and neuroimaging markers) (15, 16). It is possible that aversion 
to ambiguity contributes to TI as the probabilities of benefits with 
treatment escalation are typically less well known than with treat-
ment continuation. To address this possibility, we need a better 
understanding of physician-related factors influencing decisions 
about DMTs and the prevalence of TI in MS care. The application 
of experiments from behavioral economics would facilitate the 
recognition of physicians’ therapeutic preferences and beliefs 
about DMTs for MS in the real world (17).
We hypothesized that physicians’ ambiguity aversion or low 
tolerance to uncertainty are associated with TI and clinical 
decisions in MS care. In the present study, we thus assessed the 
prevalence of TI (and associated contributing factors) in typi-
cal clinical decisions among physicians caring for MS patients 
across Spain.
MaTerials anD MeThODs
We conducted a web-based study using the Qualtrics platform 
(http://qualtrics.com). The study comprised 20 MS case-
vignettes, 3 standardized surveys, and 4 behavioral experiments 
among practicing neurologists from Spain from November 3, 
2015 to March 31, 2016 (see protocol published elsewhere) (15). 
In brief, participants answered three components in the following 
order: (i) demographic information, (ii) behavioral experiments/
surveys, and (iii) case scenarios. Responses from case scenarios 
were analyzed in light of responses from the behavioral compo-
nent. MS case scenarios were derived from the most common 
situations in clinical practice as identified by experts in the field 
(Drs. Daniel Selchen and Angel P. Sempere). Behavioral experi-
ments were designed to assess risk and ambiguity aversion in the 
health and financial domains (exposure) (Figure 1) (15, 18, 19). 
Ambiguity aversion is defined as dislike for events with unknown 
probability over events with known probability (18). For example, 
an ambiguity-averse individual would rather choose a treatment 
where the probability of benefits or side effects are known (even 
if these are somewhat unfavorable) over one where these prob-
abilities are unknown. Specifically, participants were asked to 
choose between a visual option with known 50/50 probability of 
winning €400 or €0 and an option with unknown probability of 
the same outcomes. Gray bars represented the degree to which 
the winning probability was unknown (Figure  1). The degree 
of ambiguity aversion was defined as the proportion of times 
participants chose the 50/50 option over the ambiguous option. 
As the overall level of ambiguity aversion was pronounced in our 
sample (mean 61.7% preference for 50/50 option, i.e., the option 
with known probabilities) and to avoid using an arbitrary crite-
rion, we classified participants as highly ambiguity averse if they 
chose the 50/50 (known probability) option in each of the nine 
scenarios (Figure  1) (20). In order to evaluate the consistency 
of the relationship with the primary outcome, we also analyzed 
another definition of ambiguity aversion (choice of the known 
probability option instead of the option with the 50% unknown 
probability in scenario 5; Figure 1).
In principle, risk aversion is another factor that may influence 
clinical decisions (21). Risk aversion is defined as the tendency to 
prefer safe payoffs over probabilistic payoffs when the expected 
value of both options is identical (4, 18). A risk-averse patient 
would thus prefer a treatment that provides a small improve-
ment with certainty over a treatment that provides a larger or 
no improvement with equal chance (50/50). We evaluated risk 
aversion by identifying the safe amount for which a participant 
was indifferent between the safe and the risky option (22). This 
indifference amount, called certainty equivalent, reflects the 
value associated to the risky option and facilitates comparison 
between participants. For example, participants were asked what 
would be the minimal certain payoff that they would prefer over 
the equiprobable gamble of winning €400 or €0 (expected value of 
€200). The degree of risk aversion of each individual corresponded 
to the difference of the expected value of the risky option (€200) 
minus the participant’s response (proxy of certainty equivalent). 
A similar visual design and methodology was used to elicit 
aversion to risk and ambiguity in the health domains (questions 
#15 and #17) (15). Participants were asked to choose between 
Treatment A (50% probability of survival) and “Treatment B” (the 
probability of survival is unknown) with the gray bars quantify-
ing how much is unknown about the probability of survival.
We also used two standardized surveys to assess physicians’ 
willingness to take risks and tolerance to uncertainty. The German 
FigUre 1 |  Decision scenarios used to measure ambiguity in financial (a) and health (B) domains. Participants were told to imagine two different types or 
urns. For urn type A, they knew that 50% of the balls were red and the other 50% were blue. For urn type B, they did not know the exact proportion of blue to red 
balls, with the gray bar representing the unknown proportion of balls. For the financial domain, participants knew that if they drew a blue ball, they would win the full 
amount of $400. If they drew a red ball, they would win $0. For the health domain, participants decided between two treatments for a patient. With “Treatment A,” 
the patient had a 50% probability of survival. With “Treatment B,” the exact probability of survival was unknown, with the gray bar representing the unknown 
probability.
3
Saposnik et al. Decision-making in MS (DIScUTIR MS)
Frontiers in Neurology | www.frontiersin.org March 2017 | Volume 8 | Article 65
Socio-Economic Panel (SOEP) is a validated survey that evaluates 
willingness to take risks in different domains (financial matters, 
own health, driving, own occupation, etc.) (23). We used ques-
tions of the form: “How would you rate your willingness to take 
risks in the following areas….”? Areas included financial matters, 
driving, occupation, etc., and responses could range from 0 (not 
at all) to 10 (very much).
The second survey measured physicians’ tolerance to uncer-
tainty in patient care, using the reaction to uncertainty test (24). It 
comprises five questions to be rated from 0 to 5 that when added 
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gives a total score (25). Low tolerance to uncertainty was defined 
as values below the median of the total score. Further details of 
the protocol were published elsewhere (15).
Participants
Practicing neurologists actively involved in the care of 
patients with MS from across Spain were invited to participate 
in our study by the Spanish Society of Neurology (Sociedad 
Española d8e Neurologia-SEN). Physicians whose practice 
was primarily in caring for MS patients were classified as 
“MS specialists.” All participants received compensation for 
completing the survey.
Definitions
For the primary analysis, disease activity was defined as a clinical 
relapse plus the presence of new brain lesions in follow-up MRI 
scans with at least one gadolinium-enhancing lesion (26, 27). 
In a sensitivity analysis, we also used the European Medicines 
Agency (EMA) and the modified Rio criteria to evaluate varia-
tions in TI. For example, the EMA approves escalating therapy 
from interferon-beta to natalizumab or fingolimod in patients 
who had at least one relapse in the previous year and either ≥9 
T2 hyperintense lesions or ≥1 gadolinium-enhancing T1 lesion 
on brain MRI (26, 27). The high-risk profile according to the 
modified Rio score includes either an MRI with more than 5 
new T2 lesions (1 point) or 1 relapse in the first year (1 point) or 
two relapses within the first year of treatment (2 points) or the 
combination of these criteria (8, 28). The use of these definitions 
combining a clinical relapse and MRI activity is consistent with 
recent evidence regarding the risk of treatment failure among 
patients receiving interferon-beta (29).
Disease progression was defined as at least one point worsen-
ing from baseline in the Expanded Disability Status Scale (EDSS) 
score (Table S1 in Supplementary Material) (28).
Recent meta-analysis confirmed that alemtuzumab, natali-
zumab, and fingolimod are the best available choices for prevent-
ing clinical relapses in patients with RRMS (30). However, there 
is no consensus algorithm available despite the publication of 
national or regional recommendations (8, 16, 26, 31–33). As a 
result, the current landscape of DMTs for the treatment of RRMS 
includes first-line therapies (beta interferons, glatiramer acetate, 
teriflunomide, and dimethyl fumarate) and second-line therapies 
(fingolimod, natalizumab, and alemtuzumab). For the present 
analysis, we used the aforementioned scheme according to the 
current clinical practice.
Outcome Measures
The primary outcome of the study was the proportion of par-
ticipants who exhibited TI and its association with aversion to 
ambiguity (14, 18). TI (presence/absence) was determined as the 
lack of escalation of therapy given disease activity while patients 
received a DMT in at least one case scenario.
Secondary outcome measures included the association 
between tolerance to uncertainty, risk aversion, and the SOEP 
surveys, on the one hand, and with TI and therapeutic decisions, 
on the other hand.
statistical analysis
The primary analysis assessed the possible association between 
physicians’ aversion to ambiguity and TI. A multiple logistic 
regression analysis with backward selection was completed to 
determine the association between physicians’ characteristics 
with the primary outcome of interest. We included the following 
explanatory variables: age, gender, MS patients seen per week, 
practice setting (academic vs. non-academic), % of time devoted 
to clinical care, coauthor in a peer-reviewed publication within 
the last 3 years (yes/no), attendance to the European Committee 
for Treatment and Research in Multiple Sclerosis 2015 annual 
meeting, risk aversion, overconfidence, tolerance to uncertainty 
(above/below the median), willingness to take risks in all domains 
(SOEP survey—above/below the median), and herding (follow-
ing recommendations made by another colleague). As there was 
a high correlation between MS specialists (self-defined) and 
number of MS patients assessed per week (Spearman’s rho = 0.58; 
p < 0.001), only the latter was entered in the multivariate analysis. 
Linear regression analysis was used to test for a relation between 
the number of patients assessed per week and the outcomes of 
interest. A sensitivity analysis was completed by using different 
criteria of TI and building models including all variables of inter-
est (Supplementary Material).
All tests were 2-tailed, and p-values <0.05 were considered 
significant. We calculated the power of the study for the primary 
outcome of interest with an alpha error level of 0.05 and found 
that we had 100% power to detect a 27% difference between 
groups for the primary outcome measure.
The study was approved by the Research Ethics Board of St. 
Michael’s Hospital, University of Toronto, ON, Canada.
resUlTs
Out of the 161 neurologists who were invited to participate in 
the study from representative areas of Spain, 136 cooperated 
(cooperation rate 84.5%) and 96 completed the survey (response 
rate 60%). There was representation from all regional territories 
except the Canary Islands (Figure S1 in Supplementary Material).
Overall, the mean (SD) age was 39.5 (±8.5) years; 51 (53%) 
were female. Two-thirds primarily focused their practice on MS 
care (n = 64; 66.7%). The mean years in practice was 14, com-
monly assessing 20 (±15) MS patients per week. Table 1 sum-
marizes baseline characteristics of the study population.
For the measurement of risk preferences, the mean safe payoffs 
were €200 (±33) in the financial domain and 12.3 (±4.3) years in 
the health domain.
For the measurement of ambiguity, total aversion to unknown 
probability (all nine scenarios) was observed in 23% of partici-
pants in the financial domain and 27.1% for the health domain. 
For the scenario where the ambiguous option contained 50% 
unknown probability (scenario 5), 59.4% of participants chose 
the known probability (50/50) option in the financial domain and 
73.7% in the health domain. The median time for completing the 
study was 39 min (IQR 30–52 min).
Therapeutic inertia was present in 68.8% of participants. Similar 
findings were observed when we applied the modified Rio criteria 
(61.5%), modified Rio or neurological progression (67.7%), but 
TaBle 2 | Prevalence of therapeutic inertia (Ti) among multiple sclerosis 
(Ms) specialists and general neurologists.







Clinico-radiological 40 (62.5) 26 (81.3) 0.062
European Medicines Agency 13 (20.3) 15 (46.9) 0.007
Modified Rio or progression 39 (60.9) 26 (81.3) 0.045
TaBle 1 | Baseline characteristics of participants.
characteristics
age (mean ± SD), in years 39.5 ± 8.5




Multiple sclerosis (MS) specialist 64 (66.7)




Both (academic and community) 21 (21.9)
Other 1 (1.0)
% time in clinical practice
>75% 70 (72.9)
Years in practice, mean ± SD 14.1 ± 10
Ms patients seen per week, mean ± SD 20 ± 15
attended latest european committee 
for Treatment and research in Multiple 
sclerosis conference
56 (58)
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TI was less common (29.2%) when we applied the EMA criteria. 
TI was less common among MS specialists (Table 2). Moreover, a 
higher number of MS patients seen per week were associated with 
a significantly lower risk of TI. Linear regression analysis suggests 
that the assessment of 10 more MS patients per week (from a 
baseline of 16) was associated with lower risk of TI (adjusted 
coefficient −10.2; 95%CI −18.4 to −2.0).
aversion to ambiguity and Ti
For the primary outcome, high aversion to ambiguity in the finan-
cial domain was associated with TI (86.4 vs. 63.5%; p = 0.042). 
High ambiguity aversion in the health domain was not associated 
with TI (76.9 vs. 65.7%; adjusted OR 1.79, 95%CI 0.61–5.25). 
Multivariable logistic regression analysis showed that high aver-
sion to ambiguity in the financial domain was the strongest predic-
tor of TI, significantly stronger even than aversion to ambiguity in 
the health domain (adjusted OR 7.39; 1.40–38.9) (Table 3; Table 
S2 and Figures S2 and S3 in Supplementary Material). The results 
were also consistent when ambiguity aversion was defined by 50% 
unknown probability (adjusted OR 3.29; 1.21–8.99).
A sensitivity analysis showed that high aversion to ambiguity 
was also the strongest predictor of TI when applying the EMA 
criteria (adjusted OR 8.01; 95%CI 1.73–37.1) for the composite 
outcome of disease activity (modified Rio criteria) or evidence of 
progression (OR 4.41; 95%CI 1.04–18.7). The results remained 
consistent when models included all explanatory variables of 
interest, including number of patients seen per week (Table S2 in 
Supplementary Material).
Low tolerance to uncertainty (physician’s reaction to uncer-
tainty survey) was associated with higher prevalence of TI (85.4 vs. 
56.4%; adjusted OR 4.73, 1.63–13.7) (Figure 2). The association 
between TI and low tolerance to uncertainty was independent of 
the association between TI and high ambiguity aversion (Table S2 
in Supplementary Material).
Conversely, willingness to take risk in multiple domains (as 
measured by the SOEP survey) or herding was not associated 
with TI (Table S2 in Supplementary Material).
DiscUssiOn
Multiple sclerosis patients and their treating physicians are rou-
tinely confronted with uncertainties concerning the diagnosis, 
prognosis, disease course, and disease-modifying therapies (27).
In the present study, we applied validated experiments and 
surveys from behavioral economics to evaluate the association 
between physicians’ aversion to risk or ambiguity and TI (15). 
We found that TI affects nearly 7 out of 10 neurologists caring 
for MS patients but was less common among physicians with 
greater patient volumes per week or MS specialists. High aversion 
to ambiguity was the strongest predictor of TI even after adjust-
ing for relevant confounders (e.g., age, practice setting, years in 
practice, percentage of time in clinical practice, overconfidence, 
time of survey completion, etc.). Lower tolerance to uncertainty 
was also associated with 3.5-fold higher risk of TI. On average, 
the assessment of 10 more MS patients per week was associated 
with lower risk of TI. Our results were consistent when employing 
various criteria on when to escalate therapy, as defined based on 
disease activity and/or progression. Physicians’ characteristics 
(e.g., age, gender, practice setting, years in practice, percentage of 
time in clinical practice) were not associated with TI.
In the last few years, there has been an increase in the avail-
ability and variability of therapeutic options for the management 
of MS. Although having more options is perceived as beneficial, 
consumer studies in psychology suggest the higher the number of 
options, the more difficult the decision, leading to a higher number 
of less satisfactory choices (labeled as “choice overload”) (34, 35).
Our results have practical implications that deserve comment. 
We showed that either a simple experiment or a short survey out-
side of the medical domain that assess aversion to ambiguity or 
tolerance to uncertainty may help to identify TI among neurolo-
gists and MS experts. The lack of escalation of therapies may lead 
to greater disability of MS patients, increasing the health-care 
costs and production losses due to incapacity to work. In Europe, 
the mean annual cost per person with MS has been estimated 
at €23,000 for EDSS score 0.0–3.5, rising as disability increases 
to €46,000 for EDSS score 4.0–6.5, and €77,000 for EDSS score 
7.0–9.5 (36). 129
FigUre 2 | Prevalence of therapeutic inertia (Ti) among participants with high ambiguity aversion in the financial domain and low tolerance to 
uncertainty in patient care. See description in the text for the criteria of TI. *p = 0.042; **p < 0.01.
TaBle 3 | effect of high ambiguity aversion according to different definitions of therapeutic inertia (Ti).
Outcome Prevalence (%) of Ti in the 
cohort
adjusted model for ambiguity 
aversiona
adjusted model for 
ambiguity aversionb
Or (95%ci) c-statistics Or (95%ci) c-statistics
Ti (criterion)
Clinico-radiological 66 (68.8) 7.39 (1.40–38.9) 0.804 8.01 (1.01–73.3) 0.828
European Medicines Agency 28 (29.2) 8.02 (1.37–37.1) 0.777 7.17 (1.36–37.6) 0.796
Modified Rio or progression (Expanded Disability Status Scale >1) 65 (67.7) 4.41 (1.04–18.7) 0.791 4.01 (0.83–19.3) 0.811
aModels derived from stepwise logistic regression with backward selection with p > 0.2 level for removal.
bModels derived from logistic regression including all variables of interest (age, sex, number of multiple sclerosis patients seen per week, practice setting, academic profile, risk 
aversion, ambiguity aversion, tolerance to uncertainty, herding, and overconfidence).
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Factors associated with TI include low volume of MS patients, 
non-specialty, and physicians’ ambiguity preferences (e.g., low 
tolerance to uncertainty in patient care, high aversion to financial 
ambiguity). Taken together, TI may be explained, at least in part, 
by (i) the aversion of neurologists to escalate treatment when 
the available options can have more serious side effects; (ii) the 
limited education (or experience) of neurologists regarding the 
risk profile of new DMTs, and (iii) participants’ preference to 
continue with a known medication profile vs. the unknown risks 
of a new agent. Other studies have found that TI was associated 
with lack of training and clinical uncertainty (5). Physicians with 
better coping strategies and more tolerance to ambiguity may 
be more likely to choose optimal treatments leading to better 
patients’ outcomes (37).
The prevailing significance of aversion to ambiguity in the 
financial over the health domain in the multivariate analysis may 
be related to either methodological differences when measuring 
each variable or suggest an underlying hardwired representa-
tion of aversion to ambiguity and TI that is easier elicited in the 
financial domain (18).
The results of DIScUTIR MS may not only be relevant for 
MS care but also be seen as the initial step to inform the design 
of a larger worldwide intervention, including physicians’ high 
aversion to ambiguity in the financial domain and low tolerance 
to uncertainty in patient care when assessing the use of new 
agents.
Our study has limitations that deserve comment. First, the 
study was conducted in Spain exclusively, thus limiting the gen-
eralizability of our results to other cultural contexts. Moreover, 
some participants may have responded based on their current 
local restrictions to prescribe specific DMTs. However, cognitive 
distortions and risk preferences have been identified in several 
studies of physicians’ decisions across the world and are thus 
probably not limited to a specific region or country (38). Second, 
the assessment of case scenarios may not fully capture decisions 
made in real clinical practice, even though specialists designed 
and recognized the scenarios as close to daily practice. In addi-
tion, participants may refer their MS patients to an MS outpatient 
clinic as part of a standard practice, which may have influenced 
our results. Third, considering the relatively low sample size, our 
findings should be viewed as exploratory. However, our results 
were consistent across several criteria of TI and adjusted models. 
Fourth, the concept and definition of TI applied to MS care is 
not widely disseminated and not yet generally accepted in MS 
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care. Nevertheless, we used a practical definition of TI (absence of 
escalation in the face of a clinical relapse plus evidence of imaging 
activity), which is supported by consensus panels, as well as by 
MS studies and other areas showing improvements in clinical 
outcomes when escalating therapies (i.e., blood pressure and 
diabetes) (14, 39, 40).
Despite these limitations, our study is the first step in the 
understanding of how specific characteristics of physicians 
(i.e., high ambiguity aversion, low tolerance to uncertainty) 
directly influence therapeutic decisions in MS patients beyond 
demographic factors, medical expertise, practice setting, patients’ 
factors, or their treatment preferences. Using a novel approach 
that combines case-vignettes with the assessment of cognitive 
distortions through experiments from behavioral economics, 
we were able to expand our current understanding of decision-
making under uncertainty in MS care.
Although MS experts have an expanded therapeutic arse-
nal compared to a decade ago, our study shows that nearly 
7 out of 10 neurologists exhibited TI leading to suboptimal 
decisions. The results of DIScUTIR MS provide vital infor-
mation to initiate discussions on behavioral strategies and 
incentives in order to ameliorate physicians’ inertia to escalate 
therapies leading to better outcomes and quality of life for 
MS patients (41). For example, training in risk management 
and decision-making, as well as, educational interventions are 
needed to overcome knowledge-to-action gaps (and reduce 
the TI) in MS care. This is relevant considering the lack of 
well-established MS guidelines concerning clinical scenarios 
under uncertainty or progression of disease and the limited 
understanding on how physicians’ preferences (e.g., aversion 
to ambiguity) have a global impact on medical and daily life 
decisions (42).
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Table S1. Criteria of Therapeutic inertia and case-scenarios 
Criteria Clinical + 
Radiological 
EMA criteria Composite modified 
Rio ≥2 or MS 
progression 
Case-scenario number 
 7 4  4 
8 8 7 
13 14 13 
14 15  14 
   15 
Definition Clinical relapse + at 
least 1 Gad enhancing 
lesion 
1 relapse last year 
+ ≥ 9 new T2 OR ≥ 1 
Gad T1 
MRI criterion: 1 if >5 
new T2 lesions 
Clinical criterion:  
1 if 1 relapse 
2 if ≥ 2 relapses over 
the first year or EDSS 
≥1 from baseline 
Overlap with other 
measures 
NO Herding NO 
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Table S2. Variables associated with therapeutic inertia: full logistic regression models   
 
 
Clinical + Radiological EMA 
Modified Rio or 
progression 
OR; 95% CI 
Ambiguity aversion-
(Financial domain) 
8.6 (1.01-73.32) 7.16; 1.36-37.63 3.91; 0.63-23.96 
Ambiguity aversion-
(Health domain) 
0.75 (0.17-3.34) 0.16; 0.30-0.92 1.10; 0.26-4.56 
Age 0.93; 0.81-1.07 1.07; 0.84-1.36 0.95; 0.85-1.07 
Gender, male 0.54; 0.18-1.67 0.85; 0.28-2.51 0.52; 0.17-1.56 
Years in practice 1.02; 0.89-1.17 0.90; 0.69-1.17 1.01; 0.91-1.13 
Authorship 1.18; 0.24-5.69 2.81; 0.73-10.74 1.37; 0.28-6.5 
Patients seen/week 0.96; 0.93-1.00 0.96; 0.91-1.01 0.97; 0.93-1.00 
Setting, academic 1.48; 0.41-5.28 0.44; 0.12-1.60 1.25; 0.36-4.31 
Attendance ECTRIMS 
2015 
1.38; 0.44-4.30 1.60; 0.54-4.77 1.26; 0.41-3.85 
SOEP 0.74; 0.25-2.18 1.26; 0.43-3.70 0.87; 0.30-2.5 
Low tolerance to 
uncertainty 
3.9; 1.22-12.45 0.65; 0.21-1.93 4.27; 1.36-13.4 
Herding experiment 0.37; 0.06-2.08 0.36; 0.09-1.37 0.34; 0.062-1.85 
Risk Aversion 0.70; 0.18-2.68 2.35; 0.62-8.86 0.83; 0.22-3.11 
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Figure S1. Representation of participants in DIScUTIR MS  
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Figure S2. Preference for the known probability (50/50) option for each the nine scenarios with unknown 
probability (ambiguity aversion) 
 
Note the increasing number of participants choosing the known probability option (aversion to ambiguity) when the unknown probability increases. 
  
Figure S3. Number of times that participant choose the known probability (50/50) option over the ambiguous option 
  
 
Note: This figure represents the number of scenarios that participants choose the known probability option (50/50) over the ambiguous 
(unknown probability) option. For example, 20.8% of participants selected the 50/50 option in 4 scenarios, 16.7% selected the 
50/50option in 6 scenarios. Overall, 22.9% of participants selected the known probability (50/50) option in all nine scenarios suggestive 
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Abstract
IMPORTANCE There is growing interest in understanding and addressing factors that govern the
decision-making process in multiple sclerosis (MS) care. Therapeutic inertia (TI) is the failure to
escalate therapywhen goals are unmet. Limited data are available on the prevalence of TI and factors
affecting therapeutic decisions in themanagement of patients with MSworldwide.
OBJECTIVES To compare TI across 4 countries (Canada, Argentina, Chile, and Spain) and to identify
factors contributing to TI.
DESIGN, SETTING, AND PARTICIPANTS Prospective cohort study conducted between July 10,
2017, andMay 4, 2018. Participants were exposed to behavioral experiments in which instruments
were used to assess their risk preferences (eg, aversion to ambiguity) and therapeutic decisions in 10
simulatedMS case scenarios. Mixed-effects linear and logistic regression analyses were performed
to determine the association between the participants’ baseline characteristics and TI. The
association of unmeasured confounders was assessed by the E-value and a bootstrapping analysis.
This multicenter study included neurologists practicing at academic and community centers in
Canada, Argentina, Chile, and Spain whomake therapeutic decisions for patients with MS.
MAIN OUTCOMES ANDMEASURES The primary outcome was the prevalence of TI. The TI score
was calculated by dividing the number of case scenarios in which participants showed TI by the
number of case scenarios that measured TI. Higher TI scores indicated greater degrees of TI. The
secondary outcomewas the identification of factors that contributed to TI.
RESULTS Of 300 neurologists with expertise in MS care who were invited to be part of the study,
226 (75.3%) agreed to participate. Among those who initially showed interest in participating, 195
physicians (86.3%) completed the study, while 31 did not. The mean (SD) age of participants was
43.3 (11.2) years; 52.3%weremale. Therapeutic inertia was present in 72.8% (142 of 195) of
participants, leading to suboptimal decisions in 20.4% (318 of 1560) of case scenarios. The
prevalence of TI among the Canadian group was the lowest compared with the other 3 countries
(60.0% [33 of 55] vs 77.9% [109 of 140]; P = .01). For the primary outcome, the TI score in the
Canadian group (mean [SD], 0.98 [1.15]) was significantly lower compared with groups from other
countries (mean [SD], 1.70 [1.43] for Argentina, 2.24 [1.54] for Chile, and 2.56 [1.64] for Spain)
(P = .001). The mixed-effects linear models revealed that participants from Argentina, Chile, and
Spain (combined) had higher TI scores compared with their Canadian counterparts (β coefficient,
0.90; 95%CI, 0.52-1.28; P < .001). A higher number of patients withMS per week (OR, 0.44; 95%CI,
0.22-0.88), years of practice (OR, 0.93; 95% CI, 0.86-0.99), and participation from Canada (OR,
0.47; 95% CI, 0.23-0.96) were associated with a lower likelihood of TI. Aversion to ambiguity was
(continued)
Key Points
Question What is the prevalence of
therapeutic inertia and its
associated factors?
Findings In this cohort study that
included 195 neurologists with expertise
inmultiple sclerosis, the prevalence and
magnitude of therapeutic inertia among
a Canadian group were the lowest
compared with Argentina, Chile, and
Spain. Seeing a higher number of
patients per week, years of practice, and
participation from Canada were
associated with a lower likelihood of
therapeutic inertia, whereas aversion to
ambiguity was associatedwith a higher
likelihood of therapeutic inertia.
Meaning Therapeutic inertia is
common among practicing neurologists,
with practical implications for patients
with multiple sclerosis.
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associated with a 2-fold higher likelihood of TI (OR, 2.25; 95% CI, 1.02-5.00). All 95% CIs of the β
coefficients of covariates were lower than the E-value of 2.35, making it unlikely for the results to be
due to the association of unmeasured confounders.
CONCLUSIONS ANDRELEVANCE This study showed that Canadian participants had the lowest
prevalence andmagnitude of TI. Higher TI scores were associated with a lower expertise in MS care
and with a greater tendency for aversion to ambiguity.
JAMA Network Open. 2019;2(7):e197093. doi:10.1001/jamanetworkopen.2019.7093
Introduction
Multiple sclerosis (MS) is an evolving field, with an increasing number of proven effective therapies.1-3
Given the broad spectrumof disease-modifying therapies (DMTs), neurologistsmay face therapeutic
dilemmas when individualizing decisions regarding themost appropriate DMT for their patients.4,5
It is challenging to decide on an optimal DMT for an individual patient based on the patient’s clinical
disease activity, magnetic resonance imaging (MRI) lesion burden, drug availability, adverse effect
profile, and patient preferences.1 Despite the recent advances in MS therapeutics, many patients
remain undertreated.6Numerous factors contribute to the suboptimal management, including
education gaps in both risk management and decisionmaking among treating physicians.7
The concept of clinical inertia was initially introduced by Phillips et al8 in 2001, who defined it as
lack of therapy escalationwhen it is clinically indicated. The term clinical inertiawas substitutedwith
therapeutic inertia (TI) in 2006 by Okonofua et al.9 Therapeutic inertia is prevalent not only among
patients with MS but also in other chronic conditions, such as diabetes and hypertension.10-12
There is growing interest in understanding and addressing factors that govern the decision-
making process13,14 in MS. A particular interest is identifying variables that alter the therapeutic
decisionmaking of remaining on the same DMT or escalating to a more effective agent, which can be
associated with a possible increase in the risk of serious adverse effects.1,2
Factors contributing to TI remain poorly understood. However, the results of some studies6,15
suggest that physician-associated factors (eg, low tolerance to uncertainty and aversion to
ambiguity) may have a role in the decision-making process. In addition, there is limited
understanding of country-specific differences with regard to the prevalence of TI. Accordingly, the
primary aim of this study was to compare the prevalence of TI among MS-treating physicians in 4
countries (Canada, Argentina, Chile, and Spain). The secondary aim of the study was to identify
factors contributing to TI.
Methods
Study Population
This prospective cohort study was conducted between July 10, 2017, andMay 4, 2018, and followed
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting
guideline. Our study population consisted of neurologists who primarily focus their clinical practice
onMS care from 4 countries (55 in Canada, 90 in Argentina, 25 in Chile, and 25 in Spain). Participants
were invited to take part in the study via email by scientific organizations based in each country
(Canadian Consortium of MS Clinics and NeuroSens, Instituto de Neurociencias Buenos Aires [INEBA]
and Argentine Neurological Society, Chilean Society of Neurology, and Spanish Neurological Society).
Each participant received an email with instructions and a link to start the study. Participants not actively
involved in patient care or those who followed up a low volume of patients withMS (<12 patients with
MS per year) were excluded.
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Informed consent was provided online at the beginning of the study by each participant.
Participants received compensation for completing the surveys that is equivalent to US $100. The
study was approved by the Research Ethics Board of St Michael’s Hospital, University of Toronto,
Toronto, Ontario, Canada.
Data Collection
Participants provided information regarding their clinical practice and expertise and completed
behavioral experiments to assess their risk preferences. Thereafter, participants were exposed to 10
simulated MS case scenarios and made therapeutic choices (case scenarios are available in the
eAppendix in the Supplement). Case scenarios were designed by teammembers (M.T. and G.S.) and
byMS experts (J.O. and a nonauthor) to reflect current clinical practice. Eight of the cases required
escalation of therapy; therefore, the failure to do so by the participant was considered as TI. The
other 2 cases were designed to detect overtreatment when treatment escalation was not deemed
medically necessary. All participants were exposed to the same case scenarios. Details of behavioral
experiments in which instruments were used in the assessment of tolerance to uncertainty and risk
aversion are described elsewhere.6,16,17 In brief, participants were asked to choose between 2 options
of (1) either winning US $400 or $0 when the probability is 50/50 (represented by a blue/red bar)
vs (2) an option of unknown probability (represented by a blue/red bar covered by a gray bar) of the
same outcome. Participants who favored the known probability of 50/50 were deemed to have
aversion to ambiguity, while other participants were considered as having tolerance to uncertainty.
Risk was assessed by asking participants to provide the minimal amount of US dollars (or healthy
years) that they would prefer over a 50/50 chance of winning US $400 (or longer survival with
adverse effects of a treatment). The degree of risk aversion of each individual corresponded to the
difference of the expected value of the risky option (US $200)minus the participant’s response.16
We also evaluated physicians’ tolerance to uncertainty in a patient’s care using the Reaction to
Uncertainty Test.17 The test was composed of 5 questions that the respondent rated from 0 to 5,
which were summed to give a total score. Higher scores represent a lower tolerance to uncertainty.
Low tolerance to uncertainty was defined as values above the median of the total score. Further
details of the protocol are published elsewhere.18 Responses from case scenarios were analyzed in
light of responses from the behavioral components.
Definitions
Disease activity was defined as a clinical relapse that was associated with the presence of one of the
following MRI findings: at least 1 gadolinium-enhancing lesion or 5 or more new brain lesions.19,20
These thresholds were defined based on prior studies demonstrating in patients receiving interferon
beta that risk of treatment failure highly correlates with a clinical relapse andMRI lesions as defined
above.21 Disease progression in MS was defined as at least 1 point of sustained worsening from
baseline in the Expanded Disability Status Scale Score.22
At the time of the study, treatment options for relapsing-remitting MS included first-line
therapies (beta interferons, glatiramer acetate, teriflunomide, and dimethyl fumarate), second-line
therapy (fingolimod), and third-line therapies (natalizumab and alemtuzumab).4 Given variation in
market approval status of some DMTs among the countries in which the study was conducted,
ocrelizumab and cladribine were not included in case scenarios. For this analysis, we used the 3-line
treatment escalation scheme according to current clinical practice.6,23
OutcomeMeasures
The primary outcomewas the prevalence of TI. As in previous studies,6,24 the TI score was calculated
by dividing the number of case scenarios in which participants showed TI by the number of case
scenarios that measured TI (n = 8). Higher TI scores indicated greater degrees of TI. The TI score
ranged between 0 and 8.
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Therapeutic inertia prevalence was defined as the proportion of participants with TI in at least 1
case scenario. The secondary outcomewas the identification of factors that contributed to TI.
Statistical Analysis
The primary analysis compared TI between Canada and the other 3 countries combined (ie,
Argentina, Chile, and Spain).We included differentmeasures of TI as both continuous and categorical
variables to determine the consistency of our results. We usedmixed-effects linear and logistic
models to assess associations between TI score and TI to determine the association between the
participants’ baseline characteristics and the primary outcome of interest after accounting for
clustering. We included the following explanatory variables: age, sex, specialty, number of patients
with MS seen per week, proportion of time devoted to clinical care, coauthor of a peer-reviewed
publication in the last year (yes or no), practice setting (academic vs nonacademic), risk aversion,
aversion to ambiguity, and physicians’ reaction to uncertainty (above or below themedian).
This multicenter study included neurologists practicing at academic and community centers in
Canada, Argentina, Chile, and Spain whomake therapeutic decisions for patients withMS. To account
for unmeasured confounding, we used an E-value estimate and a bootstrapping analysis to compare
the β coefficients in the normal, percentile, bias-corrected, and bias-corrected and accelerated 95%
CIs. The E-value is a tool to assess the consequences of unmeasured confounding in observational
studies.25 By comparing the upper 95% CI with the 95% CI of covariates included in themodels, the
E-value provides an estimate of the residual confounding that could explain an observed association
if an unmeasured covariate exists.25
All tests were 2 tailed, and P values less than .05 were considered statistically significant. The
area under the curve was used to assess the discrimination, and the Hosmer-Lemeshow test was
used to assess the calibration of themodel.
Results
Of 300 neurologists with expertise in MS care whowere invited to be part of the study, 226 (75.3%)
agreed to participate. Among those who initially showed interest in participating, 195 physicians
(86.3%) completed the study, while 31 did not. Themean (SD) age of participants was 43.3 (11.2)
years; 52.3%weremale. Eighty-six (44.1%) wereMS specialists. Table 1 summarizes baseline
characteristics by country.
Overall, the prevalence of TI was 72.8% (142 of 195), leading to suboptimal decisions in 20.4%
(318 of 1560) of case scenarios. Themean (SD) TI score for the accountable 8 case scenarios was 1.68
(1.50). For every 10 case scenarios withmoderate to high risk of disease progression, this suggested







(n = 140)a P Value
Age, mean (SD), y 43.3 (11.2) 41.8 (12.0) 43.9 (10.8) .24
Sex, No. (%)
Female 93 (47.7) 26 (47.3) 67 (47.9)
.94
Male 102 (52.3) 29 (52.7) 73 (52.1)
Specialty, No. (%)
General neurologist who cares for MS 109 (55.9) 24 (43.6) 85 (60.7)
.03
MS specialist 86 (44.1) 31 (56.4) 55 (39.3)
No. of patients with MS seen/week, mean (SD) 19.4 (11.6) 22.2 (14.6) 18.4 (10.0) .04
Years of practice, mean (SD) 16.7 (11.4) 13.3 (11.2) 17.9 (12.2) .01
≥75% of time devoted to clinical practice, No. (%) 98 (50.3) 30 (54.5) 68 (48.6) .45
Coauthor of a peer-reviewed publication in the last
year, No. (%)
92 (47.2) 31 (56.4) 61 (43.6) .11 Abbreviation: MS, multiple sclerosis.
a Combined countries are Argentina, Chile, and Spain.
JAMANetworkOpen | Neurology Physician Therapeutic Inertia for Management of Patients With Multiple Sclerosis
JAMA Network Open. 2019;2(7):e197093. doi:10.1001/jamanetworkopen.2019.7093 (Reprinted) July 17, 2019 4/10
Downloaded From: https://jamanetwork.com/ on 05/24/2020
141
that there would be 2 suboptimal decisions (eg, lack of treatment escalation) when clinical evidence
of relapses and radiological evidence of disease activity exist.
OutcomeMeasures
Comparison of TI Between Canada andOther Countries
For the primary outcome, the TI score in the Canadian group (mean [SD], 0.98 [1.15]) was significantly
lower compared with groups from other countries (mean [SD], 1.70 [1.43] for Argentina, 2.24 [1.54]
for Chile, and 2.56 [1.64] for Spain) (P = .001). The prevalence of TI among the Canadian group was
also the lowest compared with the other 3 countries (60.0% [33 of 55] vs 77.9% [109 of 140],
P = .01). Values adjusted for age, specialty, number of patients with MS seen per week, years of
practice, and aversion to ambiguity are summarized in Table 2 and Figure 1.
Participant’s risk preferences based on assessments with behavioral instruments are listed in
Table 3. Comparedwith Canada, participants from the other countries weremore risk averse and had
a lower tolerance to uncertainty (reflected by higher scores) (Table 3). For example, the Canadian
group had a lower proportion of participants with values below the certainty equivalence of US $120






β Coefficient (95% CI) P Valuea
Prevalence of TI,
% (95% CI)a
Canada 0.98 (0.63-1.33) 1 [Reference] NA 63.7 (49.4-76.0)
Argentina, Chile,
and Spain combined
1.95 (1.73-2.17) 0.90 (0.52-1.28) <.001 78.0 (70.0-84.2)
Argentina 1.70 (1.42-1.98) 0.65 (0.24-1.06) .002 72.5 (62.9-82.2)
Chile 2.24 (1.72-2.76) 0.92 (0.21-1.64) .01 61.7 (39.3-84.1)
Spain 2.56 (2.04-3.08) 1.74 (1.07-2.42) <.001 96.4 (89.5-100)
Abbreviations: NA, not applicable; TI,
therapeutic inertia.
a Adjusted for age, specialty, number of patients with
multiple sclerosis seen per week, years of practice,
and aversion to ambiguity after accounting for
clustering.
















Combined Argentina Chile Spain
Adjusted TI scores are compared across the studied
countries. The vertical bars represent 95% CIs.
Estimates were derived from linear regressionmodels
after adjustment for age, specialty, number of patients
with multiple sclerosis seen per week, years of
practice, and aversion to ambiguity.











Canada 213.5 (77.2) 14.9 (3.4) 41/55 (74.5) 19.1 (8.6)
Argentina, Chile,
and Spain combined
179.5 (97.0)c 14.3 (4.9) 93/140 (66.4) 23.1 (9.3)d
Argentina 159.6 (102.3)e 12.7 (7.0)c 54/90 (60.0) 23.3 (9.3)e
Chile 233.2 (104.0) 11.2 (5.1)e 20/25 (80.0) 23.1 (10.6)
Spain 183.2 (47.9) 14.9 (3.7) 19/25 (76.0) 22.5 (7.9)
a P values are for comparison with Canada
(reference group).
b Higher scores indicate a lower tolerance to
uncertainty.
c P = .02.
d P = .006.
e P < .001.
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(value that identifies participants with risk aversion) compared with their counterparts (20.0% [11 of
55] vs 37.1% [52 of 140], P = .02).
Participants with an aversion to ambiguity had higher TI scores, although this factor did not
reach statistical significance (mean, 1.90 vs 1.57; P = .15). Participants with an aversion to ambiguity
also had a significantly higher TI prevalence (82.0% [50 of 61] vs 68.7% [92 of 134], P = .047).
Themixed-effects linear models revealed that participants from Argentina, Chile, and Spain
(combined) had higher TI scores compared with their Canadian counterparts (β coefficient, 0.90;
95% CI, 0.52-1.28; P < .001). Similarly, participants from Argentina, Chile, and Spain (combined) had
a higher likelihood of TI compared with the Canadian participants (odds ratio [OR], 2.30; 95% CI,
1.10-4.82; P = .03). The observed vs predicted TI scores after adjustment for covariates are shown in
the eFigure in the Supplement. Details by country are listed in Table 2.
Factors AssociatedWith TI
Themultivariable analysis aimed at identifying factors associated with the prevalence of TI revealed
that a higher number of patients with MS per week (OR, 0.44; 95% CI, 0.22-0.88), years of practice
(OR, 0.93; 95% CI, 0.86-0.99), and participation from Canada (OR, 0.47; 95% CI, 0.23-0.96) were
associated with a lower likelihood of TI. Aversion to ambiguity was associated with a 2-fold higher
likelihood of TI (OR, 2.25; 95% CI, 1.02-5.00) (Figure 2). The model showed good discrimination
(area under the curve, 0.783) and calibration (Hosmer-Lemeshow test P = .90). Participants from
Argentina, Chile, and Spain (combined) had 2.40 (95% CI, 1.16-5.06) higher odds of TI.
Assessment of Unmeasured Confounding
We estimated the E-value using the standardized difference of themean TI score (point estimate,
0.667; standard error, 0.128; and true association with shift estimate, 0.227). The E-value for the
point estimate was 2.35, and the CI was 1.66. All 95% CIs of the β coefficients of covariates were
lower than the E-value of 2.35 (eTable 1 in the Supplement), making it unlikely for the results to be
due to the association of unmeasured confounders. The bootstrapping analysis showed similarities
among the β coefficients within each covariate, suggesting unbiased estimates of the TI scores
(eTable 2 in the Supplement).
Discussion
Therapeutic inertia is a well-known phenomenon influencing physicians whomanage patients with
chronic conditions, including MS.6 Our study showed that neurologists with expertise in MS from 4
different countries exhibited varying degrees of TI. Overall, TI was present in 72.8% (142 of 195) of
participants and altered at least 1 in 5 therapeutic decisions. Therapeutic inertia was 2.3-fold more
prevalent among neurologists from Argentina, Chile, and Spain (combined) compared with their
Canadian counterparts.






Adjusted OR (95% CI) for TI
Factors Associated With Therapeutic Inertia
Age ≥45 y vs ≤44 y
OR
(95% CI)
Sex male vs female 0.86 (0.43-1.71)
1.58 (0.76-3.26)
Time devoted to clinical care ≥75% vs ≤74% 1.21 (0.61-2.38)
Tolerance to uncertainty ≥23 vs ≤22 1.54 (0.78-3.05)
Risk financial domain ≥200 vs ≤199 1.28 (0.61-2.68)
Aversion to ambiguity present vs absent 2.25 (1.02-5.00)
Canada vs other countries
No. of patients with MS seen per week ≥22 vs ≤21 0.44 (0.22-0.88)
0.47 (0.23-0.96)
Factors associated with TI are shown. A higher number
of patients withmultiple sclerosis (MS) seen per week
and country (ie, Canada) were associated with a lower
TI, whereas aversion to ambiguitywas associatedwith
a higher TI. OR indicates odds ratio.
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Themost important factors associated with TI include a lower expertise in MS care (eg, fewer
years of experience and a lower number of patients with MS seen per week), country of practice, and
a higher aversion to ambiguity. Themixedmultivariable analysis supports the contention that
aversion to ambiguity was an independent predictor of the prevalence of TI after accounting for
demographic factors, level of expertise, and regional variations. We also found that unmeasured
confounders were unlikely to have altered our findings.
The country of primary clinical practice was also identified as an independent predictor of TI.
The observed differences among countries can be partially explained by variations in adherence to
published MS management guidelines,2,26,27 regional differences regarding eligibility and access to
DMTs,28 public funding of DMTs, and physician-related factors, such as risk preferences and
education in risk management and decisionmaking.
Recognizing the presence of TI and contributing factors is essential in identifying strategies
aimed at improving medical education, which could lead to better patient outcomes. For example,
the results of recent studies suggest that innovative therapeutic interventions (eg, a traffic light
system)may be useful to ameliorate the prevalence andmagnitude of TI. In brief, the traffic light
system creates a link between a color (representing a risk level) and an action. Red light indicates
“high risk” or “stop and think,” yellow light indicates “intermediate risk” or “reassess soon,” and green
light indicates “low risk” or “continue the same strategy.”When applied in clinical sittings, thismethod
facilitates the decision-making process.29 A subsequent randomized clinical trial targeting
neurologists with MS expertise showed a 70% reduction in TI (OR, 0.30; 95% CI, 0.10-0.89) for the
traffic light system educational intervention arm compared with usual care.30
Limitations
Our study has several limitations. The small numbers of participants from Chile and Spain may have
altered the accuracy of estimates. As a result, we reported the comparison of TI between Canada and
the other 3 countries combined and also analyzed the role of unmeasured confounders. Another
limitation is that physicians’ decisions to escalate therapy are influenced by factors like availability of
the drug, local policies, drug costs, variations in treatment guidelines in different countries, and other
unmeasured variables that can alter the assessment of TI.26,31,32However, all included countries
shared private and government-fundedMS drug coverage in the absence of private health
insurance.33,34 A previous study35 showed a limited role of costs in explaining therapeutic decisions
and TI. In addition, physicians’ performance on case scenarios might not accurately mirror real-life
decisions, although such inconsistency would be expected to underestimate the true prevalence of
TI among participants. Also, we cannot rule out the possibility of some residual confounding despite
a comprehensive adjustment of baseline characteristics.
Conclusions
This study demonstrates the high prevalence of and factors associated with TI even among
neurologists with expertise in MS care. To date, our study is the first, to our knowledge, to
systematically compare TI using identical case scenarios across countries. This study constitutes a
first step in understanding themechanisms of TI and increases awareness of its high prevalence. Our
findings may also lead to the development of further studies that assess strategies to reduce TI,
whichmay result in improved outcomes for patients with MS. We propose larger studies to evaluate
the potential benefits of educational interventions to ameliorate TI. If proven effective, these
strategies could be included in curricula for undergraduate and postgraduate medical programs to
improve the existing education gaps of formal training in risk management and decision-making.
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Overcoming Therapeutic inertia in 
Multiple sclerosis care: a Pilot 
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Background: Physicians often do not initiate or intensify treatments when clearly war-
ranted, a phenomenon known as therapeutic inertia (TI). Limited information is available 
on educational interventions to ameliorate knowledge-to-action gaps in TI.
Objectives: To evaluate the feasibility and efficacy of an educational intervention 
compared to usual care among practicing neurologists caring for patients with multiple 
sclerosis (MS).
Methods: We conducted a pilot double-blind, parallel-group, randomized clinical 
trial. Inclusion criteria included neurologists who are actively involved in managing 
MS patients. Participants were exposed to 20 simulated case-scenarios (10 cases at 
baseline, and 10 cases post-randomization to usual care vs. educational intervention) 
of relapsing–remitting MS with moderate or high risk of disease progression. The edu-
cational intervention employed a traffic light system (TLS) to facilitate decisions, allowing 
participants to easily recognize high-risk scenarios requiring treatment escalation. We 
also measured differences between blocks to invoke decision fatigue. The control group 
responded as they would do in their usual clinical practice not exposed to the educa-
tional intervention. The primary feasibility outcome was the proportion of participants 
who completed the study and the proportion of participants who correctly identified 
a high-risk case-scenario with the “red traffic light.” Secondary outcomes included 
decision fatigue (defined as an increment of TI in the second block of case-scenarios 
compared to the first block) and the efficacy of the educational intervention measured 
as a reduction in TI for MS treatment.
results: Of 30 neurologists invited to be part of the study, the participation rate was 
83.3% (n = 25). Of the 25 participants, 14 were randomly assigned to the control group 
and 11 to the intervention group. TI was present in 72.0% of participants in at least one 
case scenario. For the primary feasibility outcome, the completion rate of the study 
2
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was 100% (25/25 participants). Overall, 77.4% of participants correctly identified the 
“red traffic light” for clinical-scenarios with high risk of disease progression. Similarly, 
86.4% of participants correctly identified the “yellow traffic light” for cases that would 
require a reassessment within 6–12 months. For the secondary fatigue outcome, with-
in-group analysis showed a significant increased prevalence of TI in the second block of 
case-scenarios (decision fatigue) among participants randomized to the control group 
(TI pre-intervention 57.1% vs. TI post-intervention 71.4%; p  =  0.015), but not in the 
active group (TI pre-intervention 54.6% vs. TI post-intervention 63.6%; p = 0.14). For the 
efficacy outcome, we found a non-significant reduction in TI for the targeted intervention 
compared to controls (22.6 vs. 33.9% post-intervention; OR 0.57; 95% CI 0.26–1.22).
conclusion: An educational intervention applying the TLS is feasible and shows some 
promising results in the identification of high-risk scenarios to reduce decision fatigue 
and TI. Larger studies are needed to determine the efficacy of the proposed educational 
intervention.
clinical Trial registration: www.ClinicalTrials.gov, identifier NCT03134794.
Keywords: multiple sclerosis, disease-modifying therapy, neuroeconomics, decision making, risk aversion
BacKgrOUnD
Despite significant therapeutic advances, many patients remain 
undertreated, especially those with chronic medical conditions, 
such as atrial fibrillation, hypertension, and multiple sclerosis 
(MS) (1–4). One of the explanations relates to knowledge integra-
tion and knowledge-to-action gaps in therapeutic decisions. For 
example, it is known that physicians can be aware and informed 
about the current management of the common medical condi-
tions they see in their daily clinical practice, but fail to integrate 
available information (e.g., severity of the condition, risk of 
progression, imaging findings, demographic factors affecting 
outcomes) and to implement best practice recommendations 
based on the available knowledge. This phenomenon may lead to 
therapeutic inertia (TI) usually associated with poorer outcomes 
(2–4). TI is a term that defines the absence of treatment initiation 
or intensification in patients when treatment goals are unmet. 
It affects 30–70% of clinicians caring for patients with chronic 
conditions (2, 5–7). Physician factors (e.g., low tolerance to 
uncertainty, status quo bias) are considered to be the main con-
tributors to TI, but remain poorly studied (8–10).
Given physicians’ limited training in risk management and 
formal learning in medical decision-making, educational inter-
ventions could optimize medical decisions (11). Previous research 
suggests that such interventions can improve medical decisions. 
A meta-analysis comprising 609 eligible studies enrolling 35,226 
trainees compared the efficacy of simulation-based educational 
interventions (e.g., case-scenarios) in clinical skills and medical 
decision-making. The authors showed that a simulation-based 
educational intervention was more effective than standard edu-
cational programs for outcomes of knowledge, skills, and trainee’s 
behavior (12). Other studies using a simulation-based interven-
tion and clinical reasoning revealed a reduction in medical errors 
(13, 14). We have scarce information on strategies to overcome TI 
and only little evidence is available regarding effective educational 
interventions to reduce “knowledge-to-action” gaps.
The traffic light system (TLS) is an strategy that facilitates the 
decision-making process using traffic light terminology to match 
three types of situations: red light (“high risk”/“stop and think”), 
yellow light (warning), and green light (“stable”/“continue the 
same strategy”). The TLS emerged as a warning and risk cat-
egorization strategy to reduce human errors (15). It relies in a 
“hard-wired” cross-cultural color-coded concept that facilitates 
the integration of specific situations with an action (16–18). For 
example, studies showed that the TLS facilitated healthier food 
choices by interfering with automatic decisions and triggering re-
evaluation processes (19). We focus on MS because of the broad 
availability of therapeutic options and clear definitions (clinical 
and radiological) of disease activity as the accepted criteria to 
escalate treatment.
We hypothesized that an educational intervention using 
the TLS may be feasible and effective to overcome insufficient 
knowledge integration and knowledge-to action gaps in the man-
agement of MS. In the present study, we evaluated the feasibility 
of an educational intervention to identify clinical situations of 
moderate and high risk of disease progression that may lead to 
TI. Our intervention was designed following the results of our 
previous studies on TI in MS care (4, 20).
MeThODs
study Design and Participants
This pilot, double-blinded, parallel-group, randomized clinical 
trial evaluated the feasibility of an educational intervention (active 
group) compared to usual care (control group) in the manage-
ment of MS (Figure 1—CONSORT flow diagram). The goal of the 
education intervention was to facilitate risk stratification-action 
FigUre 1 | CONSORT flow diagram.
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gaps in MS care. We expected the TLS would facilitate the iden-
tification of high-risk clinical-scenarios (i.e., “red” in the TLS) 
leading to assertive therapeutic decisions (e.g., escalate therapy 
when appropriate). Inclusion criteria included neurologists who 
were actively involved in managing MS patients. Physicians 
whose practice was primarily in caring for MS patients were clas-
sified as “MS specialists.”
Candidates were invited to participate in a face-to-face meet-
ing held in Madrid, Spain. The recruitment of participants was 
facilitated by the Spanish Neurological Society. We targeted the 
first 30 participants who replied to an e-mail invitation from a 
pool of neurologists who met the inclusion criteria. The study 
was conducted using Qualtrics, a web-based platform (www.
Qualtrics.com). Each participant was provided with a tablet PC 
to complete the study. Participants were randomized (1:1 ratio), 
an automatic process in Qualtrics. Allocation concealment 
was facilitated in Qualtrics, so participants did not know what 
intervention will be allocated to after completing the 10 initial 
case-scenarios.
The study comprised 20 MS case-scenarios (see Appendix). 
Participants were exposed to 10 baselines case-scenarios (Block 1). 
Then, participants were randomized to usual care vs. educational 
intervention (TLS) followed by 10 additional similar case-
scenarios (Block 2). In-line with the learning and education 
literature, case-vignettes, clinical scenarios, or “real world” 
encounters are regarded as the best simple strategy to evaluate 
cognitive biases among physicians (21, 22).
Case-scenarios were designed by our research team and MS 
experts (Angel P. Sempere, Gustavo Saposnik, Jorge Maurino, 
and Xavier Montalban). Overall, 16 cases were designed to assess 
appropriate escalation of treatment (absence of treatment escala-
tion corresponding to TI; cases # 1–5, 8–10, 11–15, and 18–20), 
whereas the remaining four cases (case # 6, 7, 16, and 17) were 
designed to assess overtreatment (treatment escalation when there 
was no evidence of disease activity). Participants randomized 
to the intervention group (TLS) were also asked to identify the 
appropriate traffic light that would match the case-scenario. That 
question was prior to the selection of the therapeutic option.
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In Block 2, eight cases corresponded to clinical situations of 
high risk of MS progression, which participants in the interven-
tion group should associate with the “red traffic light,” whereas 
two cases were associated with moderate risk of progression 
requiring a re-assessment in a 6- to 12-month period, which 
participants should associate with the “yellow traffic light” 
(see Figures 2 and 3).
Data management, research coordination, and statistical 
analyses were conducted at the Li Ka Shing Knowledge Institute 
of St. Michael’s Hospital, Toronto. Operational procedures, 
guidelines for the implementation of both arms of the study, and 
the consent form were approved by the ethics review board at 
St. Michael’s Hospital, University of Toronto. Online informed 
consent was obtained from all participants. The study was 
conducted in Spanish. Participants received compensation for 
transportation. Further details of the protocol were published in 
www.ClinicalTrials.gov # NCT03134794 and elsewhere (20).
rationale and Description  
of the interventions
The current evidence suggests that medical decisions leading to 
TI are likely related to knowledge-to-action gaps (23, 24). We 
developed a simulation-based educational intervention aimed 
FigUre 2 | Continued
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at facilitating the integration of knowledge and overcoming 
knowledge-to-action gaps in MS care (25). The action component 
is the therapeutic decision (e.g., continue on the same treatment, 
change to a treatment that would not affect the clinical course or 
escalating to a more effective agent). We followed the Guideline for 
Reporting of Evidence-based practice Educational interventions 
and Teaching (GREET) statement to describe our educational 
intervention (Figure 2) (26).
educational intervention: The Tls
Our study included two phases: pre-intervention and post-
intervention periods (Figure  3). Participants were randomly 
assigned to the educational intervention or control groups after 
the pre-intervention period.
Our educational intervention is based on the application of 
the TLS to medical decision-making (16–19, 27). In our study, 
the TLS was applied to help participants identify high-risk 
FigUre 2 | Continued
FigUre 2 | Description of the educational intervention according to the GREET guidelines.
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cases-scenarios, where MS patients had both clinical and radio-
logical activity. Consequently, participants should be able to 
identify the “red” traffic light and escalate treatment. The “yellow” 
represents caution when MS patients had either a clinical relapse 
or some degree of activity on brain imaging (but not both), which 
requires a reassessment within 6–12 months.
The control group made therapeutic decisions without being 
exposed to the educational intervention as part of the current 
standard practice. They had the option to take a break or continue 
the study. The estimated time of study completion per participant 
ranged between 30 and 35 min and did not differ between groups.
Definitions
For the primary analysis, high risk of progression was defined 
as the combination of a clinical relapse plus the presence of new 
brain lesions in follow-up magnetic resonance imaging (MRI) 
scans or at least one gadolinium-enhancing lesion (28, 29). All 
high-risk simulated clinical cases included a description of an 
MRI with more than five new T2 lesions or at least one enhanc-
ing lesion (30). The use of these definitions combining a clinical 
relapse and MRI activity is consistent with recent evidence 
regarding the risk of treatment failure among patients receiving 
interferon-β (31). Disease progression was defined as at least one 
point worsening from baseline in the Expanded Disability Status 
Scale score (32).
Recent meta-analysis confirmed that alemtuzumab, natali-
zumab, and fingolimod are the best available choices for preventing 
clinical relapses in patients with relapsing–remitting MS (RRMS) 
(33). The current treatment option for RRMS include first-line 
(beta interferons, glatiramer acetate), second-line (fingolimod), 
and third-line (natalizumab, alemtuzumab) therapies. For the 
present analysis, we used the aforementioned scheme according 
to the current clinical practice (4, 34, 35).
Outcome Measures
The primary feasibility outcome was the proportion of par-
ticipants who completed the study. A completion rate of 70% or 
higher was our pre-specified outcome. The feasibility of delivering 
the intervention was defined as the number of participants who 
correctly identified the “red traffic light” for clinical-scenarios 
comprising a high-risk of progression. A pre-specified criterion 
of at least 70% correct responses was used to classify the educa-
tional intervention as feasible.
Efficacy of the educational intervention, a secondary out-
come measure, was defined as a reduction in TI based on each 
individual response. We also evaluated secondary outcome the 
capability of the intervention to protect against decision fatigue 
decision fatigue [defined as the difference in TI within groups 
before (Block 1) and after the intervention (Block 2)] (36, 37). 
A significantly higher prevalence of TI in the 10 case-scenarios 
post-intervention (Block 2) would be indicative of decision 
fatigue.
statistical analysis
Given the pilot nature of this study, we performed primarily 
descriptive statistics. We used non-parametric tests to compare 
continuous and categorical variables between groups. A Welch’s 
t-test was used to rule out large differences in TI. Logistic regres-
sion analysis was completed to determine the efficacy of the 
educational intervention in the reduction of TI after adjusting 
for responses in the pre-intervention period (Block 1).
We evaluated two different outcome measures: (i) TI defined 
as lack of treatment escalation in at least one case scenario and (ii) 
number of participants’ responses representing TI. We also com-
pared the total number of correct responses for each case-scenario 
between and within groups before and after the intervention. 
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FigUre 3 | Continued
Given our pre-specified target intervention, we compared the 
proportion of responses associated with TI between those who 
selected the “red light” in the active group vs. control group.
All tests were two-tailed, and p-values <0.05 were considered 
significant. We used STATA 13 (College Station, TX, USA: 
StataCorp LP) to conduct all analyses.
FigUre 3 | Educational intervention: the traffic light system may facilitate therapeutic decisions in multiple sclerosis care. Participants viewed the two informative 
panels (a,B) and a third panel providing an example (c).
TaBle 1 | Baseline characteristics of participants.






Age (mean ± SD), in years 35.4 ± 7.3 33.8 ± 5.5 36.6 ± 8.4
Sex
Female 16 (64.0) 8 (72.7) 8 (57.1)
Specialty
Multiple sclerosis (MS) specialists 15 (60.0) 6 (54.6) 9 (64.3)
General neurologists who care for 
MS patients
10 (40.0) 5 (45.5) 5 (35.7)
Practice setting
Academic 22 (88.0) 11 (100) 11 (78.6)
Community 2 (8.0) 0 (0) 2 (14.3)
Both (academic and 
non-academic)
1 (4.0) 0 (0) 1 (7.1)
% time in clinical practice
Greater than 75% 16 (64.0) 6 (54.6) 10 (71.4)
Years in practice, mean (±SD) 9.9 ± 7.3 8.5 ± 5.0 11.1 ± 8.7
MS patients seen per week, mean 
(±SD)
17 ± 11.0 15.9 ± 10.5 17.8 ± 11.7
Attended latest ECTRIMS 
conference
14 (56.0) 5 (45.5) 9 (64.3)
Author of a peer-reviewed 
publication in the last 12 months
12 (48.0) 3 (27.3) 9 (64.3)
Numbers in brackets indicate percentages, unless otherwise indicated.
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resUlTs
Of 30 neurologists from across Spain who were invited to partici-
pate in the study, 25 (83.3%) attended the meeting. Eleven par-
ticipants were randomly assigned to the educational intervention, 
whereas the remaining 14 were assigned to the control group.
Overall, the mean (SD) age was 35.4 (±7.3) years; 16 (64%) 
were females. Sixty percent (15/25) of participants primarily 
focused their practice on MS care. Table 1 summarizes baseline 
characteristics of the study population. Baseline characteristics 
appeared similar between groups. None of the participants 
choose to have a break.
The mean time to start the second set of cases post- 
randomization (block 2) was 12.7  s in the control group and 
11.8 s in the intervention group.
For the primary feasibility outcome, the completion rate of the 
study was 100% (25/25 participants). TI was present in 72.0% of 
participants in at least one case scenario. Only 4 (16%) partici-
pants did not exhibit TI (all case-scenarios were correct), whereas 
one-third of participants (8/25) exhibited TI in five or more simu-
lated case-scenarios. In the within-group analysis, we observed 
an increased prevalence of TI in the second set of case-scenarios 
(defined as decision fatigue) among participants in the control 
group (TI pre-intervention 57.1% vs. TI post-intervention 71.4%; 
p = 0.015), but not in the active group (TI pre-intervention 54.6% 
vs. TI post-intervention 63.6%; p = 0.14). Decision fatigue was 
associated with higher odds of TI (OR 3.99; 95% CI 1.05–15.1).
There was no TI block-by-intervention group interaction 
(p = 0.61). Comparative results between pre- and post-interven-
tion within and between groups are summarized in Table 2.
FigUre 4 | Prevalence of therapeutic inertia (TI) for the targeted intervention accounting for each individual response in the active and control groups. Lower 
numbers represent lower TI (more optimal therapeutic decisions). *p = 0.74, **p = 0.12. Note the lower trend in the prevalence of TI in the intervention group 
compared to the control group (22.6 vs. 33.9%; OR 0.57; 95% CI 0.26–1.22).
TaBle 2 | Efficacy outcome measures: comparison pre- and post-intervention within and between groups.



















n = 11 n = 11 n = 14 n = 14
Mean (SD) number of 
individual responses 
related to therapeutic 
inertia (TI)
1.91 (1.3) 2.36 (1.5) 0.45 (−2.20, 1.31) 2.14 (1.4) 2.71 (1.8) 0.57 (−2.61, 1.48) 0.35 (−1.01, 1.71)
Individual responses 
related to TI, n/N (%)
21/88 (0.24) 26/88 (0.30) 0.056 (−1.30, 1.41) 30/112 (0.27) 38/112 (0.34)  0.071 (−1.18, 1.32) 0.044 (−1.33, 1.42)
% (SD) of participants 
with TIc
54.5 (27.2) 63.6 (25.4) 9.1 (−14.2, 32.4) 57.1 (26.4) 71.4 (22.0) 14.3 (−4.5, 33.1) 7.80 (−12.2, 27.8)
n, number of responses related with TI; N, total number of responses. Numbers were rounded to two decimals.
aRepresents the difference and 95% CI in the efficacy outcomes between pre- and post-intervention within groups.
bRepresents the difference and 95% CI in the efficacy outcomes post-intervention between groups.
cTI identified in at least one case-scenario.
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Overall, 77.4% of participants correctly identified the “red 
traffic light” for clinical scenarios with high-risk of disease pro-
gression. Similarly, 86.4% of participants correctly identified the 
“yellow traffic light” for cases that would require a reassessment 
within 6–12  months. Thus, participants knew what should be 
done with different cases.
The analysis of each individual case-scenario revealed that TI 
was present in 23.9% of responses in the interventional group and 
26.8% of responses in the control group in the pre-intervention 
period (p = 0.74) (Figure 4). The multivariate analysis of each 
individual response revealed a non-significant reduction in TI 
in favor of the intervention group (OR 0.82; 95% CI 0.25–2.69) 
after adjusting for pre-intervention TI. The analysis evaluating 
individual responses targeted by the intervention (those cases 
where participants correctly identified the red light for high-
risk scenarios) revealed a non-significant reduction of TI in the 
157
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intervention group compared to the control group (OR 0.57; 95% 
CI 0.26–1.22) (Figure 4).
DiscUssiOn
Therapeutic inertia is a common phenomenon in the manage-
ment of patients with chronic medical conditions (2, 8). Moreover, 
there is limited information regarding educational interventions 
to overcome the effects of TI. In the present study, we used the 
well-defined paradigm of MS care, with its broad variability of 
therapeutic options to escalate treatment as a response to evi-
dence in disease activity.
We conducted a pilot randomized study allocating participat-
ing neurologists to an educational intervention (using the TLS) 
or usual care (control group). We found that TI was present in 
at least one case-scenario in 7 out of 10 participants. Overall, 
the great majority of participants correctly matched the traffic 
light (yellow and red) with the simulated case-scenario and 
appropriately escalated treatment. We found a non-significant 
43% reduction in the odds of TI by identifying the red traffic 
light. We also identified decision fatigue in the control group, 
but not in the intervention group. This finding suggests that 
the educational intervention may promote the continuity of 
accurate therapeutic decisions over time (by ameliorating the 
impact of decision fatigue on TI) despite the increasing number 
of case-scenarios.
The use of the TLS is a novel initiative to optimize decisions. 
It has been successfully applied to different medical fields, 
including the selection of healthier food choices leading to 
weight loss or the detection of children with fever at high risk 
of developing a serious bacterial infection (16, 18). Stangel and 
colleagues proposed the TLS to monitor treatment response 
in patients with RRMS. They included a more sophisticated 
scoring system (0–3) to categorize clinical relapses, evidence of 
disease progression, a cognitive assessment, and MRI findings. 
This scoring system leads to a decision model that uses the TLS 
to facilitate therapeutic choices (38). At the time of writing this 
manuscript, there were no data available on the application of 
this strategy.
Our study has some significant limitations. First, the sample 
size is small given the pilot design. As a consequence, our study 
was not powered to determine the efficacy of the educational 
intervention. Second, we used simulated case-scenarios that 
may not accurately reflect therapeutic decisions in clinical 
practice or known patients followed up over time. Third, 
some participants’ responses may reflect local limitations in 
the prescription of disease modifying agents. Fourth, we only 
tested some physician-level factors that may influence TI. 
Finally, we do not know if the educational intervention would 
require reinforcement months later to maintain its potential 
effect on TI.
Despite these limitations, our study suggests that a simple 
educational intervention applying the TLS is feasible to increase 
clinician’s recognition of MS patients at high risk of progression 
and overcome decision fatigue. Although our study evaluated 
therapeutic decisions in MS, the educational intervention could be 
applied to the management of other medical conditions and thus 
have wider-reaching implications for clinical care. Furthermore, 
our results serve as the basis for sample size calculations in the 
design of future studies.
Increasing awareness is the first step in the decision-making 
process to reduce the effects of TI. We used the TLS to increase 
awareness of treatment-relevant knowledge. Our study is also 
strengthened by: (i) a randomized design, (ii) the application of 
an evidence-based educational approach following the GREET 
guidelines (26), (iii) the implementation of a simple educational 
intervention that links to the neural pathways involved in 
decision-making under uncertainty (19, 27), and (iv) the target 
of a clinically relevant outcome (i.e., TI and decision fatigue) 
(4, 36) with the goal of overcoming knowledge-to-action gaps in 
MS treatment.
The next steps would include the implementation of studies at 
a larger scale to determine the efficacy of our educational inter-
vention in overcoming decision fatigue and reducing TI among 
primary care physicians and specialists managing patients with 
neurological (MS, stroke) and other chronic conditions (e.g., atrial 
fibrillation, diabetes).
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Abstract
Background: Therapeutic inertia (TI) is a common phenomenon among physicians who care for patients with chronic
conditions. We evaluated the efficacy of the traffic light system (TLS) educational intervention to reduce TI among
neurologists with MS expertise. Methods: In this randomised, controlled trial, 90 neurologists who provide care to
MS patients were randomly assigned to the TLS intervention (n = 45) or to the control group (n = 45). The educa-
tional intervention employed the TLS, a behavioral strategy that facilitates therapeutic choices by facilitating reflec-
tive decisions. The TLS consisted in a short, structured, single session intervention of 5-7 min duration. Participants
made therapeutic choices of 10 simulated case-scenarios. The primary outcome was a reduction in TI based on a
published TI score (case-scenarios in which a participant showed TI divided by the total number of scenarios where
TI was possible ranging from 0 to 8). Results: All participants completed the study and were included in the primary
analysis. TI was lower in the TLS group (1.47, 95% CI 1.32-1.61) compared to controls (1.93; 95% CI 1.79-2.08).
The TLS group had a lower prevalence of TI compared to controls (0.67, 95% CI 0.62-0.71 vs. 0.82, 95% CI 0.78-
0.86; p = 0.001). The multivariate analysis, adjusted for age, specialty, years of practice, and risk preference showed
a 70% reduction in TI for the TLS intervention compared to controls (OR 0.30; 95% CI 0.10-0.89). Conclusions: In
this randomized trial, the TLS strategy decreases the incidence of TI in MS care irrespective of age, expertise, years
for training, and risk preference of participants, which would lead to better patient outcomes.
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decision making, disease-modifying therapy, educational intervention, multiple sclerosis, randomized clinical trial
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The management of multiple sclerosis (MS) evolves with
the availability of new disease-modifying agents, varying
dosage forms (oral, injectable, infusion), and different
safety and efficacy profiles. As a result, physicians who care
for MS patients face more complex therapeutic decisions
when considering individual patients, number of relapses,
activity on brain imaging, and the need to escalate therapy.
Moreover, many MS patients remain undertreated.1–3
Therapeutic inertia (TI) corresponds to the absence of
treatment initiation or intensification when treatment
goals are unmet. It affects more than 50% of clinicians
caring for patients with chronic conditions.1,4–6 Insufficient
knowledge integration and knowledge-to-action gaps are
among the most common explanations for suboptimal
therapeutic decisions. However, TI is a complex process
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also related to other characteristics of the providers such
as lack of knowledge about appropriate goals, high patient
volume, and time constraints. Some physicians fail to inte-
grate the available information (e.g., severity of the condi-
tion, risk of progression, imaging findings affecting
outcomes) with best practice recommendations for a given
risk-scenario.7–10 Furthermore, physicians have limited
training in risk management and formal learning in medi-
cal decision making.11–13 All of these factors may contrib-
ute to TI and undertreatment.
Educational interventions have been designed to
optimize knowledge integration and bridge knowledge-
to-action gaps for complex medical decisions (e.g., diag-
nostic challenges, varying risk categories, availability of
multiple agents with a broad range of safety/efficacy
ratio).11 One such intervention is the traffic lights system
(TLS). The TLS emerged as risk categorization and
warning strategy to reduce human errors that relies on
a relatively automatic, well-established, and cross-
cultural concept to increase the chance of an optimal
course of action.14,15 The TLS facilitates the decision-
making process using traffic light terminology, which
creates a link between a color, representing a risk level,
and an action: red light (‘‘high risk’’/‘‘stop and think’’),
yellow light (‘‘intermediate risk’’/‘‘reassess soon’’), and
green light (‘‘low risk’’/‘‘continue the same strategy’’).
For example, studies showed that the TLS facilitates
healthier food choices by interrupting automatic behavior
and triggering a reevaluation processes.16 A functional
magnetic resonance imaging study showed that TLS
labels enhance the coupling between brain regions associ-
ated with valuation (i.e., ventromedial prefrontal cortex)
and self-control.17 Evidence from the literature suggests
that medical decisions leading to TI are likely related to
knowledge-to-action gaps.7 The design and application of
the TLS as an educational intervention provides a unique
opportunity to overcome knowledge-to-action gaps in
MS care.18
In a previous pilot study, we assessed the feasibility
and potential efficacy of a TLS educational intervention
in 25 neurologists from Spain.19 TI was present in
72.0% of participants in at least one case scenario. The
primary feasibility outcome, the completion rate of the
study, was 100% (25/25 participants). While not pow-
ered to detect a significant difference between groups,
our pilot study demonstrated a nonsignificant reduc-
tion in TI for the targeted intervention group relative
to the control group (22.6% v. 33.9% postintervention;
odds ratio [OR] = 0.57; 95% confidence interval [CI]
= 0.26 to 1.22).19 The TLS also showed a high usabil-
ity score (74.7; 95% CI = 70.1 to 79.2) when tested in
a larger study comprising neurologists from Argentina,
Chile, and Canada.20
In the present study, we evaluated the efficacy of our
simple and pilot-tested educational TLS intervention for
reducing TI among neurologists who routinely provide
care of MS patients.
Methods
Study Design and Participants
The overarching goal of the TLS intervention was to
facilitate the integration of gaps between risk stratifica-
tion and treatment decisions (initiation or escalation) in
MS care. Specifically, our randomized parallel trial tested
the efficacy of an educational TLS intervention (active
group) against usual care (control group) for reducing TI
in the management of MS (Figure 1). Participants were
randomly assigned (1:1 ratio) to the TLS or the control
group by Qualtrics (Qualtrics.com; Online Appendix,
Figure e1). Allocation concealment was implemented in
Qualtrics, so that participants did not know which inter-
vention they were allocated to after completing the initial
demographic information. Investigators were also
blinded to the treatment allocation. Participants were
recruited by automatic e-mail invitation from the study
platform. The Institute of Neuroscience Buenos Aires
and the Argentinian Neurological Society facilitated the
mailing of information to potential participants who met
the inclusion criteria.
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Data Collection
Participants answered questions as follows: 1) demo-
graphic and practice-based information, 2) behavioral
experiments, and 3) 10 case scenarios that assessed TI.
Behavioral experiments used previously established
designs to assess participants’ risk preferences and toler-
ance to ambiguity in the health and financial
domains.21,22 In brief, ambiguity aversion is defined as
dislike for events with unknown probability compared to
events with known probability.21 For example, in the
medical domain, an ambiguity-averse individual would
rather choose a treatment where the probability of bene-
fits or side effects is known (even if these are somewhat
unfavorable) over one where this probability is unknown
(Figure 2A and B). Risk experiments involved determin-
ing the subjective value of a risky (50/50) option in terms
of a safe (100%) option. By asking participants to indi-
cate the magnitude of the safe option at which they
would be indifferent between the two options, we were in
a position to determine the point of subjective equiva-
lence of the risky and the safe option. The higher this
point, the higher the propensity to take risk. Further
details of these experiments were published in previous
studies (and appendix).3
Participants were also asked to select those MS drugs
that they use and then rank them from a list including all
available agents approved by the local regulatory body in
Figure 1 Consort flow diagram. Of 117 eligible participants, 90 participants were randomized to the educational intervention (n =
45) and control (n = 45). All participants completed the intervention and contributed a complete set of data to the analysis.
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Figure 2 Experiments to assess ambiguity in the financial and health domains. Participants were told to imagine two different
types or urns. For urn type A, they knew that 50% of the balls were red and the other 50% were blue. For urn type B, they did
not know the exact proportion of blue to red balls, with the grey bar representing the unknown proportion of balls. For the
financial domain (Panel A), participants knew that if they drew a blue ball, they would win the full amount of $400. If they drew
a red ball, they would win $ 0. For the health domain (Panel B), participants decided between two treatments for a patient. With
‘‘Treatment A,’’ the patient had a 50% probability of survival. With ‘‘Treatment B,’’ the exact probability of survival was
unknown, with the grey bar representing the unknown probability. In our tasks, participants were asked to choose between one
option (presented as two-colored bar) with known 50/50 probability of winning 400 or 0 American dollars (urn A) versus an
option with unknown probability of the same outcomes (urn B). Participants who chose the 50/50 options were classified as
averse to ambiguity; the remaining participants were classified as tolerant to ambiguity.1 A similar approach was used to
determine aversion to ambiguity in the health domain (Panel B).
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Argentina by March 30, 2018. The purpose of this strat-
egy was to compare how TI derived from case scenarios
relates with agents used for treatment escalation (e.g., fin-
golimod, natalizumab, alemtuzumab) in routine clinical
practice. At the time of conducting this trial, cladribine
and ocrelizumab were not available and therefore not
included in case scenarios.
In line with the learning and education literature,
vignettes, clinical case scenarios, or ‘‘real-world’’ encoun-
ters are regarded as the best simple strategy to evaluate
potential cognitive biases and medical decisions.23 Case
scenarios were designed by our research team and MS
experts derived from the most common situations in clin-
ical practice as previously reported in our pilot study.19
Eight case scenarios were designed to assess appropriate
treatment initiation or escalation, whereas the remaining
two cases were designed to assess overtreatment (defined
as treatment escalation when there was low risk of dis-
ease progression and no evidence of disease activity).24–26
Participants from each randomized group were exposed
to the same case scenarios. Inclusion criteria comprised
neurologists who were actively involved in managing MS
patients. Physicians whose practice was primarily in car-
ing for MS patients or who obtained a subspecialty
degree were classified as ‘‘MS specialists.’’ Physicians
who were not practicing neurology or seeing less than
one MS patient per month were excluded from the study.
Definitions
For the primary analysis, bad prognosis was defined as
the combination of a clinical relapse plus the presence of
new brain lesions in follow-up magnetic resonance ima-
ging (MRI) scans or at least one gadolinium-enhancing
lesion.27,28 All high-risk cases included a description of
an MRI with more than five new T2 lesions or at least
one enhancing lesion.29 The use of these definitions com-
bining a clinical relapse and MRI activity is consistent
with recent evidence regarding the risk of treatment fail-
ure among patients receiving interferon-b.30 Disease pro-
gression was defined as at least one point worsening
from baseline to 1-year follow-up in the Expanded
Disability Status Scale (EDSS) score.31 Recent meta-
analysis confirmed that alemtuzumab, natalizumab, and
fingolimod are the best available choices for preventing
clinical relapses in patients with relapsing-remitting MS
(RRMS).32 The current treatment option for RRMS
include first-line (b-interferons, glatiramer acetate),
second-line (fingolimod, cladribine), and third-line (nata-
lizumab, alemtuzumab, ocrelizumab) therapies. For the
present analysis, we used the aforementioned scheme
according to the current clinical practice.24–26,33
The Traffic Light System (Figure 3)
In our study, the TLS was applied to help participants
identify scenarios with poor prognosis (high risk of dis-
ease progression; Figure 3B). Consequently, participants
would be able to identify the ‘‘red’’ traffic light as a
warning sign for a high-risk situation, and subsequently
escalate treatment. The ‘‘yellow’’ traffic light represents
caution for scenarios with either a clinical relapse or
some degree of activity on brain imaging (but not both),
which requires a reassessment within 6 to 12 months.
The control group made therapeutic decisions without
being exposed to the TLS intervention as part of the cur-
rent standard practice. Further details of the TLS inter-
vention are described elsewhere.19 An example of the
presented case scenario is represented in Figure 3C.
Outcome Measures
Therapeutic inertia was the primary outcome of interest,
measured as a continuous variable (TI score) and as bin-
ary. The TI score was defined as the number of case sce-
narios in which a participant showed TI (ranging from 0
to 8). The TI score was reported in our previous studies
to reflect the magnitude of TI.19,34 A low TI score repre-
sents low TI, whereas a higher score represents higher. A
0.5 point difference in the TI score was deemed as clini-
cally meaningful given the impact in clinical practice. In
our study, detecting a difference equal to or greater than
0.50 between groups in the TI score would represent a
clinically meaningful improvement. The TI score was
derived from case scenarios, which were aligned with the
current Argentinian, North American, and European
practice recommendations.24–26
A reduction in the TI score reflects that participants
appropriately switched from a first-line agent (e.g., gla-
tiramer, interferons) to a high-efficacy treatment (e.g.,
fingolimod as a second-line therapy or monoclonal anti-
bodies as third-line therapies) when clinical and radiolo-
gical evidence of disease progression.
TI as a binary outcome was defined as the proportion
of participants demonstrating TI in at least one of the
eight scenarios (prevalence of TI).
Statistical Analysis
We used parametric tests (t test and Fisher’s exact test) to
compare continuous and categorical variables between
Saposnik et al. 5
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Figure 3 The TLS intervention. Panel A illustrates background information on the TLS and application to therapeutic decisions.
Panel B illustrates how the TLS facilitates the decision-making process using traffic light terminology, which creates a link
between a color, representing a risk level, and an action: red light (‘‘high risk’’/‘‘stop and think’’), yellow light (‘‘intermediate
risk’’/‘‘reassess soon’’), and green light (‘‘low risk’’/‘‘continue the same strategy’’). Panel C provides a case scenario as an example
of those given the participants.
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groups. Linear regression analysis was used to determine
the efficacy of the TLS for reducing TI scores in the inter-
vention group versus the control group. Similarly, logistic
regression analysis was used to determine the efficacy of
the TLS with respect to the proportion of participants
with TI in at least one case scenario. We also evaluated
the association between restrictions for prescribing DMTs
and the number of second- and third-line agents com-
monly used in clinical practice with the TI score.
For multivariate analysis of individual responses, we
constructed multilevel mixed-effects models where parti-
cipants (n = 90) and individual responses (n = 720; 90
participants each completing 8 case scenarios) entered as
random effects. The aim of this analysis was to evaluate
the contribution of individual-specific variables to the
variation of TI. Given the findings from our previous
studies, we included the following a priori variables: par-
ticipant age, expertise (MS specialist v. general neurolo-
gist), years of experience, and aversion to ambiguity.3,19
All tests were 2-tailed, and P values \0.05 were consid-
ered significant. We used STATA 13 (StataCorp LP,
College Station, TX) to conduct all analyses.
Further details of the protocol are published in
ClinicalTrials.gov (# NCT03134794).
Results
Out of the 117 neurologists with expertise in MS care
who were invited to participate in the study, 90
completed the survey (response rate 76.9%) between
April and September 2018. There was representation
from all provincial territories. The mean (SD) age was
46.4 (610.3) years; 48 (53%) were male neurologists.
Thirty-one (34.4%) participants primarily focused their
practice on MS care. They had 20.3 (610.9) years of
practice and were assessing 22 (66.6) MS patients per
week. Table 1 compares baseline characteristics between
groups. Groups did not differ in demographics or in risk
preferences as measured by the behavioral risk tasks (P
= 0.40 for risk preferences and P = 0.63 for aversion to
ambiguity). There were no differences in treatment esca-
lation at baseline between groups. On average, partici-
pants in the TLS group used 3.09 agents for treatment
escalation versus 2.91 in the control group (P = 0.62).
There was no association between participants’ restric-
tions to prescribe MS drugs and TI score (P = 0.44) or
the prevalence of TI (P = 0.78).
Table 2 summarizes the primary and secondary out-
come measures at the participant and individual response
levels. TI scores were significantly lower in the TLS inter-
vention group than in the control group (1.36, 95%
CI = 1.23 to 1.50, v. 2.04, 95% CI = 1.90 to 2.17) after
adjustment for the prespecified variables (age, specialty,
years of practice, and risk preferences). The observed
0.68 difference between groups in the adjusted TI scores
was greater than the minimal clinically meaningful mea-
sure of 0.5 to detect an improvement. Similarly, partici-
pants in the TLS intervention group had a lower
Table 1 Baseline Characteristics of Participants
Characteristics Control (N = 45) Educational Intervention (N = 45) P Value
Age in years (mean 6 SD) 46.8 6 10.3 46.0 6 10.4 0.72
Sex, n (%) 0.67
Female 20 (44.4) 22 (48.9)
Male 25 (55.6) 23 (51.0)
Specialty, n (%) 0.82
General neurologists who care for MS patients 29 (64.4) 30 (66.7)
MS specialists 16 (35.6) 15 (33.3)
Practice setting, n (%) 0.37
Public 17 (37.8) 13 (28.9)
Private 28 (62.2) 32 (71.1)
% time in clinical practice, n (%)
.75% 19 (42.2) 20 (44.4) 0.83
Years in practice (mean 6 SD) 21.1 6 10.5 19.5 6 11 0.48
MS patients seen per week (mean 6 SD) 21.8 6 4.5 23.0 6 8.3 0.37
Author of a peer-reviewed publication in the last 1 year, n (%) 20 (44.4) 23 (51.1) 0.53
Restriction to prescribe MS drugs, n (%) 0.83
No restrictions 28 (62.2) 29 (64.4)
Treatment escalation, mean drugs (6SD) 2.91 (1.24) 3.09 (2.05) 0.62
MS, multiple sclerosis
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prevalence of TI compared to controls (63.7%, 95%
CI = 58.9% to 68.6%, v. 83.9%, 95% CI = 80.4% to
88.4%) (Figure 4).
The multivariate analysis also revealed a significant
reduction in the TI score for the TLS intervention com-
pared to the control group (b = 20.68; 95% CI =
21.24 to 20.11). The multivariate logistic regression
analysis showed 70% reduction in the odds of TI for the
TLS group (OR = 0.30, 95% CI = 0.10 to 0.89).
Specialist status (P = 0.002), higher years of experience
(P = 0.007), and tolerance to ambiguity (P = 0.043)
were associated with lower TI. The adjusted models
showed good discrimination (c-statistic = 0.74) and cali-
bration (goodness-of-fit test P = 0.52).
Results were consistent for the analyses of individual
responses (Table 2). There were no significant differences
between fixed and random effect models (data not
shown). Figure 3 represents the relationship between the
observed and predicted TI scores (Figure 5A) and strati-
fies the data by group (Figure 5B), revealing that TI was
consistently lower in the intervention group.
Participants who commonly used agents for treatment
escalation in their daily practice had lower TI scores
(1.48 v. 1.8; P \ 0.01). Accordingly, participants who
do not commonly use agents for treatment escalation in
their daily practice benefited from the intervention (for
TI score: b = 20.78, 95% CI = 21.03 to 20.52; for TI
prevalence: OR = 0.56, 95% CI = 0.36-0.88).
The analysis of individual responses also revealed that
for every 100 MS patients with a bad prognosis (e.g.,
both clinical and radiological evidence of disease
activity), there will be over 24 patients who will remain
with the same treatment if managed by neurologists
without educational intervention (control group). That
number would be decreased to 10 patients if treated by
neurologists who received the TLS educational
intervention.
Discussion
In the present randomized controlled trial (RCT), we
evaluated the efficacy of a newly designed pilot-tested19
educational intervention to overcome TI among practi-
cing neurologist care for MS patients. We found TI in 7
out of 10 participating neurologists in at least one case
scenario. The TLS educational intervention was associ-
ated with a 68% reduction in the TI score or 70% reduc-
tion in the odds of TI. In other words, participants
appropriately choose a higher efficacy treatment (e.g.,
monoclonal antibodies) instead of continuing with the
same agents (e.g., glatiramer, interferon) when clinical
and radiological evidence of disease progression. The
effect of the educational intervention was similar for all
categories of TI scores. Specialist status, years of experi-
ence, and tolerance to ambiguity were associated with
lower TI. Moreover, selection of common agents used
for treatment escalation in participants’ routine practice
was associated with lower TI scores. More interestingly,
the TLS intervention was effective among participants
who do not commonly use agents for treatment escala-
tion in their daily practice by showing a significant
reduction in TI. Our results were consistent for the
Table 2 Multivariate Analysis for the Primary and Secondary Outcome Measuresa






Participant-level analysis n = 45 n = 45
TI score, mean (SD) 1.93 (1.42) 1.47 (1.42) (0.46) 20.68 (21.24 to 20.11)b
Secondary outcome measures
TI (present v. absent) in at least one
case scenario, n (%)
37 (82.2) 30 (66.7) (15.5) 0.30 (0.10 to 0.89)c
Individual responses n = 360 n = 360
TI score, mean (SD) 1.93 (1.41) 1.47 (1.41) (0.46) 20.68 (20.87 to 20.48)d
TI present versus absent, n of
individual responses/total
87/360 (24.2) 66/360 (18.3) (5.9) 0.60 (0.41, 0.88)d
CI, confidence interval; OR, odds ratio; TI, therapeutic inertia.
aAll models adjusted for age, specialty, years of practice, risk preference, and group (intervention v. control).
bDerived from linear regression models and expressed in b coefficients (95% CI) with TI score as dependent variable.
cDerived from multivariate logistic regression analysis with TI (present v. absent) as dependent variable.
dDerived from multilevel mixed effects models expressed as OR (95% CI) for binary outcomes (TI present v. absent) and b coefficients (95% CI)
for the TI score.
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analysis at the participant level and individual responses
for both categories of TI and TI scores.
There are not many proven effective interventions in
medical education associated with improvements in clini-
cally meaningful outcomes.35 A recent systematic review
evaluated 302 controlled studies that had investigated the
effect of evidence-based educational interventions. Of 85
articles that met the inclusion criteria, 46 (54%) studies were
randomized trials, 51 (60%) included postgraduate-level
participants. Although the authors evaluated outcomes in
multiple domains (e.g., self-efficacy, knowledge, behavior
change), none of the studies assessed patients’ benefits.35 In
MS care, TI may lead to undertreatment. By extension, the
TLS intervention used here may eventually have patient
benefits if it reduces TI in MS care.
We used TLS to reduce TI in MS care. Previous
authors proposed the TLS to monitor treatment response
in patients with RRMS. They included a more
Figure 4 TLS intervention decreased therapeutic inertia (TI). (A) Comparison of adjusted TI scores in the intervention and
control groups. This graph was derived from the multivariate linear regression analysis adjusted for age, years of practice,
participants risk preference, and specialty (general neurologist v. MS expert). TI scores were significantly higher in the control
group compared to the intervention group (*P value\0.001). (B) Comparison of adjusted prevalence of TI between the
intervention and control groups. This graph was derived from the multivariate logistic regression analysis adjusted for age, years
of practice, participants risk preference, and specialty (general neurologist v. MS expert). The prevalence of TI was significantly
higher in the control group compared with the intervention group (*P value\0.001).
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sophisticated scoring system (0 to 3) for different cate-
gories (clinical relapses, evidence of disease progression,
cognitive status, and MRI findings) making practical use
in daily practice more difficult. This scoring system leads
to a decision model that uses the TLS to facilitate thera-
peutic choices.36 However, this strategy has not been pre-
viously tested in a RCT. The findings of our RCT
suggest that the TLS may be a useful medical educational
intervention, in keeping with research on the manage-
ment of obesity, fever in children, blood pressure control,
and healthy food choices.14,15
Our results have limitations that deserve comment.
First, our sample size is relatively small. However, our
RCT was designed and powered to detect differences in
TI following our pilot study.19 Second, case scenarios
may not necessarily reflect participants’ daily practice.
It is also possible that general neurologists apply the
‘‘first do not harm rule’’ when not escalating treatment
(commonly associated with more severe side effects).
Following these arguments, our study underestimates the
prevalence of TI in real-life practice given a tightly con-
trolled environment and applicability of treatment
Figure 5 Adjusted probability of therapeutic inertia (TI). (A) Adjusted probability of TI as a function of TI scores. (B) Adjusted
TI score categories stratified by intervention assignment group. The x-axis represents categories of the TI to evaluate whether the
intervention had a different effect among participants with low, medium, and high TI scores. The y-axis represents the TI scores
to be able to show the lack of overlap of 95% CI between TLS and controls for each TI category (P value TLS v. controls =
0.02). Data derived from multivariate linear regression with TI score as the dependent variable. ‘‘I’’ represent 95% CI error bars.
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recommendations in our RCT design. Third, we cannot
rule out the possibility that unmeasured confounders
(e.g., health policy, restrictive prescription rules) may
play a role for the studied outcome measures. We con-
trolled for this issue by measuring the prevalence of pre-
scription restrictions in the workplace for each
participant. No association was found between prescrip-
tion restrictions and the outcomes of interest. Fourth, we
have no information regarding the sustainability of the
TLS effect on TI given the design of our study. Future
research will be needed to investigate this question.
Finally, the definition of TI applied to MS care may not
be widely used. Nevertheless, we used a practical and
conservative definition of TI (absence of escalation with
the concomitant presence of a clinical relapse and evi-
dence of imaging activity) consistent with our previous
studies, which is supported by guidelines showing
improvements in clinical outcomes when escalating
therapies (i.e., blood pressure and diabetes).6,24,26
In the evolving landscape of MS treatment, new and
more effective agents with improvements in safety pro-
files are becoming available.33 Despite such advance-
ments, many MS patients remained undertreated.25,26
Several conditions affect the risk of TI, but physicians’
factors are regarded as the most influential.33 Our results
revealed that an innovative and highly usable educa-
tional intervention may revert the incident risk of TI
among neurologists who care for MS patients. This is
also supported by the following facts: 1) participants
who commonly use agents for treatment escalation had
lower TI, 2) the significant reduction in TI for the TLS
intervention group among neurologist who do not com-
monly use agents for treatment escalation, and 3) the
relevance of the role of MS specialist in making thera-
peutic decisions given the lower prevalence of TI.
Our findings have practical clinical and health policy
implications, which may not only lead to improving out-
comes for patients but also to the implementation of
educational interventions in physicians managing high-
risk and complex patients. Our intervention has the
potential to be translated to other highly prevalent medi-
cal conditions, including the management of hyperten-
sion, diabetes, and dyslipidemia commonly affecting
individuals at high risk of cardiovascular and cerebro-
vascular diseases.
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Key Points: 42 
 43 
Question:  How physicians handle uncertainty when making live therapeutic decisions?  44 
 45 
Findings: In this randomized clinical trial 34 neurologists with expertise in multiple sclerosis (MS) 46 
were allocated to an educational intervention or usual care to make 680 therapeutic decisions while 47 
we simultaneously measure central arousal (acquired by pupillary responses) a proxy for uncertainty. 48 
Arousal responsivity was associated with therapeutic inertia (TI). Our educational intervention showed 49 
a 31% significant reduction in TI compared to the control group. Our intervention ameliorates TI by 50 
reducing arousal responses.  51 
 52 
Meaning: Our results suggest that arousal response (pupil dilation) is an indicator of how physicians 53 
handle uncertainty when making live therapeutic decisions. Pupil dilation also indicates how the 54 
educational intervention would alter changes in physician’s decisions under uncertainty, thus 55 
decreasing TI. 56 
 57 
 58 
  59 
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Abstract:  60 
Importance:  Therapeutic inertia (TI) is a common problem in patient care usually triggered by uncertainty. 61 
However, limited information is available on how physicians handle therapeutic decisions under uncertainty. 62 
 63 
Objective: To evaluate the relationship between arousal (pupil dilation), a proxy measure of therapeutic 64 
decisions under uncertainty, a proven effective educational intervention and TI.  65 
  66 
Design, Setting, and Participants: In this randomised controlled trial, we enrolled 34 neurologists with 67 
expertise in multiple sclerosis (MS) practicing at 15 outpatient MS clinics in academic and community 68 
institutions from across Canada. Participants were randomly assigned to an educational intervention that 69 
facilitates treatment decisions (intervention group) or usual care (control group) from December 2017 to 70 
March 2018. Participants listened to 20 audio-recorded simulated case-scenarios while pupil responses were 71 
assessed by eye-trackers. Arousal was assessed as pupil dilation in time-periods where critical information was 72 
provided (T1: clinical data, T2: neurological status, T3: MRI data).  73 
 74 
Interventions: Traffic-light system based educational intervention (TLS) vs. usual care (not exposed to the 75 
educational intervention). The TLS assist participants identify clinical patterns associated with poor prognosis 76 
in MS care, thereby facilitating the decision-making process by exploiting existing associations between colors, 77 
representing risk levels, and actions (treatment decisions).  78 
 79 
Main outcome and measures: TI is defined as lack of treatment escalation despite evidence of disease 80 
progression. Pupil dilation was used as a measure of central arousal.  81 
 82 
Results: Of 38 eligible participants, 34 (89.4%) neurologists completed the study. The mean age (SD) was 44.6 83 
(11.6) years; 38.3% were female. TI was present in 50.0% (17/34) of all participants and was associated with 84 
greater pupil dilation (p<0.05). For every additional standard deviation of pupil dilation, the odds of TI 85 
increased by 51% for T1 (95%CI 1.12-2.03), by 31% for T2 (95%CI 1.08-1.59) and by 49% for T3 (95%CI 1.13-86 
1.97). The intervention significantly reduced TI (RR 31.5%; 95%CI 16.1-47.0). Arousal responses mediated 87 
29.0% of the effect of the educational intervention on TI.  88 
 89 
Conclusions and Relevance: Individual arousal is an indicator of how physicians handle uncertainty when 90 
making live therapeutic decisions. Arousal responses regulate the treatment effect of an educational 91 
intervention and therapeutic decisions in MS care.    92 
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Introduction:  93 
Therapeutic decisions requires an individualized balance of the safety and efficacy profiles of different agents 94 
with either imperfect or uncertain information about the outcomes of that choice.1,2  One decision bias 95 
occurring in the context of this uncertainty is therapeutic inertia (TI). TI is characterized by suboptimal 96 
decisions to not initiate or intensify treatment when treatment goals are unmet.3-5  TI affects 60% to 90% of 97 
physicians caring for patients with chronic conditions (e.g. hypertension, diabetes, multiple sclerosis). Such 98 
suboptimal decisions lead to poorer clinical outcomes and higher health care costs.3-6  Yet, TI can be reduced: 99 
In a randomized controlled trial on multiple sclerosis (MS) care, we found a 70% reduction of TI in neurologists, 100 
using a short (less than five minutes) and simple (application of the traffic light system) educational 101 
intervention.7 For MS, overcoming TI corresponds to appropriately switching from a first-line agent (e.g. 102 
Glatiramer, Interferons) to a high-efficacy treatment (e.g. Fingolimod, Monoclonal antibodies, etc.) given both 103 
clinical and radiological evidence of disease progression.7-11 104 
Recent studies showed that decisions under uncertainty are associated with central arousal, as measured by 105 
pupil dilation.12,13 In particular, phasic pupil size increases are associated with suboptimal or erroneous 106 
decisions involving high uncertainty.14,15 However, the role of autonomic arousal during therapeutic decisions 107 
under uncertainty is unknown.  108 
We hypothesized that our educational intervention would decrease uncertainty about therapeutic choices, as 109 
reflected in decreased arousal responses, and thereby lead to an improvement in therapeutic decisions.12,14,15   110 
A better understanding of the link between pupil dilation as a marker of an autonomic arousal response and TI 111 
may help to develop more effective educational strategies to overcome suboptimal or erroneous decisions.  112 
In this randomized controlled trial (RCT), we aimed to: i) evaluate the relation between arousal responses and 113 
TI, ii) investigate how our previously tested and effective educational intervention7 affects arousal responses 114 
and TI, and iii) assess whether arousal responses mediate the association between the educational 115 
intervention and TI (i.e., mediation analysis). We used MS care as an ideal model for complex therapeutic 116 
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decisions arising in the management of chronic medical conditions, while taking advantage of our previously 117 
tested and effective educational intervention to reduce TI in an RCT.7  Nevertheless, our findings may also 118 
apply to other chronic medical conditions such as hypertension, diabetes, and dyslipidemia.  119 
 120 
METHODS:  121 
Study design: We randomly assigned participants to an educational intervention group or a usual care control 122 
group. The educational intervention used the traffic light system (TLS) to reduce TI in the management of MS 123 
(details below). The control group made therapeutic decisions without being exposed to the TLS intervention, 124 
in line with the current standard practice. Randomized group assignment and allocation concealment was 125 
controlled by Qualtrics. Participants were not aware to which group they were allocated. Investigators were 126 
also blinded to the treatment allocation. The mean (median) time of study completion was 44.9 (39.9) minutes 127 
and participants received 450 Canadian dollars (equivalent to USD 350). Further details of the protocol were 128 
published in ClinicalTrials.gov # NCT03134794 and elsewhere.7  129 
 130 
Inclusion criteria and Participants: Neurologists actively caring for MS patients from across Canada were 131 
invited to participate by e-mail sent from the Canadian Network of MS Clinics and Neuro-sens (Neuro-132 
sens.com). These networks comprise most MS neurologists in Canada. Participants were recruited from 133 
December 13, 2017 to March 2, 2018. Physicians whose practice focuses primarily on caring for MS patients 134 
were classified as ‘MS specialists’. Physicians seeing less than one MS patient per month were excluded from 135 
the study. Participants provided written informed consent. The study was approved by the Research Ethics 136 
Board of St. Michael’s Hospital-University of Toronto.  137 
 138 
Educational intervention: The traffic light system (TLS). We used our previously established TLS-intervention7 139 
to assist participants identify clinical patterns associated with poor prognosis (high risk of disease progression 140 
based on clinical and imaging profile) in simulated case-scenarios. The TLS facilitates the decision-making 141 
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process by exploiting existing associations between colors, representing risk levels, and actions.7,16-18 For 142 
example, the red light represents “high risk” and triggers a “stop and think” action, whereas the green light 143 
associates “low risk” with a “continue the same strategy” action. Previous studies showed that the TLS can 144 
interrupt automatic behavior leading to more optimal decisions.19  In our MS care model, the TLS facilitates 145 
associating the red traffic light, as a warning sign of disease progression, with switching from a low-efficacy 146 
agent (e.g., interferon or glatiramer) to a more effective disease modifying treatment (e.g. monoclonal 147 
antibodies).8-10  Conversely, the green traffic light represents a stable patient following a good clinical course 148 
(e.g., no relapse and stable activity on brain imaging) and therefore requiring no immediate therapeutic 149 
changes. 150 
 151 
Data collection and study flow (Error! Reference source not found. 1A): The study progressed as follows: i) 152 
Collection of demographic and practice-based information, ii) completion of behavioral experiments, and iii) 153 
completion of 20 simulated and standardized case-scenarios (10 before and 10 after the intervention) to 154 
assess TI. We used simulated case-scenarios, reflecting common situations in clinical practice, that were 155 
previously validated and designed by our research team and MS experts.7 All simulated case-scenarios were 156 
presented auditorily (via headphones connected to the computer) to avoid interference of visual stimulation 157 
and automatic eye movements with pupil responses. The mean ±SD duration of case-scenarios was 35.4 ±7.1 158 
seconds (range 27-50). For each simulated case scenario, we identified three time-periods during which critical 159 
information was provided (Appendix, Table e1). Time-period T1 provided critical clinical information (present 160 
and previous clinical relapses, type of relapse and/or symptoms). T2 informed about the neurological status of 161 
the patient (Expanded Disability Status Scale [EDSS]). T3 provided critical brain imaging information (number 162 
and nature of new lesions, GAD enhancing lesions). Time-period T0 before the start of case-scenarios served as 163 
baseline, while T4 represented the final segment where standardized questions (e.g., “What would you do? 164 
Please select one of the following options”) were asked in preparation to the treatment options (Error! 165 
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Reference source not found. 1A). Compared to the baseline T0, we expected an arousal response during 166 
critical information periods T1-T3 and little responding during T4. 167 
Based on previously reported associations of risk and ambiguity aversion with TI20,21, we considered also their 168 
relation to arousal responses and TI, using established measures in the financial domain.22,23  Further details of 169 
these measures were published previously (see Appendix).20 170 
 171 
Outcome measures: TI is defined as lack of treatment escalation despite evidence of disease progression. 172 
Following best-practice guidelines, we defined disease progression as the combination of a clinical relapse plus 173 
the presence of five or more new lesions (T2 or Flair sequences) or at least one gadolinium-enhancing lesion in 174 
follow-up magnetic resonance imaging (MRI) scans.8,9 Using the combination of clinical relapse and MRI 175 
activity is consistent with evidence regarding the risk of treatment failure in patients receiving interferon-β.24 176 
For each of our case-scenarios, we determined TI as a binary variable (present vs absent; primary outcome). A 177 
secondary outcome included TI greater than or equal to 25% of responses, meaning that participants did not 178 
escalate treatment when recommended in at least 1 out of 4 simulated case-scenarios.7-10 179 
 180 
Experimental procedures: The study was conducted in an ambulatory clinic-type setting to increase ecological 181 
validity. Room temperature, light conditions (100 lumens), and participants’ sitting positions were held 182 
constant. Pupil time-series were z-scored within each participant, to allow comparison of pupil dilation 183 
between and within simulated case-scenarios, critical time-periods, and participants. The average pupil size 184 
(measured at T0, i.e., 1500ms - 500ms before scenario onset) was taken as pupil baseline.25 For each simulated 185 
case-scenario, we estimated arousal responses by subtracting the average baseline pupil diameter from the 186 
peak pupil dilation during each critical time-period (T1-T3, see figure 1B).13,26  Further details are explained in 187 
the appendix. 188 
 189 
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Sample size: Given our main goal and the application of our proven effective educational intervention7 we 190 
conducted a post-hoc calculation. The power to determine differences in phasic pupil response in relation to TI 191 
was 99%. 192 
Statistical analysis: We applied three analytical approaches: i) comparison of arousal responses across critical 193 
time-periods, ii) treatment-effect analysis evaluating the association between arousal responses and TI, and iii) 194 
a mediation analysis to assess how the association between individual participant characteristics and TI may be 195 
mediated by arousal responses. For (i) we used non-parametric tests (Wilcoxon and Mann-Whitney tests for 196 
continuous and categorical variables, respectively).  For (ii) we compared high vs. low arousal between groups 197 
stratified by intervention period (pre- vs. post-intervention). We used generalized estimating equations (GEE) 198 
to assess relationships between the variables of interest with TI accounting for clustering (repeated 199 
observations on participants). This analysis controlled for the pre-defined explanatory variables age, specialist 200 
status (MS expert vs. general neurologists), years of practice, risk preferences, and ambiguity aversion as 201 
identified in our previous research.20  To test the treatment effect of the educational intervention (TLS), we 202 
used difference-in-differences models (also called untreated control group design with pre- and post-test).27  203 
This allowed us to measure the treatment effect of our intervention by comparing the change over time (post-204 
test minus pre-test performance) between the intervention and control group.  Pupil dilation for each 205 
participants and case-scenario was tested as a mediator (see below). As a result, we were able to evaluate 206 
whether the benefits of the educational intervention on TI were mediated by individual arousal responsivity. 207 
Mediation analysis (iii) is a technique commonly used in the social sciences to explain a relation between an 208 
independent variable (e.g. demographic variables) and an outcome via a third variable (called ‘mediator’).28,29  209 
The greatest value of mediation analysis in RCT data is that it can establish whether the effects of the 210 
intervention (or any independent variable preceding the outcome of interest) on the outcome are mediated by 211 
the another standardized measured covariate. Here we measured whether the effect of our intervention on TI 212 
is mediated by pupil-indexed arousal.  213 
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All tests were 2-tailed, and p-values <0.05 were considered significant. We used STATA 13 (College Station, TX: 214 
StataCorp LP) and SAS to conduct all analyses. 215 
 216 
RESULTS:  217 
Participant characteristics: Thirty-eight neurologists with expertise in MS were invited to participate in the 218 
study. The cooperation rate was 89.5% (n=34/38); the completion rate 100%. Of the 34 participants who 219 
completed the study, pupillary data was available in 30 (88.2%) participants. Two participants in each group 220 
had incomplete or missing pupil data (CONSORT Figure). The mean age (SD) was 44.6 (± 11.6) years; 13 221 
participants (38.2%) were female. Table 1 summarizes baseline characteristics of the study population. 222 
Participants had a mean of 12.5 (± 12) years of experience and assessed 23.1 (± 16) MS patients per week. 223 
Participants showed risk-neutrality in our measures of risk attitudes and the minimal safe amounts participants 224 
preferred over the 50/50 gamble did not differ between groups [(Mann-Whitney p-value=0.14; control: $ 225 
175.7 (± 45.2); intervention: 211 (± 78.8)]. Nineteen (55.9%) participants showed aversion to ambiguity in the 226 
financial domain. 227 
TI was present in 50.0% (17/34) of participants in at least one case-scenario, representing 7.7% (42/544) of all 228 
individual responses that assessed TI. There was no difference in baseline pupil data between groups for each 229 
simulated case-scenario (2.82 mm vs. 2.96 mm; Mann-Whitney p=0.57).  230 
 231 
1) Arousal responses predict therapeutic inertia 232 
Overall, pupil size increased for each time-period relative to baseline (F-test for linear regression analysis, all 233 
p<0.0001). The results remained robust after adjustment for the pre-specified covariates (p<0.0001).   234 
Importantly, the multivariate analysis adjusted for age, sex, MS expertise, risk preferences, ambiguity aversion, 235 
pre-vs. post-intervention period, and intervention group by time-period (Table 2) showed that pupil dilation 236 
was positively related to TI for all critical time-periods (T1 to T3). For every additional standard deviation of 237 
pupil dilation, the odds of TI increased by 51% for T1 (OR 1.51; 95%CI 1.12-2.03), by 31% for T2 (OR 1.31; 238 
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95%CI 1.08-1.59) and by 49% for T3 (OR 1.49; 95%CI 1.13-1.97). As expected, there was no association 239 
between pupil dilation and TI for T4 (OR 1.07; 95%CI 0.86-1.34) as there was no critical information provided.  240 
Our results were robust to using secondary outcome measures (Table 2). Together, stronger arousal responses 241 
at critical time-periods were associated with stronger TI. 242 
 243 
2) Pre vs. Post-intervention and group allocation (intervention vs. control) affect arousal responses 244 
Pupil size did not differ significantly between intervention and control groups before the intervention but did 245 
so after the intervention for T2, T3, and T4 (Error! Reference source not found.. Overall, the multivariable 246 
analysis showed that in the post-intervention period, participants in the control group had significantly 247 
enlarged pupils compared to the intervention group for T2 (p=0.049), T3 (p=0.004), and T4 (p<0.0001). No 248 
difference was observed for T1 (p=0.47). The analysis of dichotomized pupil response (maximum-peak minus 249 
mean-baseline greater than or equal to 0.1 z-scored difference as a high arousal vs. below 0.1 z-scored 250 
difference -low arousal response) showed similar results (Figure 3). After adjusting for the pre-specified 251 
covariates, the multivariate analysis revealed similar results (Table 2).  252 
 253 
3) Effect of the educational intervention on TI 254 
In our previous study, the educational intervention showed a significant reduction in TI.7 To assess the 255 
presence of a treatment effect on individual TI, we use the difference-in-difference analytical strategy (Table 256 
3). We found that participants in the educational intervention group had a significant 31.5% (95%CI 16.1-47.0) 257 
reduction in TI compared to the control group (Figure 4). Linear regression analysis adjusted for participant 258 
age, gender, expertise, risk preference and pupil dilation showed that for every therapeutic decision, there was 259 
a significant TI decrease of 5.0% (-5.0%, 95%CI -0.8%, -9.3%) in the intervention group. The difference-in-260 
difference analysis revealed no evidence for confounding endogenous effects. Together, these data replicate 261 
the previous findings that the TLS intervention reduces TI.7 262 
 263 
4) Arousal response mediates the relationship between the educational intervention and TI 264 
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We found strong mediation: arousal responses explained 29.0% of the total mediated intervention effect on TI 265 
(Figure 5A). Notably, the mediated effect of arousal on TI was greater than the direct effect of the intervention 266 
(full mediator). This is also reflected in the larger values of the multiplication of β coefficients for the indirect 267 
effect compared to the smaller β coefficient of the direct effect (intervention on TI) (Figure 5B).  The direct 268 
effect of the educational intervention on TI was -3.5% (95%CI -9.2, 3.5). Other factors (e.g. age, sex, risk 269 
preference), had a non-significant or a negligible effect. Further details are in the appendix. The sensitivity 270 
analyses of adding or removing covariates (i.e., risk preference, age, sex, academic practice) revealed no 271 
significant changes in the β coefficients (<10%) of the direct or indirect effects (data not shown). 272 
 273 
DISCUSSION 274 
The role of autonomic arousal for therapeutic decision making has been entirely unexplored. In the present 275 
study, we addressed this gap in the framework of therapeutic MS care decisions, with a focus on decisions not 276 
to escalate treatment when recommended by best practice guidelines (i.e. TI). We analyzed pupil dilation as an 277 
established marker of autonomic arousal12,13 and found that both continuously measured pupil dilation and 278 
dichotomized high vs. low pupil responses were associated with TI. For every additional standard deviation of 279 
pupil dilation, the odds of TI increased by 30% to 50% depending on the critical clinical information being 280 
provided. Even though our study had low statistical power and Canadian neurologists show comparatively little 281 
TI 21, we found that participants in the control group would have reduced TI by almost a third if they would 282 
have been randomized to the intervention group. Our data suggest that the intervention may ameliorate TI by 283 
reducing arousal responses to critical information. Indeed, pupil dilation mediated the effects of the 284 
educational intervention on TI (explaining 29% of the total mediated effect).  285 
 286 
Uncertainty may drive rapid pupil-linked arousal responses, affecting behavioral choices12 and the updating of 287 
beliefs with presented evidence.30 Our results are consistent with this notion. Our educational intervention 288 
may reduce arousal by reducing uncertainty and thereby facilitating alternative behavioral strategies. 289 
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Specifically, the warning function of a red traffic light makes the need for switching to a more effective agent 290 
salient7 and may concurrently boost confidence in the therapeutic decision.  291 
What is the relevance of our findings for clinical practice? 292 
TI commonly affects physicians caring for patients with chronic medical conditions such as MS, diabetes, 293 
hypertension, and chronic obstructive pulmonary disease.31-33 TI has been associated with poorer outcomes, 294 
including greater disability, diminished quality of life at the individual level and higher hospitalizations and 295 
costs at the health-care level.6,20,34  Limited knowledge integration and knowledge-to-action gaps may result in 296 
automatic responses leading to suboptimal therapeutic decisions.35  297 
 298 
Our study has several limitations. First, pupil size is not a standard measure in clinical practice. To the extent 299 
that arousal plays a significant role in therapeutic decisions, our proof-of-concept suggests that there is value 300 
in this measure. Second, arousal responses may have different triggers and effects than the ones we tested. 301 
Third, our sample size was small, reducing the precision of our results. Fourth, simulated case-scenarios may 302 
not truly reflect therapeutic decisions in clinical practice. Fifth, the traffic light system we used is just one 303 
example of an intervention suitable for MS care. Other interventions may be needed and more effective for 304 
the management of other prevalent acute and chronic conditions.  305 
Despite these limitations, our conclusions are strengthened by a randomized intervention design showing an 306 
arousal-modulated link between an effective therapeutic intervention and therapeutic decisions made by 307 
physicians who care for MS patients (Figure 5C).   308 
In conclusion, this study increases our understanding on how physicians make therapeutic decisions under 309 
uncertainty. Critical information (i.e., clinical course, neurological status and brain imaging) increases arousal 310 
and stronger arousal responses are associated with suboptimal therapeutic decisions (i.e., therapeutic inertia). 311 
Moreover, the inertia-reducing effects of an educational intervention appear to be mediated by reduced 312 
arousal responses. We are now able to identify physicians making more than 25% suboptimal decisions and to 313 
estimate the inertia-reducing benefits of novel educational interventions using the autonomic arousal 314 
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response as a marker of their effectiveness. Crucially, this marker is unaffected by demand effects or cognitive 315 
biases. Consequently, our findings open avenues to tailor educational interventions and formal risk-316 
assessment training to decision makers (medical students, family doctors, and specialists). In the future, this 317 
approach may help optimize treatment decisions for other more prevalent chronic diseases (e.g. hypertension, 318 
diabetes) leading to improved medical education and better patients’ outcomes.    319 
  320 
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Figure legends 439 
Figure 1. Design and basic data 440 
A. Study flow. Participants first answered demographic and practice-based questions and provided risk 441 
preferences and ambiguity preferences. Next, they listened to simulated case-scenarios. Each scenario was 442 
followed by six therapeutic choices, which remained on the screen until the participant selected one of them. 443 
After the first ten simulated case scenarios (pre-intervention), participants were randomized to the 444 
intervention (traffic light system) or the control group. Finally, all participants performed another ten 445 
simulated case scenarios. The dots after therapeutic choices #1 and #11 represent case scenarios #2-10 and 446 
#12-20.  447 
 448 
B. Time- and group-resolved pupil dilation. Pupil dilation peaked at relevant time-periods both for participants 449 
in the control and the intervention group. The black dots represent the peak pupil size within each time-period 450 
used to compute pupil responses (pupil peak for each time-period minus mean baseline at time-period 0 (T0). 451 
Peaks were determined similarly for both groups across all time-periods and case-scenarios. 452 
 453 
Figure 2. Effects of intervention and group allocation on pupil responses  454 
Pupil-linked arousal responses (peak minus mean baseline) are shown separately for intervention and control 455 
groups, stratified by the intervention period. * p<0.01 for the comparison of pupil responses between control 456 
and intervention groups. Note that lower responses in the intervention group extend to T4, where no critical 457 
information was provided, which may suggest that the protective effect of the intervention extends into the 458 
period when participants made decisions under uncertainty. 459 
 460 
Figure 3. Differences in TI by pupil dilation (dichotomized) and intervention groups 461 
Plot of TI as a function of dichotomized pupil responses (peak minus mean baseline; high responses: ≥0.1 z-462 
scored difference; low responses: <0.1 z-scored difference). The graph was derived from adjusted analysis 463 
using GEE accounting for clustering within participants. Dispersion bars indicate 95% confidence 464 
intervals.* p<0.01 for the comparison of TI between groups. The control group with high arousal response 465 
served as reference category. Participants with low pupil responses showed less TI. There was no difference in 466 
TI between the intervention and control group for low response individuals. Conversely, high responders 467 









Figure 4. Treatment effects using difference-in-differences  471 
Unadjusted TI before and after intervention allocation group, controlling for confounding endogenous factors. 472 
The dotted line illustrates the expected reduction of TI (31.5%, 95%CI 16.1-47.0) if the control group would 473 
have received the intervention using difference-in-difference analysis. 474 
 475 
Figure 5. Mediation Analysis  476 
A. Schematic representation of generic mediation analysis. The mediation analysis characterizes the 477 
relationship between the independent variable (X) and variables that are related with an outcome of interest 478 
(Y). A mediating variable (M) is hypothesized to be intermediate in the relation between an independent 479 
variable (X) and an outcome (Y). B. Structural equation model used for mediation analysis. The mediation 480 
model characterizes the relationship between the independent variable X (Educational intervention) and 481 
variables (age, years of practice, MS expert, risk preference) that are related with an outcome of interest Y (TI). 482 
The mediating variable M (pupil enlargement from baseline) is hypothesized to be intermediate in the relation 483 
between the educational intervention and TI. This figure illustrates the direct, indirect, and total effect of the 484 
educational intervention on TI with pupil dilation as the mediator. Pupil responses mediated the effect of the 485 
intervention on TI. The Sobel test confirmed that the mediation effect was significant (p=0.029). The effect of 486 
covariates on pupil dilation are omitted in the graph for simplicity. C. Proposed pathways associated with 487 
therapeutic inertia in MS care. Summary schematic illustrating integration of autonomic, behavioral (decision-488 
making), and participant characteristics associated with TI. The reduction in TI (therapeutic decision) by the 489 
educational intervention is mediated by pupil dilation. Other covariates may also directly or indirectly 490 
influence TI, but in the present study had negligible or non-existent effects (mediation effect <3%). 491 
  492 
192





Table 1. Baseline characteristics of participants Table 1 493 






Age, mean (SD), in years 44.6 (11.6) 40.5 (8.5) 47.5 (13.5) 
Sex   
  Female 13 (38.2) 6 (42.9) 7 (35.0) 
Practice characteristics   
  MS specialists 20 (58.8) 6 (42.9) 14 (70.0) 
  General Neurologists who care for MS patients 14 (41.2) 8 (57.1) 6 (30.0) 
   Practice setting: Academic Hospitals 28 (82.4) 6 (42.9) 14 (70.0) 
   Years in practice, mean (SD) 12.5 (11.8) 9.4 (9.5) 14.7 (12.9) 
   MS patients seen per week (≥20) 15 (44.1) 4 (28.6) 11 (55.0) 
Author of a peer-reviewed publication in the 
last 12 months 
22 (64.7) 10 (71.4) 12 (60.0) 
Risk preference, minimal safe amount, mean 
(SD) in $ 
196.5 (68.5) 175.7 (45.2) 211 (78.8) 
Ambiguity aversion 19 (55.9) 8 (57.1) 11 (55.0) 
Pupil data  
Pupil size, mean baseline in mm (SD) 2.90 (0.87) 2.82 (0.35) 2.96 (0.99) 
Pupil size, mean peak in mm (SD) * 3.27 (1.10) 3.15 (0.5) 3.35 (1.35) 
Pupil size, response (peak minus mean baseline), 
mean in mm (SD)* 
1.60 (1.42) 1.69 (1.34) 1.54 (1.47) 
 494 
Numbers in brackets indicate percentages, unless otherwise indicated.  495 
Pupil data reflect averages across the study after interpolation and z-scored.   496 
* only including critical time-periods T1, T2, T3  497 
There were no differences in baseline characteristics between groups  498 
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Table 2. Relationship between pupil dilation by critical time-periods and therapeutic inertia Table 2 499 
Outcome: Therapeutic Inertia Model for T1 
OR (95%CI) 
Model for T2 
OR (95%CI) 
Model for T3 
OR (95%CI) 
Model for T4 
OR (95%CI) 
Significance of time-period Clinical presentation Functional status MRI findings Standardized question 
Maximum pupil dilation minus 
baseline for TI indicator 
1.51 (1.12-2.03) 1.31 (1.08-1.59) 1.49 (1.13-1.97) 1.07 (0.86-1.34) 
Maximum pupil dilation minus 
baseline for TI >25%  
1.53 (1.11-2.12) 1.33 (1.07-1.63) 1.51 (1.13-2.00) 1.08 (0.86-1.36) 
Maximum pupil dilation minus 
baseline (aggregated results T1 
to T3) for TI indicator 
1.47 (1.24-1.74) NA 
Maximum pupil dilation minus 
baseline (aggregated results T1 
to T3) for TI >25% 
1.49 (1.19-1.87) NA 
 500 
This table represents the results of the multivariate models adjusted for age, sex, MS expertise, risk preferences, ambiguity aversion, pre-vs. post-501 
intervention period, and intervention group. Across all case scenarios, pupil responses (maximum dilation minus mean baseline) were associated with 502 
TI for all critical time-periods (T1 to T3). For every additional standard deviation of pupil dilation, the odds of TI increase by 31% to 51%. As expected, 503 
there was no association between pupil dilation and TI for time-period 4 (standardized questions at the end of the presentation for each case-504 
scenario). The analysis of aggregated pupil data for T1, T2 and T3 revealed the for every additional standard deviation of pupil dilation, the odds of TI 505 
increase by 47% to 49% for the TI indicator or for TI greater than or equal to 25% of responses, respectively. 506 
 507 
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Table 3. Effect of group on pupil dilation: Difference-in-difference analysis Table 3 508 
Outcome: Pupil response 
Model for T1 Model for T2 Model for T3 Model for T4 
Time-period Clinical presentation Functional status MRI findings Standardized question 
Pupil response (peak minus mean baseline size)     
 β coef. (95%CI) β coef. (95%CI) β coef. (95%CI) β coef. (95%CI) 
Intervention vs. control 
(unadjusted) 
- 0.23 (-0.64, 0.19) -0.46 (-0.91, -0.02) -0.63 (-1.04, -0.22) -0.75 (-1.12, -0.38) 
Intervention vs. control 
(adjusted) 
- 0.23 (-0.64, 0.19) -0.46 (-0.90, -0.01) -0.63 (-1.04, -0.22) -0.75 (-1.12, -0.37) 
Intervention vs. control 
(adjusted) 
- 0.68 (-1.10, -0.25) NA 
 509 
This table represents the results of the univariate and multivariate models adjusted for age, sex, MS expertise, risk preferences, ambiguity aversion, 510 
pre-vs. post-intervention period, and intervention group. Across all case scenarios, participants in the intervention group showed significantly smaller 511 
pupil responses (difference in difference post-period minus pre-period) compared to controls for time-periods T2, T3 and T4. For example, pupil 512 
responses were reduced by an estimated 0.46 mm for T2, 0.63 mm for T3 and 0.75 mm for T4 in the intervention group compared to the control 513 
group. This is equivalent to a significant relative reduction of pupil responses of 29.3% for T2, 32.5% for T3 and 38.7% for T4 in the intervention group 514 









Figure 1A: Study flow Fig 
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A B S T R A C T
Background: Emotions play a critical role in our daily decisions. However, it remains unclear how and what sort
of emotional expressions are associated with therapeutic decisions in multiple sclerosis (MS) care. Our goal was
to evaluate the relationship between emotions and affective states (as captured by muscle facial activity and
emotional expressions) and TI amongst neurologists caring for MS patients when making therapeutic decisions.
Methods: 38 neurologists with expertise in MS were invited to participate in a face-to-face study across Canada.
Participants answered questions regarding their clinical practice, aversion to ambiguity, and the management of
10 simulated case-scenarios. TI was defined as lack of treatment initiation or escalation when there was clear
evidence of clinical and radiological disease activity. We recorded facial muscle activations and their associated
emotional expressions during the study, while participants made therapeutic choices. We used a validated
machine learning algorithm of the AFFDEX software to code for facial muscle activations and a predefined
mapping to emotional expressions (disgust, fear, surprise, etc.). Mixed effects models and mediation analyses
were used to evaluate the relationship between ambiguity aversion, facial muscle activity/emotional expressions
and TI measured as a binary variable and a continuous score.
Results: 34 (89.4%) neurologists completed the study. The mean age [standard deviation (SD)] was 44.6 (11.5)
years; 38.3% were female and 58.8% self-identified as MS specialists. Overall, 17 (50%) participants showed TI
in at least one case-scenario and the mean (SD) TI score was 0.74 (0.90). Nineteen (55.9%) participants had
aversion to ambiguity in the financial domain. The multivariate analysis adjusted for age, sex and MS expertise
showed that aversion to ambiguity in the financial domain (OR 1.56, 95%CI 1.32–1.86) was associated with TI.
Most common muscle activations included mouth open (23.4%), brow furrow (20.9%), brow raise (17.6%), and
eye widening (13.1%). Most common emotional expressions included fear (5.1%), disgust (3.2%), sadness
(2.9%), and surprise (2.8%). After adjustment for age, sex, and physicians’ expertise, the multivariate analysis
revealed that brow furrow (OR 1.04; 95%CI 1.003–1.09) and lip suck (OR 1.06; 95%CI 1.01–1.11) were asso-
ciated with an increase in TI prevalence, whereas upper lip raise (OR 0.30; 95%CI 0.15–0.59), and chin raise (OR
0.90; 95%CI 0.83–0.98) were associated with lower likelihood of TI. Disgust and surprise were associated with a
lower TI score (disgust: p < 0.001; surprise: p=0.008) and lower prevalence of TI (ORdisgust: 0.14, 95%CI
0.03–0.65; ORsurprise: 0.66, 94%CI 0.47–0.92) after adjusting for covariates. The mediation analysis showed that
brow furrow was a partial mediator explaining 21.2% (95%CI 14.9%-38.9%) of the association between aversion
to ambiguity and TI score, followed by nose wrinkle 12.8% (95%CI 8.9%-23.4%). Similarly, disgust was the
single emotional expression (partial mediator) that attenuated (-13.2%, 95%CI -9.2% to -24.3%) the effect of
aversion to ambiguity on TI.
Conclusions: TI was observed in half of participants in at least one case-scenario. Our data suggest that facial
https://doi.org/10.1016/j.msard.2019.05.029
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Fig. 1. Study design and facial landmarks. (A) Sequence of study events. After answering demographic and practice-based questions and determining medical and
financial ambiguity aversion, participants listened to a case-scenario and then viewed 6 therapeutic choices. This procedure was repeated for each of the 10 case-
scenarios ranging from 25 to 50 s. All the stimuli remained on the screen until the participant selected one of the therapeutic choices. Then, the participant was able
to see the next screen and play the next case-scenario. The dots between the screen presenting the therapeutic choices #1 and the case-scenario #10 represent the
progression through scenarios #2-#9. (B) Facial landmarks. The region of interest in AFFDEX software contains the whole face including eyes, mouth and nose. Each
of the 34 facial landmarks are the main unit of study to represent 20 facial expression metrics that are mapped to represent emotional expressions (https://developer.
affectiva.com/mapping-expressions-to-emotions/). This figure illustrates the representation of the data at a particular time-point of the study, including: facial
metrics, screens of the stimulus presentation, and time landmarks according to the study design and flow. A value of zero indicates no evidence and a value of one the
highest evidence that a certain facial metric or emotion is fully expressed. (Levy et al., 2010) .
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metrics (e.g. brow furrow, nose wrinkle) and emotional expressions (e.g. disgust) are associated with physicians’
choices and partially mediate the effect of aversion to ambiguity on TI.
1. Background
The role of emotions in decision-making has been investigated for
decades. Recent studies have shown that emotions are the dominant
driver of the majority of meaningful goal-directed decisions in life
(Ekman, 2007; d'Acremont and Bossaerts, 2012). Different emotions
(fear, disgust, stress, surprise, etc.) manifested by facial muscle acti-
vation can modulate our perceptions and valuation of individual
choices by activating different pathways involving the striatum, orbi-
tofrontal cortex, the medial and dorsolateral prefrontal cortex, the in-
ferior parietal cortex, the amygdala and/or insular cortex (Phelps et al.,
2014; Cohen, 2005; Ekman and Friesen, 2003).
Previous studies have shown that decision making was associated
with muscle activation (e.g. brow furrow, brow raise, lip pucker, mouth
opening) and emotions (e.g. fear, sadness, anger, surprise) in consumers
or healthy volunteers (Phelps et al., 2014; Lerner et al., 2003, 2015).
For example, fear appears to be associated with pessimistic risk as-
sessments and risk-averse choices, whereas anger can provoke an op-
timistic estimations of risk and risk-seeking behavior (Lerner et al.,
2003, 2015; Kligyte et al., 2013) Similarly, some emotions, such as
anger, surprise, and optimism are associated with participants’ toler-
ance to ambiguity and the selection of optimal choices (Chesney and
Reiter, 2016; FeldmanHall et al., 2016). However, limited information
is available regarding how facial muscle activity (and derived emo-
tional expressions) relate to physicians’ therapeutic decisions.
Therapeutic inertia (TI) is a term that was introduced in 2006 to
define the absence of treatment initiation or intensification when
treatment goals are unmet (O'Connor et al., 2005; Mohan and
Phillips, 2011; Okonofua et al., 2006). TI is a common phenomenon
affecting 50% to 90% of doctors caring for patients with chronic con-
ditions (e.g. hypertension, diabetes, multiple sclerosis) and leading to
poorer clinical outcomes and higher health care costs (O'Connor et al.,
2005; Mohan and Phillips, 2011; Okonofua et al., 2006; Burks et al.,
2017). Previous studies have identified factors associated with TI
(Cooke et al., 2012; Saposnik and Montalban, 2018), and physician
factors (e.g. aversion to ambiguity) are considered the main con-
tributors (Saposnik and Montalban, 2018; Lebeau et al., 2014;
Saposnik et al., 2017a). To our knowledge, there are no data showing a
relationship between facial muscle activation, emotional expressions,
and therapeutic decisions under uncertainty (or ambiguity) among
practicing physicians.
In this study, we evaluated facial muscle activation (and emotional
expression) associated with therapeutic choices, particularly TI. We
also sought to evaluate the mediation effect between a physical (e.g.
facial muscle activity) or emotional (fear, disgust, surprise) response
with a therapeutic decision. Given the known associations between
specific facial muscle activation and emotional expression (anger, fear,
disgust, surprise, etc.) with an increased attention response that pre-
cedes participants’ choices (FeldmanHall et al., 2016; Stöckli et al.,
2018; McDuff et al., 2017), we hypothesized that facial muscle activity
(e.g. upper lip raise) and emotional expression (disgust, surprise) would
increase participants’ awareness and therefore mediating the relation-
ship between aversion to ambiguity and TI. We assessed emotional
expressions amongst physicians who care for people living with mul-
tiple sclerosis (MS) as this care model is representative of the paradigm
of complex therapeutic decisions (e.g. multiple therapeutic options with
a broad therapeutic range- e.g. different safety and efficacy profiles) in
the management of a chronic medical condition.
2. Methods
2.1. Study design
We conducted a cross-sectional study using the online platform
Qualtrics. The study included 10 MS case-vignettes to evaluate TI and 2
behavioural experiments to determine subject's attitudes towards am-
biguity. Case-scenarios were designed by our research team and MS
experts (JO, GS). Overall, 8 cases aimed to assess appropriate escalation
of treatment (whereby an absence of treatment change corresponds to
TI), while the remaining 2 cases were designed as controls (no indica-
tion for treatment escalation as there was no evidence of a clinical re-
lapse and disease activity on brain imaging). After completing demo-
graphic information and questions regarding their current clinical
practices, participants were exposed to behavioral experiments asses-
sing ambiguity aversion and then responded to case-scenarios (Fig. 1).
Behavioural experiments were designed to assess aversion to am-
biguity in the health and financial domains as previously reported by
our group (Saposnik et al., 2017a, 2016a; Anderson and Mellor, 2008).
Ambiguity aversion is defined as dislike for events with unknown
probability over events with known probability (Levy et al., 2010). For
example, an ambiguity-averse individual would rather choose a treat-
ment where the probability of benefits or side effects are known (even if
these are somewhat unfavourable) over one where these probabilities
are unknown. Specifically, in the health domain, participants were
asked to choose between Treatment A (50% probability of survival) or
“Treatment B” (the probability of survival is unknown). In the financial
domain, participants were asked to choose between a visual option with
known 50/50 probability of winning 400 or 0 US$ versus an option
with unknown probability of the same outcomes. In both domains, we
used grey bars to represent five levels (10%, 30%, 50%, 70%, and 90%)
of unknown probability. Aversion to ambiguity was indexed in two-
ways: binary (preference for the known probability in all 5 levels) and
as continuous variable (number of levels that participants selected the
known probability over 5). Details of the protocol and case-scenarios
were previously published (Saposnik et al., 2017a, 2016a, 2018)
Participants: Practicing neurologists actively involved in the care of
people living with MS from across Canada were invited to participate in
our study by the Canadian Network of MS Clinics and Neuro-sens
(Neuro-sens.com). These networks capture most of these neurologists in
Canada. Participants were recruited from December 13, 2017 to March
2, 2018. Physicians whose practice focuses primarily on caring for MS
patients were classified as ‘MS specialists’.
The study was conducted in an ambulatory clinic-type setting to
mimic the current clinical environment. Room temperature, light con-
ditions, and participants’ sitting positions were standardized. We used a
high definition webcam (Logitech Pro 920©) to capture facial move-
ments. All participants had at least 90% muscle detection by the camera
during the study period. Facial detection algorithms from AFFDEX (see
below) were integrated with the Qualtrics survey platform through
iMotions software (iMotions.com). The mean (median) duration of the
study was 44.9 (39.9) minutes. Participants were compensated with
400 Canadian dollars. Written informed consent was obtained from all
participants. The study was approved by the Research Ethics Board of
St. Michael's Hospital, University of Toronto, Canada.
2.2. Assessment of emotional expressions
We used AFFDEX, a machine learning algorithm software that de-
tects for emotional expressions based on facial muscle activity
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(Stöckli et al., 2018; iMotions 2016). AFFDEX has been validated in
more than 6 million facial videos from over 87 countries showing an
excellent accuracy (area under the curve greater than 0.9) (https://
www.affectiva.com/how/how-it-works/, accessed Feb 28, 2019). This
algorithm uses different features to identify 34 facial landmarks (e.g.
eye corners, eye centers, nose tip, mouth corner) with a threshold area,
discarding background regions (Fig. 2). The region of interest (ROI)
contains the whole face including eyes, mouth and nose. AFFDEX ap-
plies distinct analytical procedures to identify emotional expressions
(https://developer.affectiva.com/mapping-expressions-to-emotions/).
During our study, facial detection was recorded to analyze each video
frame. Eye blinking and closure were filtered-out. AFFDEX uses frames
with a positive detection for the subsequent analysis.
Facial muscle activity is the main unit of study in emotional ex-
pressions. Facial movements are detected and mapped on probability
values of emotional states (e.g. sadness, joy, disgust, anger, surprise,
fear, contempt). The probabilities returned by the AFFDEX module
range between zero and one. A value of zero indicates no evidence and
Fig. 2. Facial muscle activations overall and in relation to TI status. (A) Overall proportion of facial muscle activations in ascending order. Values at the top of the
bars represent the proportion of muscle activation during the study period. (B) Represents the distribution of facial muscle activations as shown in (A) stratified by
responses with (red) and without (blue) TI. Values within bars represent the proportion of muscle activations by TI status. For example, brow furrow activation was
observed in 19.1% of responses, 14.7% among participants with TI and the remaining 4.4% among participants without TI. The x-axis represents individual facial
metric as identified by the AFFDEX software for activations greater than 1%. (C) Overall proportion of emotional expressions in ascending order. Values at the top of
the bars represent the proportion of emotional expressions during the study period. (D) Represents the distribution of emotional expressions as shown in (C) stratified
by responses with (red) and without (blue) TI. For example, disgust was observed in 8% of responses, 5.8% among participants without TI and the remaining 2.2%
among participants with TI. The x-axes represent each individual emotional expression as mapped by the AFFDEX software.
* indicates p-values < 0.01, ** indicates p-values < 0.001, † indicates p-values <0.05->0.01 for differences between participants with and without TI.
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a value of one the highest evidence that a certain emotion is fully ex-
pressed (iMotions 2016). We used raw values of each individual's facial
expression to directly compare amongst participants. This approach
mitigates potential errors in the algorithms created to represent emo-
tional expressions due to lack of matching with pre-defined facial
muscle activity.
We use a proxy measure of participants’ arousal by combining the
level of attention (a summary measure of the time frame each partici-
pant was looking at the screen) and engagement (a weighted sum of
facial expressions). We compared facial muscle activity and emotional
expressions between participants with and without TI.
Multiple sclerosis and definitions: In the context of MS, TI is defined as
the lack of treatment initiation or escalation when there is evidence of
disease activity, based on clinical evidence and neuroimaging markers
(Saposnik et al., 2016a; Freedman et al., 2018; Freedman et al., 2013).
A more proactive management strategy, including earlier use of high-
efficacy DMTs and close monitoring of the clinical and radiological
response to treatment is recommended to slow the progression of
physical and cognitive impairments in patients with relapsing-remitting
multiple sclerosis (RRMS) (Noyes and Weinstock-Guttman, 2013;
Sormani et al., 2013; Duquette et al., 2016). Early treatment escalation
has been shown to reduce relapse rates, disability progression, and MRI
activity (Prosperini et al., 2012; Harding et al., 2019). For the primary
analysis, we used an accepted definition of disease activity that would
prompt treatment initiation or escalation (Freedman et al., 2018;
Prosperini et al., 2014; Bermel et al., 2013). Disease activity was de-
fined as the presence of a clinical relapse plus the presence of more than
four new brain lesions in follow-up magnetic resonance imaging (MRI)
scans or at least one gadolinium-enhancing lesion (Prosperini et al.,
2014; Bermel et al., 2013).
TI was measured as both a continuous score and as a binary vari-
able. The TI score corresponded to the number of case-scenarios where
Fig. 2. (continued)
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treatment initiation or escalation was warranted but not provided
(numerator) divided by the total number of case-scenarios where TI
could occur (denominator; n=8). TI as a binary variable (presence/
absence) was determined as the lack of treatment initiation or escala-
tion given disease activity in at least one case-scenario.
Outcome measures: The primary outcomes of the study was the as-
sociation between facial muscle activity and inferred emotional ex-
pression of participants at stimulus presentation (audio introducing MS
case-scenarios under uncertainty) when making therapeutic choices
and TI.
2.3. Statistical analysis
We utilized two analytical approaches: (i) a descriptive assessment
of facial muscle activation and emotional expressions, and (ii) a med-
iation analysis to assess how the association between aversion to am-
biguity and TI may be mediated by facial activations and emotional
expressions. Mediation analysis is a technique commonly used in social
sciences and consumer research to make causal inferences about the
influence of specific factors (e.g. demographic variables, participant's
characteristics, etc.) on an outcome via a third variable (called ‘med-
iator’) (MacKinnon et al., 2007; VanderWeele, 2016). A mediator is a
variable that modulates the relationship between that factor with the
outcome of interest (MacKinnon et al., 2007; VanderWeele, 2016). In
our analysis, the independent variable was aversion to ambiguity and
the dependent variable was therapeutic inertia. Facial muscle activity
or an emotional expression were individually included as mediators.
Further details are illustrated in the appendix (Figs. e1 and e2).
The primary analysis was a descriptive assessment of the presence of
facial muscle activation and emotional expression among participants
with and without TI (binary) and by the TI score. For each screen face
by participants, we calculated the percentage of the frames in which
each facial muscle was detected relative to the total number of available
frames as part of the AFFDEX software. Then, we identified the time
period of the stimulus presentation and the time period of participants’
responses when making therapeutic decisions to specifically evaluate
the association between facial muscle activation and emotional ex-
pressions during these two critical events. Finally, we compared the
percentages of facial muscle activation and emotional expressions be-
tween participants with and without TI and related them to the TI score.
We used a proxy measure of participants’ arousal defined as a summary
score between attention (range 0–100) and engagement (range 0–100).
Specifically, we used mixed effects logistic and linear models to
assess relationships between TI (and TI score) and the percentage of
facial muscle movements (and emotional expressions) accounting for
clustering (repeated observations on participants). The analysis was
adjusted for the following explanatory variables: age, sex, specialist
status (MS expert vs. general neurologists). Practice setting (academic
vs non-academic), percentage of time devoted to clinical care, and
number of MS patients assessed per week had no significant impact on
the association between emotional expressions and TI.
We previously found an association between aversion to ambiguity
and increased prevalence of TI (Saposnik et al., 2017a). Here, we aimed
to replicate this association and evaluated whether this observed as-
sociation is mediated by facial muscle activation or emotional expres-
sion. For the mediation analysis we used the STATA command ‘medeff’
(see details of the models in the Appendix) (Valeri and
Vanderweele, 2013; Fairchild and MacKinnon, 2009). We also use
structural equation modeling (SEM) to graphically represent the esti-
mated mediation effects of facial metrics or emotional expressions (see
details and interpretation of graphs in the Appendix) (Verkuilen, 2006).
In a sensitivity analysis, we considered the effect of adding parti-
cipants’ number of MS patients seen per week, practice type (academic
vs. non-academic), or years of practice instead of participants’ expertise
in the multivariate models.
Goodness of fit was assessed by the c-statistic for TI (binary
outcome) and R-squared for the TI score. All tests were 2-tailed, and p-
values <0.05 were considered significant. We used STATA 13 (College
Station, TX: StataCorp LP) to conduct all analyses.
To facilitate the interpretation of findings, we performed the fol-
lowing four analyses:
(1) We evaluated the prevalence of facial muscle activations and
emotional expressions; (2) We examined their association with the
likelihood of TI and the TI score; (3) We assessed the relationship be-
tween facial metrics and emotional expression with ambiguity aversion
(main predictor of TI in our previous studies)(18); and (4) we con-
ducted a mediation analysis to determine whether facial muscle acti-
vation or emotional expression modulate the relationship between the
aversion to ambiguity (independent variable) and TI (outcome).
3. Results
3.1. Participant characteristics
Of the 38 neurologists who were invited to participate in the emo-
tional recognition study, 34 cooperated (cooperation rate: 89.5%) and
34 (completion rate: 100%) completed the study. The mean age (SD) of
study participants was 44.6 (± 11.6) years; 13 participants (38.2%)
were female. Twenty participants (58.8%) primarily focused their
practice on MS care. Participants had on average 12.5 (± 12) years of
experience and assessed 23.1 (± 16) MS patients per week. Table 1
summarizes baseline characteristics of the study population.
TI was present in 50.0% of participants in at least one case-scenario.
The mean TI score was 0.74 (± 0.90), and the range was 0 to 3.
(1) Prevalence of facial or emotional expressions:
The most commonly observed muscle activations included: mouth
open (23.4%), brow furrow (20.9%), brow raise (17.6%), and eye
widening (13.1%) (Fig. 2A). Brow furrow was associated with TI
(p<0.001). The most commonly decoded emotional expressions in-
cluded: fear (5.1%), disgust (3.2%), sadness (2.9%), and surprise
(2.8%) (Fig. 2C). Differences in facial muscle activation and emotional
expressions by TI status are represented in Fig. 2B and D.
Participants with muscle facial activations and emotional expres-
sions had higher arousal scores. For example, arousal scores were sig-
nificantly higher among participants with disgust (180.7 vs. 133.1;
p=0.04), surprise (77.6 vs. 122.4; p=0.02), fear (189.9 vs 131.6;
p=0.02). Similar findings were observed for facial muscle activations
associated with TI (e.g. brow furrow [p<0.001], brow raise
[p<0.001], lip suck [p<0.001], mouth open [p=0.02], nose wrinkle
Table 1
Baseline characteristics of participants.
Characteristics Total (%) n=34
Age (mean± SD), in years 44.6 ± 11.6




MS specialists 20 (58.8)




% time in clinical practice
50–74% of their time 16 (47.2)
Greater than 75% 15 (44.1)
Years in practice (mean±SD) 12.5 ± 11.8
MS patients seen per week (mean± SD) 23.1 ± 15.8
Author of a peer-reviewed publication in the last 12
months
22 (64.7)
Numbers in brackets indicate percentages.
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[p<0.01]).
(1) Basic associations between TI and facial or emotional expressions:
The multivariate mixed effects logistic regression after adjustment
for age, sex, and physicians’ expertise revealed that brow furrow (OR
1.04; 95%CI 1.003–1.09) and lip suck (OR 1.06; 95%CI 1.01–1.11)
were associated with an increase in TI prevalence, whereas upper lip
raise (OR 0.30; 95%CI 0.15–0.59), chin raise (OR 0.90; 95%CI
0.83–0.98), and nose wrinkle (OR 0.08; 95%CI 0.007–0.97) were as-
sociated with lower likelihood of TI (c-statistic: 0.889). Similar findings
were obtained with linear mixed models (brow furrow: p=0.05; lip
suck: p<0.001; nose wrinkle: p=0.017, upper lip raise: p<0.001;
chin raise: p<0.001; R-squared: 0.373) where the TI score as the
outcome of interest.
In the emotional expression analysis, the presence of disgust
(characterized by nose-wrinkle and upper lip raise) and surprise
(characterized increased brow raise and decrease brow furrow) were
associated with lower prevalence of TI scores (disgust: p<0.001; sur-
prise: p=0.008) and TI (ORdisgust: 0.14, 95%CI 0.03–0.65; ORsurprise:
0.66, 94%CI 0.47–0.92) after adjusting for age, sex and physicians’
expertise. Fear was not associated with either TI (ORfear: 0.37, 95%CI
0.03–5.43) or the TI score (p=0.14).
(1) Relation between facial and emotional expressions to ambiguity
aversion:
In our previous studies, aversion to ambiguity in the financial do-
main was the most relevant predictor of TI (Saposnik et al., 2017a).
Similarly, in the present study, 19 (55.9%) participants never chose an
ambiguous alternative in the financial domain and 11 (32.4%) in the
health domain. The multivariate analysis adjusted for age, sex and MS
expertise showed that aversion to ambiguity in the financial (OR 1.56,
95%CI 1.32–1.86) and health (OR 1.12, 95%CI 1.02–1.22) domains
were independent predictors of TI (Table 2). Similarly, for every 20%
increase in the degree of ambiguity, there was a 21.5% increment
(95%CI 3.0%−40.0%) in the TI score.
Given the consistent association between aversion to ambiguity and
TI in this study and prior studies, we also explored the association
between facial muscle activity and emotional expression and ambiguity
aversion. The multivariate analysis revealed that mouth opening (OR
2.10, 95%CI 1.35–3.26; p=0.001), brow furrow (OR 2.93, 95%CI
1.84–4.65; p=<0.001), chin raise (OR 3.16, 95%CI 1.51–6.62;
p=0.002), and lip suck (OR 0.38, 95%CI 0.21–0.70; p=0.002) were
the facial muscle activations associated with higher aversion to ambi-
guity in the financial domain. Disgust (OR 0.22, 95%CI 0.08–0.65;
p=0.006) was the single emotional expression associated with lower
aversion to ambiguity.
The mixed linear regression analysis adjusted for age, sex, partici-
pants’ expertise, emotional expression (disgust) or facial muscle acti-
vation (brow furrow, mouth opening, and lip suck) and degree of
aversion to ambiguity in the financial domain is presented in Fig. 3. For
every 20% increase in the degree of ambiguity (e.g. from 10% to 30%,
30% to 50% and so on), there was a 21.5% increment (95%CI
16.9%−26.0%) in the TI score (R-squared 0.35) (Fig. 3A). Nearly
identical results were observed when the linear mixed model included
facial muscle activations instead of emotional expression (R-squared
0.38) (Fig. 3B). In contrast, there were no associations between facial
muscle activation and emotional expression with aversion to ambiguity
in the health domain.
(1) Mediation analysis: facial and emotional expressions modulate the
relationship between aversion to ambiguity and TI
We found that brow furrow followed by nose wrinkle were the
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14.9%−38.9%) and 12.8% (95%CI 8.9%−23.4%) of the effect of
aversion to ambiguity in the financial domain on TI (Figs. 4A and 4B).
Similarly, disgust was the single emotional expression that attenuated
(−13.2%, 95%CI −9.2% to −24.3%) the effect of aversion to ambi-
guity in the financial domain on TI (Fig. 4C).
Notably, the direct effect of ambiguity aversion on TI was greater
than the indirect effect mediated by brow furrow, nose wrinkle, or
disgust (partial mediators). For example, there was a significant, but
modest increment (<5%) in the R-square values when adding the facial
or emotional variable into the mixed models. This is also reflected in
the larger β coefficients for the direct effect between ambiguity aver-
sion and TI compared to the multiplication of β coefficients for the
indirect effect (Fig. 4 and figure e2).
Other facial muscle activations (e.g. lip suck: p-value 0.84) and
emotional expressions had a non-significant or a negligible effect (e.g.
surprise and fear <3%). The sensitivity analysis revealed no changes in
the β coefficients for ambiguity aversion when adjusting mixed models
for other covariates (see appendix, figures e3 and e4).
4. Discussion
The influence of emotions on the therapeutic decisions of physicians
is an important but largely unexplored field. In the present study, we
analyzed facial muscle activations and emotional expressions among
neurologists while they were making therapeutic decisions. By using
the paradigm of complex therapeutic decisions in MS care, we found
that emotional expressions (e.g. disgust and surprise) were associated
with lower TI. We also observed that facial components of emotional
expressions were also associated with TI. Specifically, brow furrow, lip
suck and nose wrinkle were associated with an increased prevalence of
TI, whereas upper lip raise, and chin raise were associated with a lower
likelihood of TI. We also found that aversion to ambiguity increased the
Fig. 3. Predicted TI score as a function of degrees of aversion
to ambiguity
The mixed linear regression models were adjusted for age,
sex, participants’ expertise (MS expert vs. general neurolo-
gist), disgust (panel A) or facial muscle activation (brow
furrow, mouth opening, and lip suck) (Panel B). The gray are
represents the 95%CI of the predicted TI score.
For the model accounting for emotional expression (disgust)
(Panel A), the R-squared of 0.35 represents the proportion of
the variability of the TI score explained by the model. For
every 20% increase in the degree of aversion to ambiguity
(e.g. from 10% to 30% or from 50% to 90%), there was a
21.5% increment in the TI score.
For the model accounting for facial muscle activations (Panel
B), the R-squared of 0.38 represents the proportion of the
variability of the TI score explained by the model. For every
20% increase in the degree of aversion to ambiguity (e.g.
from 10% to 30% or from 50% to 90%), there was a 19.5%
increment in the TI score. The gray are represents the 95%CI
of the predicted TI score.
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Fig. 4. Mediation analysis: graphs derived from structural
equation models with a single mediator (see also ex-
planatory figure e1 in the appendix) (A) Structural equation
model graph for the modulation of brow furrow (mediator)
on the relationship between aversion to ambiguity (in-
dependent variable) and therapeutic inertia score (out-
come). The R-squared for the model was 0.38. (B) Structural
equation model graph for the modulation of nose wrinkle
(mediator) on the relationship between aversion to ambi-
guity (independent variable) and therapeutic inertia score
(outcome). The R-squared for the model was 0.34. (C)
Structural equation model graph for the modulation of dis-
gust (mediator) on the relationship between aversion to
ambiguity (independent variable) and therapeutic inertia
score (outcome). The R-squared for the model was 0.35 Age,
sex and MS expertise were included as covariates. Values
next to the arrows represent β coefficients, ε represent the
variance of the mediator and outcome of interest (TI score).
Values within each square box represent the mean (upper
values) and variance (lower value) of each variable included
in the models.
* represents a p-value < 0.001, † represents a p-
value < 0.05 and >0.01 for the total effect models.
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likelihood of TI. Participants with the aforementioned emotional ex-
pressions and muscle facial activations had higher arousal scores
compared to those without.
The mediation analysis revealed that disgust was the single emotion
that attenuated the effect of aversion to ambiguity in the financial
domain on TI. Similarly, the assessment of component processes that
mapped to emotional expressions revealed that brow furrow and nose
wrinkle were the strongest facial factors explaining 21% and 13% of the
influence of aversion to ambiguity on TI.
4.1. What is the relevance of our findings for clinical practice?
TI is a common phenomenon affecting 50% to 90% of physicians
who manage patients with chronic medical conditions (e.g. hyperten-
sion, diabetes, chronic obstructive pulmonary disease, multiple
sclerosis, among others) (Cooke et al., 2012; Blasco et al., 2017;
Khunti et al., 2017; Ogura and Harada-Shiba, 2016;
SisoAlmirall, 2012). TI has been associated with poorer patient out-
comes and higher health care costs due to the lack of appropriate
treatment escalation (affecting one out of six clinical encounters)
leading to higher hospitalizations, greater disability, and lower pro-
ductivity (Burks et al., 2017; Saposnik et al., 2017a, 2016b;
Kobelt et al., 2006). It may occur with insufficient knowledge integra-
tion and knowledge-to-action gaps as a result of automatic responses
leading to suboptimal therapeutic decisions. Specifically, neurologists
caring for MS patients sometimes fail to integrate presented information
(e.g. MS severity, relapses within the last three years, imaging findings
with the risk of disease progression) with best practice recommenda-
tions (Gongora-Ortega et al., 2012; Kennedy et al., 2004;
Djulbegovic et al., 2014; Kostopoulou et al., 2017). In the present study,
we found an association between facial and emotional expressions with
aversion to ambiguity and TI.
Prior studies have demonstrated that interventions increasing phy-
sicians’ arousal or awareness (e.g. through warning and categorization
strategies) were associated with more accurate diagnostic or ther-
apeutic decisions (Mamede et al., 2010, 2017b). A recent randomized
clinical trial showed that neurologists who received the traffic light
system educational intervention had a 70% reduction in TI (manuscript
submitted for publication in Feb 2019). Furthermore, several studies
demonstrated a link between specific emotions (e.g. disgust) increasing
attention at early stages of visual processing (van Hooff et al., 2014).
These prior findings, together with observations from the current study
suggest that emotional expressions and strategies that enhance parti-
cipants awareness (via increasing attention or arousal) may reduce TI.
Furthermore, our findings of (i) brow furrow being associated with
both increased TI and ambiguity aversion and (ii) disgust being asso-
ciated with both reduced TI and lower ambiguity aversion indicates
that common emotional factors may contribute to both behaviors. In
our previous studies, aversion to ambiguity was the most significant
physician-level factor associated with TI (Saposnik and
Montalban, 2018; Saposnik et al., 2017a; Reach, 2014) Given the lim-
ited training in risk management and formal learning in medical deci-
sions, physicians are clearly vulnerable when handling decisions under
uncertainty, especially when having aversion to ambiguity
(Dijkstra et al., 2015; Monrouxe et al., 2017; Kostopoulou et al., 2012).
Taken together, these findings suggest that interventions reducing TI
may partly rely on emotional factors (Saposnik et al., 2017b) and that
emotional factors may play a more important role for medical decision
making than hitherto assumed.
What brain pathways that may underpin the link between emotions
and TI?
Previous studies suggest that the neural mechanisms mediating the
relation between affect and decisions depend on a participant's emo-
tional arousal and engagement with the specific choice to be made
(Phelps et al., 2014). For example, disgust has been associated with the
activation of the insular cortex which may lead to increased arousal
modulating the neural responses to aversion to ambiguity, which results
in influencing subsequent decision-making (Klucken et al., 2012;
Mataix-Cols et al., 2008). Disgust was also shown to increase arousal by
modulating emotion-specific attention (van Hooff et al., 2014). This
finding is also consistent with an increased arousal score associated
with disgust (and its muscle components) in our study.
Traditionally, the striatum, the amygdala, the medial prefrontal,
orbitofrontal and insular cortices are thought to process emotional as-
pects of the decision-making process (Phelps et al., 2014; Lerner et al.,
2015). Moreover, the dorsolateral and anterior prefrontal cortices and
the posterior parietal cortex may modulate cognitive aspects of deci-
sions (Cohen, 2005). Previous studies showed that stress reduces ac-
tivity in dorsolateral and orbital parts of prefrontal cortex while it en-
hances amygdala activity, leading to decreased goal-directed behavior
and increased emotional responses (e.g. fear, disgust, contempt) (Otto
et al., 2014; Sokol-Hessner et al., 2013). Findings from our study are in
Fig. 5. Schematic representation of factors
associated with therapeutic inertia (TI)
There is a direct effect of ambiguity aversion
and TI and an indirect effect of facial muscle
activations (e.g. brow furrow, lip suck) and
emotional expressions (e.g. disgust) mod-
ulating the relationship between ambiguity
aversion and therapeutic inertia.
Demographic and practice factors (e.g.
number of MS patients seen per week) may
also contribute to TI.
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keeping with this proposed framework as they support an association
between facial metrics and emotional expressions (disgust) which may
increase participant's awareness/arousal (reflected by increased arousal
scores) regarding a compelling decision, thereby showing a reduction in
ambiguity aversion and lowering the likelihood of TI (Fig. 5). We could
speculate that muscle activations associated with disgust and surprise
may reflect increased activity of the insular cortex and amygdala
leading to greater arousal and lower TI. Further studies using time-re-
solved neural methods are needed to test this hypothesis.
5. Limitations
Our study has a number of significant limitations. First, although we
used a validated software to detect facial muscle activation, the asso-
ciation with emotional expressions may require further assessment.
Second, there is a high variability of emotional expressions when par-
ticipants are exposed to a specific stimulus. As such, our results should
be interpreted with caution considering there are no other similar
studies available for comparison. Third, the sample size is small af-
fecting the precision of our results (e.g. wider confidence intervals).
Fourth, the prevalence of emotional expressions was relatively low
likely due to: (i) the strict pre-specified correlation mapping used by
AFFDEX software (that combines the concomitant activation of several
facial muscles to code for a single emotion) (Stöckli et al., 2018), and
(ii) emotions are inherently social, and therefore more neutral expres-
sions are commonly observed when participants are exposed to com-
puter-based simulated scenarios. (de Melo et al., 2014; van ’t Wout
et al., 2006) Finally, our stimulus was based on case-scenarios that may
not truly reflect the therapeutic decisions in clinical practice.
Despite these limitations, our study is the first to show that facial
muscle activations and emotional expressions are associated with
therapeutic decisions made by physicians who care for MS patients.
6. Conclusions
This information helps improve our understanding of the influence
of emotional expressions on physicians’ therapeutic decisions. These
findings, in conjunction with results from a prior study that demon-
strated the benefits of an educational intervention on reducing TI have
practical clinical implications. With further studies, it may be possible
to identify physicians at high risk of having TI by evaluating physical,
emotional, and behavioral responses (aversion to ambiguity) and tailor
educational interventions to these individuals. Identifying and admin-
istering appropriate educational interventions in such situations may
facilitate optimal therapeutic decisions in chronic diseases, resulting in
better patient outcomes and lower health care costs.
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